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General information on the European network for Health Technology Assessment, 
EUnetHTA 
 
Background 
Health Technology Assessment (HTA) is increasingly used in European countries to inform 
decision- and policy-making in the health care sector. Several countries have integrated HTA 
into policy, governance, reimbursement or regulatory processes. Therefore, the EU and 
Member States in 2004 expressed the need for a sustainable European network for HTA. 
 
EUnetHTA was established to respond to this need. The European Commission and Member 
States co-funded the three year project (2006–2008) with the aim to develop a sustainable 
network and information resources to inform health policy making (1, 2, 3). The project, 
which was based on three prior projects, connected national HTA agencies, research 
institutions and health ministries and enabled an effective exchange of information and 
support to policy decisions (4).  
  
What is health technology assessment? 
EUnetHTA used the definition of health technology offered by the International Network of 
Agencies for Health Technology Assessment (INAHTA): “Any intervention that may be 
used to promote health, prevent, diagnose or treat disease, or for rehabilitation or long-term 
care. This includes pharmaceuticals, devices, procedures and organisational systems used in 
health care‖ (5). 
 
EUnetHTA defined health technology assessment (HTA) as ―a multidisciplinary process that 
summarizes information about the medical, social, economic and ethical issues related to the 
use of a health technology in a systematic, transparent, unbiased, robust manner. Its aim is to 
inform the formulation of safe effective, health policies that are patient focused and seek to 
achieve best value‖. 
 
EUnetHTA aims and strategic objectives 
The EUnetHTA project was established to create an effective and sustainable network for 
HTA across Europe that could develop and implement practical tools to provide reliable, 
timely, transparent and transferable information to contribute to HTAs in Members States.  
 
The strategic objectives of the EUnetHTA project were to: 
 reduce duplication of effort in order to promote more effective use of resources 
 increase HTA input to decision making in Member States and the EU in order to 
increase the impact of HTA 
 strengthen the link between HTA and health care policy making in the EU and its 
member states 
 support countries with limited experience of HTA. 
 
Structure of EUnetHTA 
The EUnetHTA Partnership involved 64 organisations:  1 Main Partner, 33 Associated 
Partners, and 30 Collaborating Partners. In total, 33 countries (Europe: 25 EU and 2 EEA 
countries (Norway, Iceland), Switzerland and Serbia; outside Europe: Australia, Canada, 
Israel, USA) participated in the project. The list of partners is accessible at: www.eunethta.net 
. 
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Management and leadership 
EUnetHTA governance structure consisted of 
 the Steering Committee which comprised the heads of each of the Associated Partners 
or representatives appointed by the head. The head of the Main Partner chaired the 
Steering Committee. The Steering committee mandated the the management of the 
network to: 
 the Executive Committee representing the Main Partner and Work Package Lead 
Partners,  
 the Secretariat under the leadership of the Main Partner which provided managerial 
support to the overall project and ensured ongoing contact to the DG SANCO. 
 
Collaborating Partners participated in the work packages and received internal 
communication on a regular basis. 
 
The modes of operation of the network were described in a standard operating procedures 
(SOP) manual, a communication strategy, and supported by virtual and face-to-face meetings, 
website (with the Members Only work area), regular e-newsletter and other types of 
communication tools. The Associated Partners agreed on 3-year work plan during the first 
Steering Committee meeting and project results were presented at the EUnetHTA Conference 
―HTA‘s Future in Europe‖, in journal articles and conference presentations. 
 
Work Packages and major results 
The scientific work in the EUnetHTA project took place in separately managed Work 
Packages (WPs), each led by a Lead Partner. The following major results were achieved: 
 A well functioning network of partners and colleagues from HTA agencies, research 
institutions and health ministries (WP1 - DACEHTA/National Board of Health, 
Denmark) 
 A well functioning Information platform and website (www.eunethta.net) (WP2 - 
SBU, Sweden and Co-Lead Partner – DIMDI, Germany) 
 Internal evaluations that helped to adjust work plans (WP3 – NOKC, Norway) 
 A comprehensive, evidence-based and validated common framework for HTA 
information (HTA Core Model) applied to two types of technology to produce generic 
Core HTAs a) on medical and surgical interventions (Drug Eluting Stents) and b) on 
diagnostic technology (Multislice CT coronary angiography) (WP4 - FinOHTA, 
Finland) 
 A handbook instructing in the use of the Core HTA Model (WP4 -  FinOHTA, 
Finland) 
 An Adaptation Toolkit (and a guidance document) composed of a series of checklists 
and resources which address the relevance, reliability and transferability of data and 
information from existing reports (WP5 - NCCHTA, UK) 
 A book ‖Health technology assessment and health policy-making in Europe‖ (WP6 - 
DACEHTA/National Board of Health, Denmark) 
 A web-based Stakeholder Open Forum, a Draft Stakeholder Policy and Discussion 
Topic Catalogue; (WP6 - DACEHTA/National Board of Health, Denmark) 
 Web-based tools for information sharing on the monitoring of new promising 
technologies and information service on emerging technologies (WP7 – HAS, France, 
and Co-Lead Partner- LBI/HTA, Austria) 
 A handbook on HTA capacity building (WP8 - CAHTA, Spain) 
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 A proposal for a permanent EUnetHTA Collaboration after two rounds of public 
consultation (WP1 - DACEHTA/National Board of Health, Denmark) 
 
Based on best practice each Work Package developed the methods suitable for their purpose, 
which is described in WP-specific products. The Lead Partners were responsible for 
coordination within the WP, for bringing work forward, producing and reporting results, for 
sending management information reports to the Main Partner and for responding to internal 
evaluation questionnaires.  
 
The next phase 
Through a series of internal and public consultation rounds, the network developed a Proposal 
for the EUnetHTA Collaboration (published June 16, 2008) detailing the approaches for the 
future development of the network. A group of founding partners was established after this to 
implement the proposal for EUnetHTA Collaboration. 
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Editors' Notes 
This is the final deliverable of this document, Core HTA on drug eluting stents (DES). This 
Core HTA is based on the HTA Core Model for medical and surgical interventions, developed 
by EUnetHTA Work Package 4. Readers of this document are urged to familiarize themselves 
with the Core Model as well.   
 
The aim of preparing this document was to test the HTA Core Model. We wanted to gather 
experiences from a novel way of preparing a health technology assessment, rather than 
prepare a valid assessment on DES. Instead of preparing a traditional HTA-report in a single 
HTA-unit, the relevant assessment elements were defined and the work distributed into 
several research units around Europe. Because of this piloting function, not every research 
question was assessed with full thoroughness. Therefore we suggest that the results described 
in this document should not be used as a basis of decision making as such. 
 
The current document represents a considerable amount of work by many people across 
Europe. It is divided into chapters, most of which present one domain of work within HTA. In 
the beginning of each chapter the main authors have been listed. Several others, however, 
have contributed to the work. Their names can be found in the chapter "Teams" of this report. 
 
Each chapter describing domains of the model contains the following sections: 
 
 Introduction: why is it important to assess the technology from the viewpoint of this 
domain? 
 Methodology: what methodology was used to answer the research questions of this 
HTA? 
 Assessment elements: answers to the issues that are defined for this domain in the 
Core Model.  
 References 
 Assessment elements table: the relevance of each assessment element in this domain 
and issues translated into research questions. First column contains an identification 
code (ID) that refers to the element in the model. 
 
Notice that this assessment is based on a draft version of the HTA Core Model (available at 
http://www.eunethta.net/Work_Packages/WP_4/Activities/). Hence it does not address all the 
same assessment elements as the final version 1.0 of the Model.  
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The work on different domains has been done as a collaborative effort of WP4 teams. Each 
team consists of investigators that are responsible for writing the sections of the report and 
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General design 
Marjukka Mäkelä, Kristian Lampe, Finn Børlum Kristensen, 
Inger Norderhaug, Alberto Ruano-Ravina, Marcial Velasco Garrido 
Introduction  
The organization of health technology assessment 
and the settings in which HTA agencies operate vary 
considerably across countries.
3
 There are also 
significant differences in the practical application of 
HTA.
3
 In some countries, HTA focuses currently on 
clinical effectiveness, safety and cost-effectiveness 
of technologies, while in others also other issues (e.g. 
ethics or social impact) are considered.
4
 The 
timelines for different assessments also have a 
notable effect on what an HTA report can cover; a 
full 200-page report prepared over a period of 2-3 
years naturally contains a more detailed account on 
the effectiveness of an intervention than a rapid 
review of 4 pages written in a few weeks. 
The EUnetHTA project aims at facilitating HTA 
information sharing within Europe. This is especially 
important for issues that are not dependent on a 
specific context (e.g. country, region or healthcare 
system), but also for context-dependent information 
that is significant from the viewpoint of HTA. All 
information could be presented using a similar 
structure. This is difficult since the information 
structure of current HTA reports varies so much. The 
need for a clear structure, transparency, and rigorous 
handling of information in any HTA leads to a need 
for standardisation. Steps towards definition of some 
standards at the international level have been taken 
by INAHTA
5
 (checklist) and the previous European 
Projects (EUR-ASSESS
6
 and ECHTA/ECAHI
7
). 
This international work was brought forward in the EUnetHTA project 2006-2008, through 
the development of two applications of the HTA Core Model - one for medical and surgical 
interventions and the other for diagnostic technologies. The EUnetHTA Core Model enables 
future cross-national use of HTAs through a shared and more detailed structure, suggesting 
what kind of information items may belong to an HTA.  
This report is an HTA on drug eluting stents. It is an application of the HTA Core Model for 
medical and surgical interventions and hence called a "Core HTA". The aim is to test the 
model and provide feedback that will be adjusted based on the experiment. Besides the more 
 
Definitions of HTA 
 
Technology assessment in health care 
is a multidisciplinary field of policy 
analysis. It studies the medical, 
social, ethical, and economic 
implications of development, 
diffusion, and use of health 
technology. 
INAHTA 2007
1
 
 
Health technology assessment (HTA) 
is a multidisciplinary process that 
summarises information about the 
medical, social, economic and ethical 
issues related to the use of a health 
technology in a systematic, 
transparent, unbiased, robust 
manner. Its aim is to inform the 
formulation of safe, effective, health 
policies that are patient focused and 
seek to achieve best value. 
Despite its policy goals, HTA must 
always be firmly rooted in research 
and the scientific method.  
EUnetHTA 2007
2
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theoretical work, the Core HTA functions as an example of a future generic report that 
facilitates information sharing within Europe. 
Methodology 
The work is based on the HTA Core Model for a generic, transferable HTA report
8 
which was 
developed by the participants in EUnetHTA Work Package 4 (WP4). This model is limited to 
assessing medical and surgical interventions. It defines and standardises elements of a health 
technology assessment, providing tools to tackle variation in the structure and contents of 
HTA reports. 
 
The model employs the following nine domains that were originally identified in the EUR-
ASSESS project: 
1. Current use of the technology (implementation level) 
2. Description and technical characteristics of technology 
3. Safety 
4. Effectiveness 
5. Costs, economic evaluation 
6. Ethical aspects 
7. Organisational aspects 
8. Social aspects 
9. Legal aspects   
Selection of topic 
The WP4 first selected the technology to be assessed according to the HTA Core Model. The 
participating organisations of WP4 were surveyed through email a web-based questionnaire. 
From among 20 proposals, a two-step voting process identified the use of drug-eluting stents 
(DES) in coronary heart disease as a topic of high interest among the participating 
institutions and countries.  
Application of the HTA Core Model 
Assessment elements 
The model is structured into nine domains, as described above. Each domain is further 
divided into more specific topic areas to consider, and each topic is further divided into one 
or more issues, i.e. questions to be answered in an assessment.   
 
Combinations of a domain, topic and issue define the context of assessment elements, which 
are the basic units of a Core HTA. Each element asks a generic question which for each HTA 
is then specified to reflect the health problem being assessed. For example, in the domain of 
Effectiveness, under the topic of Morbidity, the assessment element asks: "What is the effect 
of the intervention on overall mortality?" For the topic covered in this report, this translates 
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to a specific question: "In patients with coronary heart disease CHD, does the insertion of 
DES compared to BMS reduce overall mortality?" 
 
The importance and transferability of each issue have been considered when the model has 
been created. These define whether the issue belongs to the Core HTA (as defined by WP4). 
Topic-specific adjustments 
When applying the core model to a single health technology assessment, topic-specific 
judgements and adjustments are made on two levels: when deciding about the relevance of 
issues, and when converting the issues into actual research questions.  
Elements relevant for the technology to be assessed should be answered within the core 
HTA, and answers to other issues may be omitted. Omissions (and reasons for them) are 
recorded in the report, as it may provide useful information.  
Issues defined in relevant assessment elements are converted to research questions. One 
issue may sometimes produce several related research questions. The core HTA finds 
answers to these questions.  
The model guides researchers in selecting the aspects of technology or its use to study. 
Research tradition, methods and guidelines within each scientific domain then inform the 
process. The PICO question, or a wider or narrower application of it, is used in the 
background (see below in "Scope of assessment").  
Structure of the Core HTA report 
The issues and answers to them can be presented in a traditional way as a text in chapters. 
For the purposes of this report we have chosen a standard structure for each domain. The 
following main chapters are included: 
 Introduction 
puts the assessment in context within the domain. It provides information on the 
reasons for assessing DES (and perhaps similar technologies) from the viewpoint of 
the domain. 
 Methodology 
reports what kind of research methodologies, paradigms and theories have been 
used in the analysis. 
 Assessment elements 
is a chapter that contains information on those assessment elements that have been 
regarded as relevant in the context of this particular technology. The elements are 
organised based on topic and the generic issues of the model are replaced by topic-
specific research questions. The main findings are reported under subheading 
"Results". Two other (optional) subheadings exist in this section. In "Methods" 
researchers may provide additional information on the research methodology that 
was used when answering this issue. In "Comment" researchers may comment on 
their findings. If the two optional headings have not been used, also the heading 
"Results" has been left out. 
 Discussion 
contains an overview of findings in this domain as well as reflections on them.   
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 References 
used within the domain are liste here. 
 Assessment element table 
is an overview of all assessment elements defined in the Core Model as well as of 
the topic-specific judgements that have been made in this particular HTA. The 
relevance of assessment elements and the translated research questions are included 
here. 
The Core Model enables the presentation of information in various formats. It also supports 
the presentation of the issues arranged in the form of a deck of cards; this could be stored in 
an electronic database and accessed for only those elements ("cards") that are relevant for the 
user. In the next steps of the EUnetHTA project, we will still experiment with various modes 
of using the Core Model and presenting the results.  
This Core HTA on drug-eluting stents covers a wide range of questions in eight domains (out 
of nine defined in the model). One further domain, Safety, was not completed because it was 
thought that the safety issues were adequately addressed in the Effectiveness domain. The 
work has been done in a decentralised manner between 17 organisations, and producing 
certain parts has often required that another part has been available. 
Scope of the assessment  
The scope of a core HTA can be defined in several manners. Typically assessment in the 
effectiveness domain is started by formulating a research question that specifies the 
technology being assessed and those methods it will be compared to, the disease and the 
patient groups that will be targeted by the technology, and the health outcomes that will be 
considered as indicators of improvement. These can be presented in a "PICO" question, that 
is, by combining the definitions of Patients, Intervention, Comparator and Outcomes. For 
this report, the PICO question is: In patients with coronary heart disease, how does the 
insertion of drug eluting stents in coronary arteries (as compared to bare metal stents) affect 
a broad spectrum of health outcomes? 
 
This PICO question may need further refinement, in case it is considered important to look 
specifically at various patient subgroups (based on age, gender, phase of disease or other 
factor), variations in the intervention (such as the type of drug in the stent) or the 
interventions to be compared (best conservative treatment, bare metal stent, or other 
intervention such as coronary artery bypass graft). The relevant details may also differ in 
different domains - if, for example a comparator carries a high risk of serious side effects, it 
is probably useful to leave this comparator outside the modelling in the Cost domain - while 
keeping it in the Ethical domain for discussion 
 
In the various domains, it is not always useful to limit the study of the technology to the 
PICO question only. The example above describes a narrower viewpoint, but it may also be 
necessary to take a broader view. Does the intervention to be studied belong, for instance, to 
a group of technologies that share similar problems? DES, for instance, is a device that 
releases a drug. There may be something common about this type of technologies in, for 
example, domains dealing with licensing. 
In this core HTA the scope has been defined in somewhat different ways in the various 
domains, as was expected due to different research traditions. The analysis focuses in some 
domains (e.g. effectiveness) on comparing drug eluting stents with bare metal stents (BMS). 
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In other domains the view is broader, such as in the social domain in which the social aspects 
of both stent types are considered. Further work is required to find most suitable scoping 
within various domains. 
Overlapping issues 
Some of the issues defined in the Core Model are relevant for two or more domains. For 
example, the issue of approval of the technology by national or other authorities may be 
relevant from the viewpoint of the following domains: Health problem and current use of 
technology, Organisational aspects and Legal aspects. Although the simple reply to the 
question - yes or no- is the same, the issue is discussed from different viewpoints under each 
domain. 
 
Findings  
The main purpose of this Core HTA on drug eluting stents is to provide a test example on 
how well the Core Model can be applied in practice. The policy question to be answered in 
relation to drug-eluting stents can vary markedly between countries; the Core HTA covers a 
wide range of questions to fulfil the different needs. The Core Model can be seen (among 
other things) as a checklist for producing an HTA on any single topic. The Core HTA in turn 
acts either as a stand-alone report that can be utilized in various settings, or as a base from 
which HTA producers can take building blocks for their own national or regional 
assessments.  
National, regional or local technology assessments based on a Core HTA can look very 
different. Depending on the country and policy question, the range of issues contained in a 
new HTA may vary.  
The resulting reports on DES (i.e. the Core HTA and any local HTAs that are based on it) 
may even give different answers to the same question; for example, the price of stents, 
salaries of health professionals, or reimbursement systems can vary notably from country to 
country. In any case, a well-done Core HTA should provide a useful starting point for 
preparing a context-specific report more rapidly than would be possible by starting from 
scratch or from a traditional full-text report from another country. 
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Health problem and 
current use of technology 
Bo Freyschuss, Marcial Velasco Garrido, Marjukka Mäkelä 
Introduction  
Drug eluting stenting (DES) is a technology indicated in certain patients with coronary artery 
disease suitable for percutaneous coronary intervention (PCI). Stenting is a quickly evolving 
field of therapy, where the most recent development has been the addition of slow-release 
drugs to bare metal stents (BMS). The next generation of bioabsorbable DESs is likely to 
appear on the market in the near future. 
 
A large number of cardiac centers worldwide have been rapid to extend the use of DES 
beyond the indications proposed by regulatory authorities such as FDA and NHS, and the ―off 
label‖ use has been extensive. The main reason for extending the indications has been an 
observed reduction in the rate of restenosis in patients treated with DES compared to those 
treated with BMS. After a period of widespread use recently published safety data indicating 
an increased risk of late stent thrombosis in patients treated with DES have led to a more 
restrictive use in many countries. 
  
This domain presents background information on the conditions possibly targeted by DES. It 
also describes alternative interventions and current use of DES in relation to its comparators 
in a national and international perspective. The proportional use of DES in relation to BMS 
varies substantially between countries and between regions within the same country. The 
reasons for these variations are not fully understood, but may depend on several factors 
including differences in the interpretation of data, local traditions and differences in 
reimbursement policies.  
 
Methodology  
This domain contains information from a variety of sources including international and 
national guidelines, HTA reports, national registers, textbooks (1) and discussions with 
experts (J Jensen, Director of Percutaneous Coronary Intervention Lab Department of 
Cardiology Karolinska University Hospital, Sweden). It does not include a systematic review 
of the alternative technologies used for the same conditions as DES. 
By literature and internet search for publications reporting data from interventional cardiology 
registers several sources were identified. The Swedish Coronary Angiography and 
Angioplasty Register (SCAAR) (2) covers 100% of centers and 99% of the procedures in 
Sweden. It gathers individual data and is linked to other registries (mortality, medicament use, 
hospitalization). SCAAR has been used as the main source in this HTA. Other sources were 
identified such as the Register of the Spanish Society on Haemodynamics and Interventional 
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Cardiology (3), that covers 96% of the Spanish centers and gathers aggregated data for each 
center (no individual data).Other usable primary sources of information may include:  
 
 Registers based on nationally or regionally collected routine statistics, including those 
from regulatory institutions (e.g. death registers). The Swedish National Board of 
Health and Welfare (4) run a number of registers including the drug register, the cause 
of mortality register and the registers containing the diagnoses of all hospitalized 
patients patients in Sweden. Similar national registers exist in for example Denmark 
and Norway. 
 Manufacturers' data 
 Collection of primary data through research. 
 
Since reliable and comparable cross-European data on this topic would have been difficult to 
collect, we have mainly used data from one country (Sweden) to exemplify how this chapter 
could be constructed. Users of this Core Topic in other countries need to identify their own 
sources of information when wishing to describe the epidemiology in their national context, 
since major differences exist between countries for several of the issues (as shown in some 
examples). 
 
In a national HTA report one would probably refer to eventual national guidelines rather than 
international guidelines as the latter may not be entirely relevant in the national perspective. 
Assessment elements  
Target Condition 
Which disease will be treated by DES? 
Drug-eluting stents are put in coronary arteries during percutaneous coronary interventions 
(PCI) to treat a number of conditions resulting from coronary artery disease (CAD). For a 
more specific description see below. The term PCI (percutaneous coronary intervention) is an 
umbrella term for several minimally invasive procedures including PTCA (percutaneous 
transluminal coronary artery angioplasty) and stenting. 
Which are the diagnoses or patient groups for which DES is or may be 
indicated? 
For treatment decisions coronary artery disease (CAD) is often divided into three categories 
(the first two being known as acute coronary syndromes (ACS)): 
 
 ST segment elevation Myocardial Infarction (STEMI), 
 non-ST segment elevation myocardial infarction (NSTEMI)and unstable angina, and  
 stable angina.  
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In a patient with STEMI, a percutaneous coronary intervention (PCI) is usually performed 
immediately if possible. Other less common indications for acute PCI exist and include 
cardiogenic shock.  
 
In a patient with NSTEMI or unstable angina, a coronary angiography (with an eventual PCI) 
is usually performed within one or two days and before the patient leaves the hospital.  
 
In a patient with stable angina, a coronary angiography and the eventual following PCI are 
clearly elective in nature and the prioritization is dependent of several clinical factors such as 
symptoms, ECG-changes, work-load test and in some cases scintigraphic findings.  
 
The decision concerning which intervention to use is based on a number of factors (5) 
including the type of coronary lesion characterised as A, B or C, extent of disease (such as 
single/multiple lesions/ vessel characteristics), patient related risk factors (such as diabetes, 
familial hypercholesterolemia (FHC), ongoing anticoagulant therapy and contraindications for 
antiplatelet agents) and the actual clinical situation (emergency intervention or elective). In 
some cases evidence based decision making will clearly indicate one intervention before 
others, whereas in other cases the choice of intervention may be less clear. 
 
The potential target groups for DES are people with the conditions described above where 
PCI is indicated. The exact target population is not clearly definable, and the practice differs 
between countries and even within countries. The proportional use of DES in relation to BMS 
has increased steadily since their introduction and until 2006. The reactions of the 
interventionalist community and the regulatory authorities to the recent publications 
concerning late serious complications related to the use of DES (6-9) have lately, however, 
decreased the target population in clinical practice. These data will be further discussed in the 
efficacy domain. 
What are the symptoms of the conditions for which DES may be indicated? 
When applying the model, we found that this and the next question should be answered 
together. 
What are the most common or serious symptoms and consequences of the 
conditions that may be treated with DES? 
CAD is caused by a reduced blood flow to the heart muscle secondary to narrowing or 
occlusion of the coronary arteries. The narrowing is due to atherosclerotic plaques the 
development of which will begin during youth and progress during life. As the disease 
progresses, the blood flow in single or multiple vessels will eventually decrease to a level 
where it leads to symptoms that can be diagnosed. Most of the diagnosed cases will have one 
of the conditions stated below. The symptomatic manifestations of coronary artery disease 
may be acute, chronic or both. The acute coronary syndromes include myocardial infarction, 
unstable angina and some less common conditions including cardiogenic shock and sudden 
death. 
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The typical symptom of CAD is chest pain, usually located on the left side or retrosternal and 
which may irradiate to left arm, neck, or jaw. It may also present as breathlessness, discomfort 
or pressure. 
 
Stable angina is a chronic condition where the patient experiences episodical chest pain, 
usually during physical or emotional stress. Stable angina is often graded using the scale from 
the Canadian Cardiovascular Society (CCS (10)). 
 
CCS Angina Classification (10) 
Class Description 
Class I Ordinary activity such as walking or climbing does not precipitate angina 
Class II Slight limitation of ordinary activity. Angina occurs on walking or 
climbing stairs rapidly, walking uphill, walking or stair climbing after 
meals, or in cold, or in wind, or under emotional stress, or only during the 
few hours after awakening. Angina occurs on walking more than 2 blocks 
on the level and climbing more than one flight of ordinary stairs at a 
normal pace and in normal condition. 
Class III Marked limitations in ordinary physical activity. Angina occurs on walking 
one to two blocks on the level and climbing one flight of stairs in normal 
conditions and at a normal pace. 
Class IV Inability to carry out any physical activity without discomfort, anginal 
symptoms may be present at rest 
 
Stable angina typically is relieved by resting and by nitrates. Progression of the disease may 
lead to instable angina or MI. 
 
Acute coronary syndromes  
Unstable angina- is a syndrome that is intermediate between stable angina and myocardial 
infarction: It is characterized by chest pain that lasts longer and/or may be more severe than in 
stable angina. It may occur at rest or with less exertion than in stable angina. It may also be 
less responsive to medication. New onset angina is also included in this syndrome. The 
progression of unstable angina may lead to Non ST elevation myocardial infarction 
(NSTEMI) or ST elevation myocardial infarction (STEMI). 
Non ST elevation myocardial infarction – has the same clinical symptoms as unstable angina 
and in addition evidence of myocardial necrosis reflected by elevated cardiac biomarkers. 
Progression may lead to STEMI. 
ST elevation myocardial infarction – is a very acute condition with severe symptoms in most 
cases. The cause is usually an occlusion of a coronary artery that without immediate treatment 
will result in necrosis of a region of the myocardium. This usually results in a reduced 
pumping capacity of the heart muscle (heart failure) leading to disability. Other complications 
exist such as arythmia, cardiogenic shock and death. 
People with CAD are at increased risk of death. Besides the increased risk of death for people 
with CAD, the disease has also other consequences. Depending on its degree, angina may 
limit daily life more or less. The limitations imposed by the disease influence mood and 
quality of life (16, 17). The quality of life of persons with CAD is reduced compared with the 
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general population (17,18). Sexual functioning is also impaired in persons suffering from 
CAD (19). 
What are the known risk factors of coronary artery disease? 
Methods 
Literature search for review articles, large cohort studies.  
Results 
The progress of atherosclerosis depends on several factors (1). In the large INTERHEART 
study (11), the researchers reviewed data from 15 000 patients with myocardial infarctions 
and an equal number of healthy controls. Approximately 90% of the myocardial infarctions 
could be explained by several easily identifiable risk factors: gender, heredity, high 
cholesterol, smoking, hypertension, abdominal obesity, diabetes, low intake of 
fruits/vegetables and an insufficient amount of physical activity.  
What will happen if DES is not used on the different conditions where DES 
may be indicated?  
The use of PCI is aimed at restoring the blood flow in the affected coronary vessels by 
increasing the lumen of the vessel. In some situations such as STEMI or cardiogenic shock, 
the intervention may be directly life-saving, whereas in other situations the intention may be 
the reduction of symptoms without shown effects on mortality. The use of DES as opposed to 
BMS is mainly aimed at reducing the rate of restenosis thereby decreasing the risk of 
recurrency in symptoms and the need for revascularisation. The evidence for the effects of 
DES compared to BMS in different patient populations (i.e. label use vs off-label use) will be 
more extensively covered in the efficacy domain. 
What is the incidence of CAD? 
Methods 
Register data from The Swedish National Board of Health and Welfare (4) and SCAAR (2) 
Report from the British Heart Foundation (20). 
Results 
The prevalence of angina pectoris among men in Sweden is about 3% in the ages between 45-
50 years and 7% in the ages between 65-70 years of age. In a population of 9 million, the 
incidence of MI is presently 42 000 per year and about 34 000 of these are admitted to 
hospital. About 15 000 are admitted to hospital for unspecified angina and 12000 for instable 
angina yearly. About 5000 coronary artery bypass grafts (CABG) and 18 000 PCIs are 
performed yearly. Coronary heart disease accounts for about 18 000 deaths each year in 
Sweden, constituting 22% of all deaths in men and 18% in women (4). 
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There are differences in the incidence of CAD across European countries and within 
European countries across regions. According to the latests available data from the MONICA 
Study, the incidence of coronary events in men varied in Europe between 835/100.000 in the 
Finland North Karelia population and 210/100.000 in the Spain-Catalonia population (20). 
Similar variations were found in women, from 777/100.000 in the UK-Glasgow population 
and 35/100.000 in the Spain-Catalonia population (20). 
 
However, not all persons having CAD can be considered to be potential targets for the use 
DES. Under the assumption that DES substitutes BMS, the target group would be the patients 
currently undergoing PCI with BMS. Following this reasoning the potential target group 
would vary across countries according to the PCI rate and especially according to the use of 
stents during PCI. Stents are used in 94% of PCI (21), thus the number of PCI would provide 
a good estimate of the potential target group for the DES technology under the assumption of 
substitution of stenting. Great variations in the use of PCI have been also identified for PCI 
(and other procedures for treating CAD), indicating potential great variations in the target 
group for use of the DES technology across countries. In the year 2002 (according to 
available data) PCI rates per million population varied between 148 in Romania and 2439 in 
Germany (20). 
What is the burden of coronary artery disease? 
Coronary artery disease (CAD) is the leading cause of death in the developed countries and 
for example accounts for around 20% of all deaths in Sweden, Germany or UK. Coronary 
Figure 1. Hospitalisations per year for certain types of coronary artery disease 
(data from the Swedish National Board of Welfare, EPC)  
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heart disease accounts for about 18 000 deaths each year in Sweden, constituting 22% of all 
deaths in men and 18% in women (4). 
 
The prevalence/incidence of early retirement due to the condition depends on the severity of 
the condition but also on the social security arrangements in each country. Thus, the 
transferability of this kind of information might be very limited. 
Current management 
How common is the use of DES in relation to other interventions for CAD? 
Stents were in 2005 used in just over 90% of all PCIs in Sweden (2). For the use of PCI in 
relation to CABG from 1982 to 2005 please see fig. 2. The use of PCI for different indications 
as well as the proportional use of DES, please see fig. 4-7. 
 
Figure 2. The number of all coronary artery interventions, coronary artery bypass 
grafts, and percutaneous coronary interventions in Sweden 1982-2005 (Data from 
SCAAR 2005). 
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Figure 3. The proportion of patients with STEMI in Sweden that have undergone CABG 
2000 to 2005 (data from SCAAR). 
 
Figure 4. The number of PCIs performed in Sweden on STEMI indication 1989 to 2005 
(data from SCAAR 2005). 
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Figure 5. The proportional number of PCIs performed due to each indication. The acute 
coronary syndromes account for just over 70% of all performed PCIs in Sweden (Data 
from SCAAR 2005). 
 
 
Figure 6. The propoprtion of patients with stable angina undergoing PCI classified using 
CCS guidelines (Data from SCAAR 2005). 
 
EUnetHTA WP4 - Core HTA on drug eluting stents (DES) 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
28 
Figure 7. Illustrates the substantial local variation of the proportional use of DES 
between the different Swedish centers during 2005. The left figure shows the number of 
DES and BMS procedures performed in each Swedish center and the right figure shows 
the proportional use of DES (Data from SCAAR 2005). 
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Figure 8. The proportional use of DES in Sweden increased steadily until 2006, when 
safety data from large observational (8) and registry studies (3, 7, 9) (SCAAR Sweden) 
indicated an increase in late stent thrombosis after cessation of anti-platelet therapy. 
After reaching a top level of over 60% (in some centers over 90%), the proportion of 
DES in Sweden in early 2007 is below 20%(data not shown). 
 
 
Are there variations in the use of DES across countries in Europe? And 
across regions within the same country? 
Both the use of PCI as such, and the proportion of DES of all stents applied, vary 
substantially between and within countries. These variations may reflect differences in 
priority setting, in funding and coverage decisions, and in other factors which influence the 
adoption of the technology. 
 
The proportion of DES among the total number of implanted stents varies across European 
countries. The table below presents data from four countries (2, 3, 20, 25). 
 
Year 
Drug Eluting Stents % of all Stents 
Spain Germany Switzerland Sweden* 
2002 4,1% - - - 
2003 20,2% - - 28% 
2004 36,5% - 66% 44% 
2005 - 30% 78% 63% 
2006 - - - 26%* 
* Data from october 2006 
 
Regional variations of the use of DES have been also described within the same country. In 
Spain for example the proportion of DES varied from 23 % to 56 % in 2004. Three regions 
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used DES in more than 50% of stent implantations, whereas four regions used DES in less 
than 25% of stent implantations (3). In Sweden the use of DES varied from 12% to 92% 
across regions (see issue above). 
How is CAD currently being managed? 
In different ways depending on the type of CAD, see above. Medical management is used in 
virtually all diagnosed cases of CAD  in order to reduce symptoms, modify risk factors and to 
prevent disease progression and serious complications. The treatment may include the use of 
several drugs such as betablockers, cholesterol lowering agents, antiplatelet agents, nitrates, 
calcium channel blockers, potassium channel blockers and anticoagulants. Medical 
management of CAD is not within the scope of this report. 
 
CABG (coronary artery bypass graft surgery) is the oldest invasive strategy presently in use. 
Its use has decreased on behalf of the widening indications for PCI over the last years. In 
certain patient cathegories, for example patients with main stem stenosis, CABG is still the 
preferred treatment alternative (1, 5). CABG is not included in the scope of this review.  
Are there published algorithms or guidelines on CAD? How should the 
condition be managed? 
Methods 
We conducted a systematic search for evidence based clinical practice guidelines providing 
advice on percutaneous coronary intervention (PCI). We searched the GIN Database of 
clinical practice guidelines using combinations of the keywords „PCI―, „Cardiovascular 
Disease― and „Coronary Heart Disease―. We identified two relevant international guidelines 
concerning PCI from the American Heart Association (5) and from the European Society of 
Cardiology (12) which had been developed following the principles of evidence based 
medicine and which provided recommendations graded by their level of underlying evidence. 
Both include details concerning the indications and procedures of PCI and DES. Many 
European countries have published guidelines or algorithms for the treatment of CAD. Most 
recommendations concerning the use of DES, however, have been issued before data from 
long-term follow up observational and registry studies showed a potential increase in the risk 
of late stent thrombosis leading to severe clinical consequences. After the presentation of 
these data (the SCAAR data being presented before their publication in NEJM) the US Food 
and Drug Administration made public its concerns regarding the adverse events related to the 
use of DES. The FDA aknowledged an small but significant increase in the rate of death and 
myocardial infarction possibly due to late stent thrombosis in patients treated with DES (13) . 
This statement and even more recent statements from authorities and cardiologist 
organisations in several nations challenge aspects of the older guidelines. For example in the 
light of this statement the German Society of Cardiology has pleaded for thoughtful and 
moderated use of DES (14) and the more recently published Swedish National Guidelines on 
DES published by the Swedish MPA in association with the Swedish National Board of 
Health and Welfare and the Swedish Society of Cardiology have put restrictions on the use of 
DES (15). 
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Are there differences in the management for different stages of coronary 
artery disease? 
Yes, depending on the severity, the type of lesion and other factors. See above.  
Do other evidence-based treatment alternatives to DES exist? If so, which? 
Yes, stenting with BMS, PTCA and CABG are evidence based alternatives and may be 
considered as alternatives depending on the clinical situation. For some situations (for 
example significant left main coronary disease) surgery (CABG) may be recommended over 
PCI (22) 
Life Cycle 
Is DES an experimental or emerging technology? 
BMS is an established technology, while DES is currently still developing. There are new 
drugs being administered by drug-eluting stents, and new types of matrix materials are being 
developed. The new variations of DES can be considered as emerging variants of a 
technology that is as such established. 
Regulatory status 
Has DES been approved for the market by national or international 
authorities? 
Yes, in several countries in both Europe and elsewhere. More information on this issue is 
found in the domain on organisational aspects as well as in the ethical domain. 
Has DES been included in / excluded from the benefit basket of any 
country? 
To our knowledge DES has not been explicitly excluded from the benefit basket of any 
European countries. However different reimbursement arrangements exist which may DESs 
are included in the benefit baskets of several care providers in several countries in and outside 
Europe. In Sweden the reimbursement for the care providers varies locally. In some regions 
all DES stents are reimbursed, whereas in some regions DES are reimbursed up to a certain 
percentage of all stents used. Some of these regulations are currently under revision due to 
new data on long-term effects of DES. 
In countries with fees for case group (DRG-systems), providers might be reimbursed a fixed 
amount for PCI disregarding whether an stent is implanted or not, and if so disregarding 
which kind of stent is implanted. However, additional payments may cover the costs of DES 
(i.e. on top of the corresponding DRG) or even a differentiated DRG may account for the cost 
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differences between DES implantation and other PCI (as is the case in some regions in Italy) 
(23). 
Discussion 
DESs were introduced as a routine PCI procedure in 2002-2003. The main advantage of DES 
as opposed to BMS was a shown decrease in the risk of restenosis and need for 
revascularisation. This swiftly led to a worldwide acceptance of DES and in the beginning of 
2006 DES was by far the most prevalent PCI procedure in some industrialised countries in 
spite of high costs and need for prolonged and costly anti-platelet therapy. The off-label use, 
i.e. the use in clinical situations/ in patients other than the ones for which efficacy has been 
proven in randomized controlled trials has been extensive (24). During 2006 and 2007 
observational safety data indicated a small but statistically significant increase in the risk of 
late stent thrombosis and death in patients treated with DES. These late complications seem to 
be related to off-label use and premature discontinuation of anti-platelet therapy. These new 
data have resulted in a rapid decrease in the use of DES in several countries. For example the 
proportional use of DES in Sweden has decreased from 60% in early 2006 to below 20% in 
early 2007.  
 
Some of the issues of this domain are highly context dependent and thus not easily 
transferable. We have shown in some examples, that the answers to the issues may vary 
significantly depending on the country. It was beyond the scope of this exercise to provide 
comprehensive comparisons including all European countries. However, such a comparison 
can be facilitated when agencies from single countries provide their data (i.e. their answers to 
the issues) following the same structure. For example if say 9 countries describe their 
coverage arrangements for DES, any other agency accesing this information can provide a 
comparative view on this issue. This kind of comparative information may be very useful for 
decision-makers. 
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Assessment elements table 
ID Domain Topic Issue Relevance in the 
context of DES 
Yes / No 
Research question(s) in the context of DES 
or 
Comment (if regarded as a not relevant issue in this 
context) 
Importance 
3=critical 
2=important 
1=optional 
Transferability 
3=complete 
2=partially 
1=not 
        
A0001 Health Problem and Current Use 
of the Technology 
Target 
Condition 
Which disease/health problem/potential 
health problem will the intervention target?* 
 
Yes Which disease will be treated by DES? 3 3 
A0002 Health Problem and Current Use 
of the Technology 
Target 
Condition 
Is there a precise definition/ characterization 
of the target disease?* 
Yes Which are the diagnoses or patient groups for which DES 
is or may be indicated? 
 
3 3 
A0003 Health Problem and Current Use 
of the Technology 
Target 
Condition 
What are the symptoms of the disease?* Yes What are the symptoms of the conditions for which DES 
may be indicated?   
 
3 3 
A0004 Health Problem and Current Use 
of the Technology 
Target 
Condition 
What are the consequences of the 
condition?* 
Yes What are the most common or serious symptoms and 
consequences of the conditions that may be treated with 
DES? 
 
3 3 
A0005 Health Problem and Current Use 
of the Technology 
Target 
Condition 
Are there known risk factors for acquiring the 
condition? 
Yes What are the known risk factors of coronary artery 
disease? 
 
2 3 
A0006 Health Problem and Current Use 
of the Technology 
Target 
Condition 
What is the natural course of the condition? Yes What will happen if DES is not used on the different 
conditions where DES may be indicated?  
 
3 3 
A0007 Health Problem and Current Use 
of the Technology 
Target 
Condition 
How many people belong at the moment (will 
belong) to the specific target group? 
Yes What is the incidence of CAD? 
 
3 2 
A0008 Health Problem and Current Use 
of the Technology 
Target 
Condition 
What is the burden of disease (mortality, 
disability, life years lost)? 
Yes What is the burden of coronary artery disease? 
 
3 2 
A0009 Health Problem and Current Use 
of the Technology 
Utilisation How much is the technology being used? 
 
Yes How common is the use of DES in relation to other 
interventions for CAD? 
 
2 1 
A0010 Health Problem and Current Use 
of the Technology 
Utilisation Are there variations in use across 
countries/regions/settings? 
Yes Are there variations in the use of DES across countries in 
Europe? And across regions within the same country? 
 
2 2 
A0011 Health Problem and Current Use 
of the Technology 
Current 
Management 
of the 
Condition 
How is the disease/health condition currently 
being managed? 
Yes How is CAD currently being managed? 
 
3 2 
A0012 Health Problem and Current Use 
of the Technology 
Current 
Management 
of the 
Are there published algorithms/guidelines? 
How should the condition be managed? 
Yes Are there published algorithms or guidelines on CAD? 
How should the condition be managed? 
 
3 2 
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ID Domain Topic Issue Relevance in the 
context of DES 
Yes / No 
Research question(s) in the context of DES 
or 
Comment (if regarded as a not relevant issue in this 
context) 
Importance 
3=critical 
2=important 
1=optional 
Transferability 
3=complete 
2=partially 
1=not 
Condition 
A0013 Health Problem and Current Use 
of the Technology 
Current 
Management 
of the 
Condition 
Are there differences in the management for 
different stages of disease? 
Yes Are there differences in the management for different 
stages of coronary artery disease? 
 
2 2 
A0014 Health Problem and Current Use 
of the Technology 
Current 
Management 
of the 
Condition 
Do other evidence-based alternatives exist? If 
so which? 
Yes Do other evidence-based treatment alternatives to DES 
exist? If so, which? 
 
3 3 
A0015 Health Problem and Current Use 
of the Technology 
Life-Cycle In which phase is the development of the 
technology (experimental, emerging, routine 
use, obsolete)? 
Yes Is DES an experimental or emerging technology? 
 
2 2 
 
A0016 Health Problem and Current Use 
of the Technology 
Regulatory 
Status 
Has the technology been market approved by 
any national/international authority? 
Yes Has DES been approved for the market by national or 
international authorities? 
 
3 3 
A0017 Health Problem and Current Use 
of the Technology 
Regulatory 
Status 
Has the technology been included in / 
excluded form the benefit basket of any 
country? 
Yes Has DES been included in / excluded from the benefit 
basket of any country? 
 
2 2 
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Description and 
technical characteristics of technology 
Hans van Brabant, Antti Malmivaara, Pekka Kuukasjärvi 
Introduction 
Percutaneous coronary intervention (PCI) is a common intervention intended to dilate narrowed 
coronary arteries. The technique has been introduced by Andreas Grüntzig 
1
 in 1977 as an extension 
of the work of Dotter and Judkins who introduced the procedure for transluminal recanalization of 
arteriosclerotic obstructions in lower limb arteries. 
2
 As such, invasive revascularisation by means 
of coronary artery bypass grafting (CABG) could be prevented in some patients.  
 
An important limitation of PCI is the risk of an acute vessel closure provoked by the injury on the 
vessel wall resulting in intimal and medial flaps projecting into the vessel wall. Furthermore, 
restenosis of the dilated vessel occurs in 30 to 40% of patients. 
3, 4
 Several mechanisms may 
contribute to the process of restenosis: elastic recoil occurring immediately (i.e. between seconds 
and minutes after balloon deflation), platelet adherence to the injury site, inflammation of the vessel 
wall, neointimal hyperplasia and vascular constrictive remodelling.  
 
Due to these limitations coronary stenting was introduced. 
Methodology 
The information concerning this domain has been obtained mainly from the literature, and partly 
from manufacturers of the technology.  
Assessment elements 
Features of the technology  
What is BMS, what is DES? 
Stenting (bare metal stent, BMS) is a technique in PCI in which a metal scaffolding is fitted into the 
coronary artery on the site of the dilated lesion.  Drug eluting stents (DES) are coated with a drug 
that will inhibit cell proliferation and therefore aim to further reduce in-stent restenosis. 
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Why is DES used instead of BMS? 
Coronary stenting (BMS) was introduced in order to try to prevent the shortcomings in PCI, 
particularly the restenosis of the target vessel. Although it was clear that BMS stenting reduced the 
occurrence of acute mechanical complications of angioplasty and diminished the rate of restenosis, 
both stent thrombosis and a residual late restenosis remained a major challenge to interventional 
cardiologists. In-stent restenosis is usually due to neointimal hyperplasia, an excessive growth of 
tissue in and around the stent as a reaction to injury. This process, which also occurs following 
standard PCI, is not prevented by the original bare metal stents; on the contrary, they actually 
exacerbate it. Drug eluting stents (DES) have been developed to try to antagonize this cellular 
reaction. The components of a DES can be divided into a platform (the stent), a carrier (usually a 
polymer) and an agent (the drug). The carrier coating facilitates a gradual release of the embedded 
drug into the local tissue. Several drugs have been studied but the current generation of DESs are 
coated with a polymer embedded with an antiproliferative drug. The theory base is that this drug 
will inhibit cell proliferation and therefore reduce in-stent restenosis. 
What is the phase of technology in BMS and DES? 
Stenting 
Stenting was first used in 1986 by Sigwart and Puel who described the technique for treating acute 
vessel closure due to blood vessel wall dissection and an  impairment of bloodflow by projecting 
intimal flaps. 
5
 In 1993 two trials, BENESTENT 3 and STRESS 4, comparing combined PCI and 
stenting with PCI only demonstrated that intracoronary stents significantly reduced the incidence of 
restenosis. Gradually, coronary stents became almost routinely used in most angioplasties. Some 
consensus panels endorsed this clinical enthusiasm even before a large body of high-quality 
evidence was available. 
6
 By 1999, stenting comprised more than 80% of percutaneous coronary 
interventions. 
7
 In a meta-analysis of data from 25 trials Brophy et al. 6 calculated that stenting was 
associated with a 48% reduction in restenosis rate. In absolute terms, stenting reduced the 
angiographic restenosis rate by 14.5%. However, routine coronary stenting was not associated with 
important reductions in rates of mortality, acute myocardial infarction or CABG compared with 
standard PCI.  
 
At the time of the STRESS and BENESTENT trials, and despite the use of an intensive coumadin 
anticoagulation regimen, acute vessel occlusion due to thrombus formation within the stent 
occurred in 3.7% of patients, a value higher than that seen with PCI alone. 
8
 The subsequent use of 
better dilatation techniques together with dual antiplatelet therapy with aspirin and a thienopyridine 
(i.e. ticlopidine or clopidogrel) rather than anticoagulation resulted in a reduction of stent 
thrombosis in 0.5 to 1.9% of patients. 
9
  
Drug eluting stents 
The agents that have been the subject of the most extensive research are sirolimus (rapamycin) and 
paclitaxel. Sirolimus is a macrolide immunosuppressant used systemically to treat renal transplant 
rejection. It halts proliferation of smooth muscle cells: it binds to a receptor protein and inhibits a 
regulatory enzyme that in turns shuts off the cell cycle. Sirolimus is incorporated in the Cypher 
stent, manufactured by Cordis. 
10
 Paclitaxel is a derivative of the yew plant. It also inhibits the cell 
cycle and has been used as an anti-proliferative drug in the treatment of breast, lung and ovarian 
cancer. 
11
 This drug is used in the Taxus stent that is manufactured by Boston-Scientific. 
12
 Both 
these DES are generally referred to as ―first generation stents‖. Although there seems to be no 
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general agreement on the definition of these terms, second and third generation DES would be 
stents with specialized designs for complex anatomy, bioabsorbable polymers and ―no polymer‖ 
systems and DES with a combination of different drugs to further reduce neointimal growth. 
13
 
Many of these newer DES are currently under investigation. 
  
The first major trial that compared DES with bare metal stents (BMS) was the RAVEL study in 
which patients with angina were randomized to a sirolimus DES or a BMS for treatment of single, 
primary lesions in native coronary arteries. 
14
 The primary endpoint was in-stent late luminal loss, 
i.e. the difference between the minimal diameter immediately after the procedure and the diameter 
at six months. Late luminal loss was significantly lower in de DES group (mean -0.01 ± SD 0.33 
mm) compared to the BMS group (mean +0.80 ± SD 0.53 mm) resulting in a clinical significant 
restenosis (i.e. > 50%) in not a single patient in the DES group versus 26.6% of patients in the BMS 
group.  
 
In the following years, different DESs were tested in patients with more complex lesions and in the 
clinical context of acute coronary syndromes. From a meta-analysis, Roiron et al. concluded that 
major adverse cardiac events (MACEs) occurrence was highly reduced with DES from 19.9% to 
10.1% compared to BMS. 
15
 MACE was defined as a composite of death, myocardial infarction and 
revasularisation. However, mortality, Q-wave myocardial infarction and stent thrombosis were not 
significantly different between DES and the control group.  
 
The widely held belief that the problem of restenosis has been ―cured‖ by using DES has resulted in 
a new paradigm in the treatment of coronary artery disease with a dramatic shift away from CABG 
and an increase in the complexity of percutaneous coronary interventions resulting in, at least in 
some countries, a virtual replacement of BMS by DES. 
13
 In 2005, in the US, 90% of stents used 
were DES. In 2003, in the New York State database the ratio of PCI vs. CABG had increased to 
3.5/1 whereas in 2001 it was 1.9/1. 
13
  
Who are the users of BMS and DES? 
Cardiologists in any catheterisation laboratory where percutaneous coronary interventions (PCI's) 
are performed for coronary artery disease.  
Where are DES and BMS used? 
In any organizations having a catheterisation laboratory where percutaneous coronary interventions 
(PCI's) are performed for coronary artery disease. 
Are there any special features relevant to DES and BMS? 
Favorable effects related to DES 
See above. 
Adverse effects related to DES 
Important side-effects, some of which typically related to the action of antiproliferative agents, have 
drawn particular attention of clinicians when using DES. In some cases, endothelial healing was 
completely inhibitited, preventing encapsulation of the stent and eventually leading to incomplete 
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apposition of it. Very late stent thrombosis (LST) has been reported and constitutes a major problem 
because it can  lead to increased cardiac mortality. 
16
 Hypersensitivity-reactions to the polymer, 
possibly leading to LST has also been reported. 
17
  A recent meta-analysis suggests the possibility 
of an increase in non-cardiac late mortality. 
18
  
 
Unlike restenosis, thrombosis is a rare but potentially life-threatening complication of coronary 
stents. The clinical consequences for these patients are often catastrophic, including short-term 
mortality rates of up to 25% and major myocardial infarction in 60% to 70% of cases. 
19
 Stent 
thrombosis usually occurs before re-endothelialization has been completed. It rarely occurs beyond 
2 to 4 weeks for BMS  
20
 but is a matter of concern in DES because of the delayed 
endothelialization. It has been the subject of long-term follow-up reports of previous trials and in 
real-world registries of unselected patient groups. Randomised controlled trials suggest that 
thrombosis following DES placement is not more frequent than following BMS at up to one year 
after the procedure. In an observational study, Pfisterer et al noticed that the discontinuation of 
clopidogrel six months after DES implant later on was followed by a doubling of documented LST 
in DES (2.6%) vs. BMS (1.3%). 
21
 
 
LST is likely to be related to a delayed healing of the injury caused by the mechanical dilatation of 
the coronary vessel. Thus, a continued presence of a foreign body predisposes to thrombus 
formation. This thrombotic tendency can be more pronounced in complex coronary lesions and in 
patients who stopped one or both of the antiplatelet drugs that were instituted following DES 
implant.  
 
Premature antiplatelet therapy discontinuation has been shown to be a risk factor for LST. In a 
prospective observational study, with follow-up at 9 months after DES implant, stent thrombosis 
occurred in 29 of 2229 patients (1.3%). 
22
 LST occurred in 5 of 17 patients (29%) who prematurely 
discontinued dual antiplatelet therapy. Other independent predictors of stent thrombosis were renal 
failure, bifurcation lesions, diabetes and a low ejection fraction.  
 
Nordmann et al. conducted a systematic review on mortality outcomes in randomized trials that 
compared DES with BMS. 
18
 They not only included peer-reviewed publications but also 
incorporated results from long-term follow-up of existing studies presented at scientific meetings 
and follow-up information obtained directly from the principal investigators and manufacturers. 
They concluded that DESs do not reduce total mortality when compared with BMSs. Surprisingly, 
their preliminary evidence suggested that sirolimus eluting stents may lead to increased non-cardiac 
mortality.  
Investments and tools required to use the technology 
What material investments are needed when using DES instead of BMS? 
The use of DES in stead of BMS does not require material for the catheterisation laboratory or 
organization beside the drug eluting stent itself. 
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What kind of special premises are needed when using DES instead of BMS? 
The use of DES instead of BMS does not require any special premises for the catheterisation 
laboratory or organization.  
What kinds of equipment and supplies are needed when using DES instead of 
BMS? 
The use of DES instead of or along BMS does not require additional equipment or supplies to use 
the technology.  
What kinds of records or registers are needed when using DES instead of BMS? 
The use of DES instead of or along BMS does bring a further need for records and registers to 
monitor patients undergoing PCI. The long term follow-up becomes more important, especially for 
documenting the late stent thrombosis.  
Training and information needed for utilizing the technology  
What kind of training is needed for the personnel using DES instead of BMS? 
In being essentially nothing more than an angioplasty with a specially designed stent, compared to a 
BMS procedure, it does not implicate specific training for the catheterisation personnel.  
What kind of training is needed for the personnel treating or investigating 
patients with DES instead of BMS? 
The training of cardiologists must be planned to cover the following topics 
For the interventional cardiologist, two items deserve special attention, both related to the fear of an 
increased risk of LST. First, it should be taken into account that the risk of stent thrombosis is 
dependent on some procedure related factors: morphometric abnormalities (undersized stents, 
underexpansion, asymmetry), morphologic abnormalities (dissection, incomplete apposition, 
thrombus, tissue protrusion), and mechanical vessel injury.
 19
 Patients treated in randomised trials 
mostly have simple coronary lesions which may be the reason why stent thrombosis in DES did not 
exceed that in BMS in these studies. The recently reported increased risk of LST can be related to 
the off-label use of DES in real world practice. According to some authors the majority of DESs are 
implanted in patients or in vessels with characteristics different than those studied to support 
marketing approval.
 23
 Following a public meeting, convened by the FDA Circulatory System 
Devices Advisory at the end of 2006, the panel generally agreed that off-label use of DES is 
associated with an increased risk of stent thrombosis, death and myocardial infarction when 
compared to on-label use of DES. The Panel did not find sufficient data were available to identify 
subsets of patients at a particularly increased risk. It is important that implanting physicians are 
aware of this.  
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Second, strong emphasis is to be put towards the patient on a correct use of antiplatelet drugs 
following DES implantation. Because BMS become endothelialised within a few weeks of 
implantation, dual antiplatelet therapy (aspirin plus thienopyridine) is only required during 3 to 4 
weeks. DES on the other hand cause delayed endothelialisation and prolonged antiplatelet therapy is 
imperative. According to the European Society of Cardiology, it should be continued during 6 to 12 
months following DES procedures.
 24
 Furthermore, physicians considering a stent implant in a 
patient should try to find out if that patient is likely to be compliant with prolonged antiplatelet 
therapy. If not, a BMS should be preferred.  
What kind of training is needed for the patients receiving DES instead of BMS? 
Informing the patients must be planned to cover the following topics: 
Because of concerns of late stent thrombosis and the association of this potential catastrophe with 
the inadequate use of antiplatelet drugs, patients must be aware that dual antiplatelet therapy should 
not be discontinued too early, even for minor procedures such as dental care.
 24
 This means that, 
before introducing a DES, patient and physician should thouroughly consider whether a subsequent 
(non-cardiac) surgical procedure necessitating the interruption of antiplatelets is expected or is 
likely to be needed. If so, a DES might not be the best choice.
 16
  
 
The continued use of dual antiplatelet therapy also leads to an increased risk of bleeding 
complications. In a population-based case control study, Hallas et al found that clopidogrel by
 
itself 
carries little if any risk of upper gastrointestinal
 
bleeding, but when it is given with aspirin the risk 
increases
 
beyond the effect of aspirin given alone.
 25
 In the Atrial Fibrillation Clopidogrel Trial 
(ACTIVE W), investigators found a comparable risk of major bleeding in patients treated with 
clopidogrel plus aspirin compared to patients on oral anticoagulation.
 26
  
 
The combination of an increased risk of bleeding when using two antiplatelet agents and the 
inscreased risk of LST when discontinuing one or both of them, demands for a continuing 
consultation between patient and physician.  
What information do patients outside the target group and the general public 
need on DES treatment instead of BMS treatment? 
Informing patients outside the target group and the general public on the effects and adverse effects 
of DES vs BMS should be considered on a case by case basis.  
 
Informing key decision makers at different levels of health care of the current evidence on DES vs 
BMS is important.  
Discussion 
Intevention contrast between DES vs BMS is limited to the carrier and the drug in DES in the metal 
stent, which both technologies possess. Thus the implications of using DES instead of BMS for the 
investments and tools to use the technology are negligible. Ensuring critically evaluated up to date 
knowledge on the pros and cons of using DES instead of BMS for the cardiologists and for the 
patients itself poses a major challenge on this rapidly evolving area. 
EUnetHTA WP4 - Core HTA on drug eluting stents (DES) 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
42 
References 
1. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: 
percutaneous transluminal coronary angioplasty. The New England journal of medicine 1979; 301(2):61-68. 
2. Dotter CT, Judkins MP. Transluminal Treatment of Arteriosclerotic Obstruction. Description of a New 
Technic and a Preliminary Report of Its Application. Circulation 1964; 30:654-670. 
3. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco 
J, Legrand V, Materne P. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients 
with coronary artery disease. Benestent Study Group. The New England journal of medicine 1994; 331(8):489-495. 
4. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, 
Nobuyoshi M. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of 
coronary artery disease. Stent Restenosis Study Investigators. The New England journal of medicine 1994; 331(8):496-
501. 
5. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion 
and restenosis after transluminal angioplasty. The New England journal of medicine 1987; 316(12):701-706. 
6. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-
analysis. Annals of internal medicine 2003; 138(10):777-786. 
7. Holmes DR, Jr., Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P, Fischman D, Goldberg S, 
Brinker JA, Zeiher AM, Shapiro LM, Willerson J, Davis BR, Ferguson JJ, Popma J, King SB, 3rd, Lincoff AM, Tcheng 
JE, Chan R, Granett JR, Poland M. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) 
trial. Circulation 2002; 106(10):1243-1250. 
8. Serruys PW, Kutryk MJB, Ong ATL. Coronary-artery stents. The New England journal of medicine 
2006; 354(5):483-495. 
9. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, Carrozza JP, Jr., Chauhan MS, 
Rodriguez O, Kuntz RE. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical 
trials. Circulation 2001; 103(15):1967-1971. 
10. Cordis. http://www.cypherusa.com/cypher-j2ee/cypherjsp/index.jsp. 
11. Hill R, Bagust A, Bakhai A, Dickson R, Dundar Y, Haycox A, Mujica Mota R, Reaney A, Roberts D, 
Williamson P, Walley T. Coronary artery stents: a rapid systematic review and economic evaluation. Health technology 
assessment (Winchester, England) 2004; 8(35):iii-iv, 1-242. 
12. Boston Scientific. http://www.taxus-stent.com/. 
13. Leon MB, Stone GW. CIT 2006 Crossfire: trials, tribulations, current trend and future directions. In; 
2006; 2006. 
14. Morice M-C, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, 
Barragan P, Guagliumi G, Molnar F, Falotico R, Lesions RSGRSwtS-CBVB-ESitToPwdNNCA. A randomized 
comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. The New England journal 
of medicine 2002; 346(23):1773-1780. 
15. Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G. Drug eluting stents: an updated meta-
analysis of randomised controlled trials. Heart (British Cardiac Society) 2006; 92(5):641-649. 
16. Eisenberg MJ. Drug-eluting stents: some bare facts. Lancet 2004; 364(9444):1466-1467. 
17. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi 
O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should 
we be cautious? Circulation 2004; 109(6):701-705. 
18. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting 
vs. bare metal stents in coronary artery disease: a meta-analysis. European heart journal 2006; 27(23):2784-2814. 
19. Honda Y, Fitzgerald PJ. Stent thrombosis: an issue revisited in a changing world. Circulation 2003; 
108(1):2-5. 
EUnetHTA WP4 - Core HTA on drug eluting stents (DES) 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
43 
20. Tung R, Kaul S, Diamond GA, Shah PK. Narrative review: drug-eluting stents for the management of 
restenosis: a critical appraisal of the evidence. Annals of internal medicine 2006; 144(12):913-919. 
21. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader 
F, Osswald S, Kaiser C, Investigators B-L. Late clinical events after clopidogrel discontinuation may limit the benefit of 
drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. Journal of the American College of 
Cardiology 2006; 48(12):2584-2591. 
22. Iakovou I, Mehran R, Dangas G. Thrombosis after implantation of drug-eluting stents. Hellenic journal 
of cardiology : HJC = Hellenike kardiologike epitheorese 2006; 47(1):31-38. 
23. Update to FDA Statement on Coronary Drug-Eluting Stents. 
http://www.fda.gov/cdrh/news/010407.html. 
24. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, 
Nordrehaug J-E, Ruzyllo W, Urban P, Stone GW, Wijns W, Task Force for Percutaneous Coronary Interventions of the 
European Society of C. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary 
Interventions of the European Society of Cardiology. European heart journal 2005; 26(8):804-847. 
25. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, Andersen M, Lassen AT. Use of 
single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-
control study. BMJ 2006; 333(7571):726. 
26. Investigators AWGobotA, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf 
S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial 
with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 
367(9526):1903-1912. 
 
 
EUnetHTA WP4 - Core HTA on drug eluting stents (DES) 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
44 
Assessment elements table 
ID Domain Topic Issue Relevance in the 
context of DES vs 
BMS 
Yes/No 
Research question(s) in the context of DES 
or 
Comment (if regarded as a not relevant issue 
in this context) 
Importance 
3=critical 
2=important 
1=optional 
Transferability 
3=complete 
2=partially 
1=not 
        
B0001 Description and technical 
characteristics of technology 
Features of the 
technology 
What is this technology?  Yes What is BMS, what is DES? 3 3 
B0002 Description and technical 
characteristics of technology 
Features of the 
technology 
Why is this technology used?  Yes Why is DES used in stead of BMS? 3 3 
B0003 Description and technical 
characteristics of technology 
Features of the 
technology 
Phase of  the technology: When 
has it been developed or 
introduced in health care? 
Yes What is the phase of technology in BMS and 
DES? 
3 3 
B0004 Description and technical 
characteristics of technology 
Features of the 
technology 
Who are the users of this 
technology? 
Yes Who are the users of BMS and DES? 3 3 
B0005 Description and technical 
characteristics of technology 
Features of the 
technology 
Where? Place and context for 
utilising the technology 
Yes Where are DES and BMS used? 3 3 
B0006 Description and technical 
characteristics of technology 
Features of the 
technology 
Are there any special features 
relevant to this technology? 
Yes Are there any special features relevant to DES 
and  BMS? 
3 3 
B0007 Description and technical 
characteristics of technology 
Investments and tools 
required to use the 
technology 
What material investments 
are needed to use the 
technology? 
No What material investments are needed when 
using DES in stead of BMS? 
1 3 
B0008 Description and technical 
characteristics of technology 
Investments and tools 
required to use the 
technology 
What kind of  special premises  
are needed to use the 
technology? 
No What kind of special premises are needed when 
using DES in stead of BMS? 
1 3 
B0009 Description and technical 
characteristics of technology 
Investments and tools 
required to use the 
technology 
What equipment and supplies are 
needed to use the technology? 
No What kind of equipment and supplies are 
needed when using DES in stead of BMS? 
1 3 
B0010 Description and technical 
characteristics of technology 
Investments and tools 
required to use the 
technology 
What kind of records 
are needed to monitor the use the 
technology? 
 
Yes What kinds of records are needed when using 
DES in stead of BMS? 
3 3 
B0011 Description and technical 
characteristics of technology 
Investments and tools 
required to use the 
technology 
What kind of registers  
are needed to monitor the use the 
technology? 
 
Yes What kinds of registers are needed when using 
DES in stead of BMS? 
3 3 
B0012 Description and technical 
characteristics of technology 
Training and 
information needed for 
utilizing the technology 
What kind of training is needed for 
the personnel using or 
maintaining the technology 
Yes What kind of training is needed for the personnel 
using or maintaining DES in stead of BMS? 
2 2 
B0013 Description and technical 
characteristics of technology 
Training and 
information needed for 
utilizing the technology 
What kind of training is needed for 
the personnel treating or 
investigating patients using this 
technology? 
Yes What kind of training is needed for the personnel 
treating or investigating patients with DES in 
stead of BMS? 
3 3 
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ID Domain Topic Issue Relevance in the 
context of DES vs 
BMS 
Yes/No 
Research question(s) in the context of DES 
or 
Comment (if regarded as a not relevant issue 
in this context) 
Importance 
3=critical 
2=important 
1=optional 
Transferability 
3=complete 
2=partially 
1=not 
B0014 Description and technical 
characteristics of technology 
Training and 
information needed for 
utilizing the technology 
What kind of training is needed for 
the patients receiving or using this 
technology & their families? 
 
Yes What kind of training is needed for the patients 
receiving DES in stead of BMS? 
3 3 
B0015 Description and technical 
characteristics of technology 
Training and 
information needed for 
utilizing the technology 
What information do patients 
outside the target group and  the 
general public need on the 
technology? 
Yes What information do patients outside the target 
group and  the general public need on DES 
treatment in stead of BMS treatment? 
2 2 
 
EUnetHTA WP4 - Core HTA on drug eluting stents (DES) 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
46 
Clinical effectiveness  
Kunz R, de Laet C, Kuukasjärvi P, Malmivaara A 
 Van Brabandt H, Makela M, Briel M, Nordmann A
i
 
Introduction 
This section is about the application of the core model to an HTA on ‖Drug Eluting Stents‖ (DES). 
The technology and its spectrum of use has been introduced in the chapters ‖Health problem and 
current use‖ and ‖Description and technical characteristics‖. 
 
For health outcomes the scope of the report has been framed as a broad PICO question: ―How does 
the insertion of DES in coronary arteries compared to bare metal stents (BMS) affect a broad 
spectrum of health outcomes‖. Our task was to assess effectiveness and we limited our 
considerations to that domain, but the concept can be easily applied to the domain ―Safety‖ and the 
domain ―Economic evaluation‖.  
 
We further confined the outcome of PICO to the primary research question: In patients with 
coronary heart disease, how does the intervention with DES compared to BMS affect mortality, i.e. 
overall mortality, cardiac mortality and non-cardiac mortality (the ‗issues‘).  The remaining topics: 
morbidity, function / quality of life, patient satisfaction, and societal issues were treated as 
secondary outcomes  
Definition of outcomes 
The outcomes relevant to the questions follow the four generic topics of an effectiveness question: 
short-term and long-term mortality, morbidity, function / quality of life (QoL) and patient 
satisfaction. We bore in mind that the outcome selection should not be determined by the available 
research evidence rather by the question what patients, clinicians, managers of the health care 
system would like to know about the technology. Formulating the right questions would thereby be 
the first step in identifying knowledge gaps. 
 
For the effectiveness domain of the core HTA on DES, we identified a comprehensive set of 
outcomes (―issues‖) for each of the five topics, independent on our expectations of finding research 
results. Our group jointly judged the importance of all issues. We felt it was essential that more than 
one person would make the decision about the importance. We had an a priori defined way of 
dealing with disagreement among raters. 
                                                 
i
 R. Kunz was primary investigator for the effectiveness part of this core HTA and wrote the first draft. C de Laet, Pekka 
Kuukasjärvi A. Malmivaara A, M Makela and H van Brabandt contributed to the concept on how to apply the core model 
to the core HTA DES, helped with writing and provided input to various versions of the draft.  Pekka Kuukasjärvi, and 
Hans van Brabandt contributed content expertise, while A. Nordmann and M Briel provided and discussed the data and 
ran further analyses beyond the analyses done in their original paper. 
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Methodology  
This section follows the outline of the Methodology section in the Core Model. The work is based 
on the review by Nordmann et al. Mortality in randomized controlled trials comparing drug-eluting 
vs. BMS in coronary artery disease: a meta-analysis. Eur Heart J 2006; 27(23):2784-2814, including 
additional analyses of unpublished data. 
Background work  
Background work for an HTA-report requires the assessment of previous work (HTA and 
systematic reviews on DES). We identified 32 HTA-reports, systematic reviews and meta-analyses 
from the HTA-database of the Centre of Reviews and Dissemination in York (published between 
2001 and 11/2006 and PubMed (published between 2003 and 11/2006) [see Appendix A] 
Phrasing the problem as a focused and standardized question 
The main question of this HTA report is about the effectiveness of DES compared to BMS in 
patients with coronary heart disease at various points in time, where ‖effectiveness‖ would be 
assessed across a broad range of outcomes.  
 
This broad question needs further refinement regarding subgroups of the population (such as 
diabetic / non-diabetic patients; single / multiple vessel disease; first event / repeated events; acute / 
subacute / non-acute intervention; men / women; long vessel / short vessel lesions), and the 
intervention (e.g. stents using different drugs such as sirolimus or paclitaxel). The comparator – 
BMS - has already been defined in the scope of the review, but one might also consider other 
current treatment options such as bypass operations (CABG), percutaneous coronary interventions 
(PCI) without stent implantation, or even medical treatment which we did not do in this review.  
The generic issues of the core model need to be translated into context-specific issues: Researchers 
need to determine whether all issues of the model need to be included in the HTA-report or whether 
some of them are irrelevant in the context of a particular technology. In the context of the core HTA 
on DES, we restricted ourselves to mortality as the primary outcome and to evidence from 
randomized controlled trials. All other outcomes (topics: morbidity, function / quality of life, patient 
satisfaction) are regarded as secondary outcomes and they will be answered from the information in 
the reviews we identified for the primary question. 
 
Since we wanted to demonstrate how to use the core model developed in this project, we limited 
ourselves to an exemplary and abbreviated approach. An exhaustive HTA, however, would require 
a comprehensive review of the literature for each question and each outcome specified in the main 
PICO–question and the related secondary questions.   
Locating and selecting studies 
The following data sources were searched: Medical databases: MEDLINE, EMBASE, Cochrane 
Library; Web of Science. (1/ 1980 to 4/2006); Additional sources: UptoDate version 2005 and 
Clinical Evidence Concise 2004 (issue 12). Furthermore, the ―grey literature‖ including oral 
presentations was also searched since publications about long-term data on mortality were still 
sparse. The following three websites, all of which focus on disseminating (cardiovascular) trial 
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results, were accessed for additional data: www.tctmd.com , www.theheart.org, 
www.clinicaltrialresults.org .  Additional information was requested from the original trial 
investigators and stent manufacturers where needed. Experts of the field were contacted and 
reference lists of relevant articles were searched for additional citations.  
 
Studies were eligible when they  
 
 included patients with coronary artery disease  
 compared: drug-eluting sirolimus or paclitaxel stents with BMS  
 reported data on mortality and morbidity  
 followed the patients for a minimum of 1 year  
 used a randomized controlled design  
 
Studies were excluded when they: 
 
 compared drug-eluting with BMS in non-native coronary arteries  
 used other eluting drugs other than sirolimus or paclitaxel (e.g. everolimus) 
 made direct comparisons of drug-eluting stents with each other  
 
DES is a rapidly evolving technology with new evidence appearing every day. Since the purpose of 
this core HTA was to demonstrate how to apply the core model to a specific technology, we 
refrained from a more recent update once the first literature search has been done and concentrated 
on the application of the core model to the collected data. 
Assessing study quality 
The following 4 criteria were used for assessing study quality:  
 
 concealment of treatment allocation 
 blinding of patients and caregivers 
 blinded outcome assessment 
 loss to follow-up, full description of losses to follow-up and withdrawals. 
Collecting data from individual studies – evidence summaries 
A structured data extraction was performed on all included studies to generate evidence summaries 
with the core set of relevant data that would allow comparability of the data:   
 
The following features were regarded as relevant:  
Patient characteristics: gender; age; diabetes mellitus/non-diabetes mellitus; prior myocardial 
infarction; length of lesion and reference diameter;  
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Features of the intervention and the comparison: Sirolimus / Paclitaxel drug plus post-interventional 
prophylaxis as co-intervention.; only comparator: BMS 
 
Primary outcomes: Mortality (overall mortality; cardiac mortality; non-cardiac mortality) at one, 
two and three years. Secondary outcomes for the remaining 4 topics morbidity, function / quality of 
life and patient satisfaction were included following the core model: Morbidity: impact on severity 
and frequency of symptoms; on severity of findings; on progression of disease (further defined as 
recurrence of target stenosis, clinical progression of disease, reduction of cardiac-specific drug 
treatment, cardiac-specific re-interventions), recurrence of findings, need for other treatments, need 
for hospitalization beyond the intervention related hospitalizations) at one, two and three years. 
Function / quality of life (impact on health related QoL; disease-specific QoL; return to work; 
return to previous living conditions; on activities of daily living) and patient satisfaction.    
Presenting and analyzing results 
The results of the analysis have been reported as relative risks (RR) or as odds ratios (OR) based on 
an intention to treat-analysis. The surrounding confidence interval (CI) indicates the precision of the 
estimate. The goal was to perform pre-specified subgroup analyses wherever possible.  
 
As it turned out, subgroup analyses were only possible for type of DES (sirolimus or paclitaxel). 
Otherwise, the data in the individual studies were not reported in a format that would have allowed 
pooling in clinically relevant subgroups. Only an individual patient data–meta-analysis would 
provide answers on the treatment effect in specific subgroups. 
 
The literature search identified a total of 120 trials, 95 of which were excluded as irrelevant based 
on abstract or title, 25 full text publications were assessed, of which 8 were excluded because of too 
short follow up (n=3) or subgroup analyses of already included trials (n=5). The study population 
consisted of 17 primary trials including more than 8200 patients at one year. (The list of trials is 
available in appendix B). Twelve trials reported two year data, and 9 trials reported 3 year data on 
mortality.  
 
In the following, we use the structure of the core model to report the results  
Assessment elements  
Mortality 
In patients with coronary heart disease CHD, does the insertion of DES 
compared to BMS reduce overall mortality at one, two and three years? 
Results 
The first analysis looked at overall mortality. At one year, eight studies were available for the 
comparison with sirolimus. The relative risk (RR) for overall mortality for sirolimus-coated stents 
was 0.94 (95% CI: 0.53 – 1.65). Ten studies were available for the comparison with paclitaxel-
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Figure 1: Drug Eluting Stents and mortality at 1, 2 and 3 
years
.5 1 2 10
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Heterogeneity (P), I2 [95% UI], % 
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Risk Ratio
coated stents. Here the RR for overall mortality was 1.02 (95% CI: 0.67 – 1.54). The combined RR 
for mortality was 0.99 (0.71 – 1.39). At two years, 5 trials on sirolumus-encoated stents were 
available, for which the RR for overall mortality was 1.31 (95% CI: 0.74 – 2.32). Seven trials 
reported on overall mortality for paclitaxel-coated stents, which demonstrated a RR of 0.97 (95% 
CI: 0.60 – 1.56). The combined RR for mortality was 1.10 (0.76 – 1.58). At three years, the 4 trials 
reporting on overall mortality for sirolimus-coated stents detected a RR of 1.45 (95% CI: 0.90 – 
2.34), compared to the RR of 1.09 (95% CI: 0.72 – 1.65) for paclitaxel-coated stents, based on 5 
trials. The combined RR for mortality was 1.23 (0.90 – 1.69). The results were highly homogeneous 
(I
2 
= 0).  
 
There was no significant difference between DES and BMS in either comparison nor was there a 
difference between the two drugs. However, there was a non-significant trend for an increase in 
mortality for sirolimus-coated stents over the years, with a RR of 0.94 at year one, a RR of 1.31 at 
year 2 and a RR of 1.45 at year 3.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In patients with coronary heart disease CHD, does the insertion of DES 
compared to BMS reduce cardiac mortality at one, two and three years? 
Results 
The first sub-analysis on mortality looked at cardiac mortality. At one year, 8 studies were 
available for the comparison with sirolimus. The relative risk for cardiac mortality for sirolimus-
coated stents was 0.81 (95% CI: 0.36 – 1.80). Ten studies were available for the comparison with 
paclitaxel-coated stents. Here, the RR for cardiac mortality for paclitaxel-coated stents was 0.93 
(95% CI: 0.54 – 1.60). The combined RR for cardiac mortality was 0.89 (0.57 – 1.40). At two 
years, 5 trials on sirolumus-encoated stents were available, for which the RR for cardiac mortality 
was 0.71 (95% CI: 0.29 – 1.74). Seven trials reported on the overall mortality for paclitaxel-coated 
stents, which found an RR of 0.78 (95% CI: 0.41 – 1.49) for paclitaxel-coated stents. The combined 
EUnetHTA WP4 - Core HTA on drug eluting stents (DES) 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
51 
RR for cardiac mortality was 0.76 (0.45 – 1.28). At three years, 4 trials reporting on overall 
mortality for sirolimus-coated stents detected an RR of 1.14 (95% CI: 0.57 – 2.20), compared to the 
RR of 0.86 (95% CI: 0.44 – 1.69) for paclitaxel-coated stents, based on 5 trials. The combined RR 
for cardiac mortality was 0.99 (0.62 – 1.59). All results were highly homogeneous (I2 = 0). There 
was no difference between DES and BMS in either comparison nor was there a difference between 
the two drugs.  
What is the effect of the intervention on the mortality due to other causes than 
the target disease at one, two and three years? 
In patients with coronary heart disease CHD, does the insertion of DES 
compared to BMS reduce non-cardiac mortality at one, two and three years? 
Results 
The second sub-analysis on mortality looked at non-cardiac mortality. At one year, 8 studies were 
available for the comparison with sirolimus. The RR for non-cardiac mortality for sirolimus-coated 
stents was 1.06 (95% CI: 0.49 – 2.30). Ten studies were available for the comparison with 
paclitaxel-coated stents. Here, the RR for non-cardiac mortality for paclitaxel-coated stents was 
1.16 (95% CI: 0.59 – 2.28). The combined RR for non-cardiac mortality was 1.11 (0.67 – 1.85). At 
two years, 5 trials on sirolimus-encoated stents were available. Here, the pooled analysis showed a 
trend for an increased non-cardiac mortality (RR 2.13 (95% CI: 0.94 – 4.82) which was not seen in 
the 7 trials on paclitaxel-coated stents (RR 1.22; (95% CI: 0.61 – 2.45). The combined RR for non-
cardiac mortality was 1.54 (0.91 – 2.62). At three years, the trend for increased non-cardiac 
mortality for the 4 trials on sirolimus-coated stents remained 1.95 (95% CI: 0.92 – 4.12), while - 
based on 5 trials - no such increase was observed in paclitaxel-coated stents (RR 1.12 (95% CI: 0.65 
– 1.96)). The combined RR for non-cardiac mortality was 1.37 (0.87 – 2.13). Again, all results were 
highly homogeneous (I
2 
= 0) 
Morbidity  
In patients with CHD, does the insertion of DES compared to BMS modify the 
overall severity and frequency of cardiac specific symptoms (angina)? 
Comment 
The studies did not report the impact of DES compared to BMS on overall severity and frequency 
of angina symptoms – independent of the target lesion. Although some studies (e.g. Weisz et al. 
JACC 2006) reported ―clinically driven repeat percutaneous intervention of the target lesion‖, 
thereby taking into account clinical symptoms of the patients to initiate the actual study end point  
―repeat percutaneous intervention of the target lesion‖, those results do not report the overall 
benefit on symptoms to the patients. 
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In patients with CHD, does the insertion of DES compared to BMS modify the 
results of tests (often surrogate measures such as ECHO)?  
Comment 
Studies reported test results such as ECHO to describe left ventricular function in their baseline 
variables, but they did not report the impact of DES compared with BMS on those tests.  
How does the intervention modify the progression of disease? 
The core model addresses 4 aspects of progression of disease: recurrence of the target stenosis; 
clinical progression of disease (such as non-fatal myocardial infarction); impact on drug treatment 
for cardiac disease; impact of cardiac specific re-treatment such as CABG. The studies did not 
provide data for all issues that the core model had identified as clinically relavant.  
In patients with CHD, does the insertion of DES compared to BMS improve the 
recurrence of the target stenosis as assessed by re-vascularisation of the target 
vessel at one, two and three years? 
Results 
The first analysis on progression of disease looked at recurrence of target stenosis, which is 
commonly used as endpoint in the DES-trials. At one year, 8 studies were available for the 
comparison with sirolimus,, which showed a significant reduction in target vessel revascularization 
(TVR), RR 0.30 (95% CI: 0.15 – 0.59). A similar but less pronounced effect was observed in the 10 
studies comparing paclitaxel-coated stents. Here, the RR was 0.56 (95% CI: 0.43 – 0.73) for 
paclitaxel-coated stents when compared to BMS. The combined RR for TVR was 0.46 (0.34 – 
0.61). At two years, the reduction in TVR was maintained in the 5 trials on sirolimus-coated stents 
RR 0.28 (95% CI: 0.14 – 0.56), compared to the 7 trials on paclitaxel-coated stents which showed a 
decrease in TVR of RR 0.53 (95% CI: 0.42 – 0.65). The combined RR for TVR was 0.43 (0.32 – 
0.59). At three years, the impact of sirolimus-coated stents in TVR was sustained in the 4 trials, the 
RR was 0.32 (95% CI: 0.23 – 0.44), as was the reduction of TVR observed in paclitaxel-coated 
stents (RR 0.47 (95% CI: 0.32 – 0.70) based on 5 trials. The combined RR for TVR was 0.39 (0.29 
– 0.52). 
Overall, there was a significant improvement in TVR for both, sirolimus-coated and paclitaxel-
coated stents. At year 1 and 2, the effect was more pronounced for sirolimus-coated stents, but here, 
the estimates were highly heterogeneous (I
2
 = 85 and I
2
 = 72 respectively) while they were less 
heterogeneous for the paclitaxel-coated stents (I
2
 = 49 and I
2
 = 1 respectively). The difference in 
treatment effect between the different DES subsided at year 3. 
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Figure 2: Drug Eluting Stents and target vessel revascularisation 
at 1, 2 and 3 years
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Risk Ratio (95% CI), 
Heterogeneity (P), I2 [95% UI], % 
0.30 (0.15-0.59), P<0.001, I2=85 [72-92]
0.56 (0.43-0.73), P=0.04, I2=49 [0-75]
0.28 (0.14-0.56), P=0.01, I2=72 [30-89]
0.53 (0.42-0.65), P=0.4, I2=1 [0-71]
0.32 (0.23-0.44), P=0.3, I2=17 [0-87]
0.47 (0.32-0.70), P=0.07, I2=54 [0-83]
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In patients with CHD, does the insertion of DES compared to BMS slow down 
the clinical progression of the disease, such as the occurrence of non-fatal 
myocardial infarction?  
Results 
The second analysis on progression of disease looked at non-fatal myocardial infarction. At one 
year, 8 studies were available for the comparison with sirolimus, which did not show a significant 
reduction in non-fatal MI; RR 0.69 (95% CI: 0.44 – 1.08), neither did the pooled estimate on the 10 
studies comparing paclitaxel-coated stents. Here, the RR was 0.96 (95% CI: 0.73 – 1.26) when 
compared to BMS. The combined RR for non-fatal myocardial infarction was 0.87 (0.69 – 1.08). 
Neither at two years, nor at three years did either stent reduce the occurrence of non-fatal MI (RR  
for sirolimus-coated stents 0.97 (95% CI: 0.62 – 1.51) and RR for paclitaxel-coated stents 1.04 
(95% CI: 0.73 – 1.47); combined RR 1.01 (0.77 – 1.33) at 2 years; RR for sirolimus-coated stents 
0.90 (95% CI: 0.60 – 1.37) and RR for paclitaxel-coated stents 0.99 (95% CI: 0.67 – 1.46); 
combined RR 0.95 (0.73 – 1.24) at 3 years). All pooled estimates were highly homogeneous (range 
for I
2 
(0 to 18). 
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Figure 3: Drug Eluting Stents and non-fatal myocardial infarction 
at 1, 2 and 3 years
.5 1 2 10
Paclitaxel  n=5
Sirolimus  n=4
3 years  
Paclitaxel n=7
Sirolimus  n=5
2 years 
Paclitaxel n=10
Sirolimus  n=8
1 year 
Nonfatal Myocardial Infarction
Risk Ratio (95% CI), 
Heterogeneity (P), I2 [95% UI], % 
0.69 (0.44-1.08), P=0.3, I2=18 [0-61]
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0.97 (0.62-1.51), P=0.7, I2=0 [0-79]
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0.99 (0.67-1.46), P=0.3, I2=16 [0-87]
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In patients with CHD, does the insertion of DES compared to BMS lower 
cardiac specific drug treatment?  
Comment 
The third issue on progression of disease looked at the impact of DES on cardiac specific drug 
treatment compared to BMS. None of the studies we reviewed addressed this question.  
In patients with CHD, does the insertion of DES compared to BMS lower 
cardiac specific re-treatment, such as CABG?  
Results 
The forth analysis on progression of disease looked at the effect of CABG-operations. The estimate 
on CABG operations was based on the same number of studies as in the previous comparisons. The 
pooled estimate showed that the impact was similar across the two different types of stents and 
across the observation period of three years. The relative risk ranged between 0.55 and 0.63 and the 
estimates are highly homogeneous (I
2 
= 0). Despite similar point estimates, the results turned only 
significant for all paclitaxel trials but remained non-significant for the sirolimus trials. This lack of 
significance, however, is most likely due to a lack of power rather than a non-existing effect.  
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In patients with CHD, does the insertion of DES compared to BMS retard or 
even prevent the recurrence of cardiac specific symptoms (angina)? 
Comment 
Some studies (e.g. Weisz JACC 2006) reported on ―clinically driven‖ repeat percutaneous 
intervention of the target lesion, where patient symptoms was one parameter among functional 
invasive or non-invasive tests. None of the studies reported patient symptoms as a separate 
outcome.  
In patients with CHD, does the insertion of DES compared to BMS modify the 
need for other treatment? 
Comment 
In the context of the core HTA on DES, this issue has already been addressed by the question about 
the progression of disease where the need for PCI or other interventions were the hard endpoints for 
progression of disease (see above). 
Figure 4: Drug Eluting Stents and CABG at 1, 2 and 3 years
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In patients with CHD, does the insertion of DES compared to BMS lower the 
need for hospitalization for CHD? 
Comment 
The studies reported indirectly the need for hospitalization in the context of repeated PCI or CABG, 
but they did not report on hospitalization for coronary heart disease unrelated to cardiac re-
interventions (e.g. admission for heart failure) or overall hospitalization.   
Function / Health Related Quality of Life  
In patients with CHD, does the insertion of DES compared to BMS leads to 
global improvement of function?  
Comment 
None of the studies assessed whether DES compared to BMS generated an impact on global 
improvement of function or quality of life.  
In patients with CHD, does the insertion of DES compared to BMS improve 
health-related quality of life? 
Comment 
None of the studies investigated whether DES compared to BMS affected health related quality of 
life.  
In patients with CHD, does the insertion of DES compared to BMS improve 
cardiac specific quality of life? 
Comment 
None of the studies reported whether DES compared to BMS affected cardiac specific quality of 
life.  
In patients with CHD, does the insertion of DES compared to BMS affect return 
to work?  
Comment 
None of the studies investigated whether DES compared to BMS affected the patients‘ general 
living conditions, such as return to work.  
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In patients with CHD, does the insertion of DES compared to BMS affect return 
to previous living conditions? 
Comment 
None of the studies investigated whether DES compared to BMS affected the patients‘ general 
living conditions,  
 
In patients with CHD, does the insertion of DES compared to BMS affect 
activities of daily living? 
Comment 
None of the studies reported whether DES compared to BMS affected the patients‘ activity of daily 
living.  
Patient satisfaction  
Do patients with CHD feel that the insertion of DES compared to BMS was 
worth the effort, the anxiety and pain?  
Comment 
None of the studies reported about the patients' perspective whether DES compared to BMS made a 
difference on the patient‘s emotional wellbeing.  
Would patients with CHD who had DES rather than BMS inserted, be willing to 
select DES (rather than BMS) again? 
Comment 
None of the studies reported data on patients‘ perspective.  
Discussion 
In our work on the core model in the domain of effectiveness, we found four generic topics 
(mortality, morbidity, function/QoL, patient satisfaction) which were sufficiently general to be 
applied across a broad range of interventions. We further subdivided the four generic topics to 
issues. We were able to reach consensus on the importance and transferability of issues relevant to 
this particular disease-technology pair. We conclude that the method of starting with the research 
question according to PICO (see core model on effectiveness), creating a generic check list of 
potentially relevant issues based on generic topics and selecting those with critical importance and 
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determining importance and transferability of these issues in the context of drug eluting stents is 
feasible.  
 
In this assessment about the impact of DES compared to BMS in a broad range of outcome areas 
(―topics‖ and ―issues‖) there is a time trend over an observation period of 3 years towards higher 
overall mortality when using drug eluted stents compared to BMS. This increased risk is more 
visible for sirolimus-coated stents compared to paclitaxel-coated stents. However, the estimates lack 
precision, i.e. the confidence intervals are broad and include the possibility of no difference 
between intervention and control.  
 
Separate analyses for cardiac mortality and non-cardiac mortality reveal that this increase in 
mortality is mainly driven by the significant increase in non-cardiac mortality with sirolimus-coated 
stents at year 2 and 3 that has not been observed for paclitaxel-coated stents.  
 
Looking at the secondary outcomes, revascularization rate is significantly lower in patients with 
DES compared to BMS and sirolimus seems to have overall larger benefit compared to paclitaxel 
stents, although the difference has never been significant and is moving closer in the third year of 
observation. However, these estimates show a high degree of unexplained heterogeneity.  
 
Re-vascularisation by CABG is homogeneously reduced by 45% to 55%, independent of the kind of 
stent. However, only the comparisons using paclitaxel turn significant while the confidence 
intervals for sirolimus consistently cross 1 and thereby remain non-significant. Nevertheless, we 
believe that the likely cause for the missing significance is lack of power rather than a non-existing 
effect. Neither of the DES had a statistically significant impact on a reduction of non-fatal 
myocardial infarction across the three years. 
 
Limitations: We did not detect any studies with those morbidity outcomes that we had pre-specified 
as important such as impact on severity and frequency of symptoms (or their recurrence), impact on 
test findings, or the impact on the conservative cardiac management, i.e. treatment with cardiac 
specific drugs.  
Furthermore, the studies we included did not cover any aspects of function and quality of life or 
patient satisfaction. However, we regard it as unlikely that such studies will be performed for the 
comparison DES versus BMS unless complaints or case reports raise a suspicion that the type of 
stent (rather than alternative approaches such as stenting versus CABG or medical treatment) could 
make a difference to function and quality of life or patient satisfaction. 
Long-term efficacy and safety: recent data and (preliminary) conclusions 
In recent months new data on long-term efficacy and safety of DES vs. BMS became available. 
These were not yet included in this draft chapter on efficacy and safety of the core HTA but will be 
included in the next version. This new information is summarized below. 
 
Important potential side-effects, some of which typically related to the action of antiproliferative 
agents, have drawn particular attention of clinicians when using DES. In some cases, endovascular 
healing was completely inhibited, preventing endothelialisation of the stent and sometimes inducing 
incomplete apposition of the stent angainst the vessel wall. Very late stent thrombosis (LST) has 
been reported and constitutes a major problem because it can lead to increased mortality.
1
 Unlike 
restenosis, thrombosis is a rare but potentially life-threatening complication of coronary stents. The 
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clinical consequences are often catastrophic, including short-term mortality rates of up to 25 % and 
major myocardial infarction in 60 % to 70 % of cases.
2
 Stent thrombosis usually occurs before 
reendothelialization has been completed. It rarely occurs beyond 2 to 4 weeks for BMS 
3
 but is a 
matter of concern in DES because of the delayed endothelialization. It is likely that occurrence of 
LST is related to a delayed healing of the injury caused by the mechanical dilatation of the coronary 
vessel and a continued presence of a foreign body predisposes to thrombus formation. This 
thrombotic tendency can be more pronounced in complex coronary lesions, but also in patients who 
stopped one or both of the antiplatelet drugs that were instituted following the DES implant.  
LST and mortality have been the subject of long-term follow-up reports of previous trials and in 
real-world registries of unselected patient groups. Premature antiplatelet therapy discontinuation has 
been shown to be one of several risk factors for LST. The early RCTs with follow-up often limited 
to 1 year, suggested that thrombosis following DES placement is not more frequent than following 
BMS at up to one year after the procedure. But, in an observational study within the BASKET trial, 
Pfisterer et al noticed that the discontinuation of clopidogrel six months after DES implant later on 
was followed by a doubling of documented LST in DES (2.6 %) vs. BMS (1.3 %).
4
 In a prospective 
observational study, with follow-up at 9 months after DES implant, stent thrombosis occurred in 29 
of 2229 patients (1.3%).
5
 LST occurred in 5 of 17 patients (29%) who prematurely discontinued 
dual antiplatelet therapy. Other independent predictors of stent thrombosis were renal failure, 
bifurcation lesions, diabetes and a low ejection fraction.  
 
At the Barcelona meeting of the World Congress of Cardiology in Sep 2006, two separate meta-
analyses caused great concern. Those studies have since been published. 
6, 7
 Nordmann et al. 
conducted a systematic review on mortality outcomes in randomized trials that compared DES with 
BMS.
6
 They not only included peer-reviewed publications but also incorporated unpublished results 
from long-term follow-up of existing studies presented at scientific meetings and follow-up 
information obtained directly from the principal investigators and manufacturers. They concluded 
that DES implantation does not reduce total mortality when compared with BMS. In addition to 
cardiac adverse effects, the Nordmann study also hinted at the possibility of an increase in non-
cardiac late mortality with sirolimus eluting stents.
6
 In the meta-analysis by Camenzind et al. a 
small but significant increase in the risk of death or Q-wave MI was found throughout a period of 3 
years after implantation of a sirolimus eluting stent. 
In reaction to those alarming reports from academic and clinical researchers, conflicting data from 
meta analyses and registries, the FDA issued a statement on Sept 14, 2006 warning that data 
available at that time were not sufficient to fully characterize the mechanisms, risk, and incidence of 
drug eluting stent associated thrombosis.
8
 In December 2006 the FDA convened a meeting with the 
various stakeholders to discuss efficacy and safety issues.
9
 As a result of this meeting an updated 
statement was issued by the FDA, and new criteria for the definition of stent thrombosis were 
agreed as proposed by the Academic Research Consortium (ARC).
10, 11
 Other controversies 
included the off-label use of drug eluting stents, i.e. use in categories of patients that were not 
included in the trials. Since in the US it is estimated that more than 60 % of drug eluting stents are 
used off-label,
12
 which is an important aspect. 
 
More importantly even, meta-analyses of follow-up up to 4 years, and based on individual patient 
data from the original pivotal trials finally became available in March 2007.
13, 10, 11, 14
. From an 
effectiveness point of view, these meta-analyses confirm earlier observations that DES are 
successful in reducing target vessel revascularisation rates, mainly in the first year of follow-up but 
with a sustained difference up to 4 years later, without however reducing the rates of MI or cardiac 
death. Those meta-analyses also indicate that the cumulative incidence of stent thrombosis at 4 
years does not differ significantly between patients with DES and those with BMS, but also that the 
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studies were not powered to detect even moderate clinically significant differences in the true rate 
of stent thrombosis. 
12
 Time trends however seem to indicate that more events occur later after DES 
implantation, possibly related to the timing of discontinuation of dual-antiplatelet therapy.  
Off-label use is more difficult to assess, since those reports rely on non-randomised observational 
and registry data.
15-17
 
 
Additionally, there is uncertainty about the ideal duration of dual antiplatelet therapy, but premature 
discontinuation of such therapy appears to be associated with an increased risk of stent thrombosis. 
Patients should therefore also be evaluated for bleeding risk before DES-stenting in order to assess 
whether long term thienopyridine treatment (at least 12 months) and lifelong aspirin treatment can 
be envisaged. Patients who cannot comply with extended dual antiplatelet therapy or who have 
planned procedures requiring early discontinuation of antiplatelet therapy may therefore not be 
good candidates for drug eluting stents.
18
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Assessment elements table 
ID Domain Topic Issue Relevance in 
the context of 
DES 
Yes / No 
Research question(s) in the context of DES 
or 
Comment (if regarded as a not relevant 
issue in this context) 
Importance 
3=critical 
2=important 
1=optional 
Transferability 
3=complete 
2=partially 
1=not 
        
D0001 Effectiveness Mortality What is the effect of the intervention on overall mortality? Yes In patients with coronary heart disease CHD, 
does the insertion of DES compared to BMS 
reduce overall mortality? 
3 3 
D0002 Effectiveness Mortality What is the effect of the intervention on the mortality caused 
by the target disease? 
Yes In patients with coronary heart disease CHD, 
does the insertion of DES compared to BMS 
reduce cardiac  mortality? 
3 3 
D0003 Effectiveness Mortality What is the effect of the intervention on the mortality due to 
other causes than the target disease? 
Yes In patients with coronary heart disease CHD, 
does the insertion of DES compared to BMS 
reduce non-cardiac mortality? 
2 3 
D0004 Effectiveness Mortality What is the mortality related to the intervention studied? Yes In patients with CHD, does the insertion of 
DES compared to BMS increase intervention-
related mortality, e.g. early stent thrombosis or 
mortality in immediate temporal connection 
with the catheterisation [related to safety]? 
3 3 
D0005 Effectiveness Morbidity 
 
How does the intervention modify the severity and 
frequency of symptoms and findings? 
Yes In patients with CHD, does the insertion of 
DES compared to BMS modify the severity 
and frequency of cardiac specific symptoms 
(angina)? 
3 2 
D0005 Effectiveness Morbidity 
 
How does the intervention modify the severity of  symptoms 
and findings? 
Yes In patients with CHD, does the insertion of 
DES compared to BMS modify the results of 
tests (often surrogate measures such as ECG-
changes or ECHO)?  
2 3 
D0006 Effectiveness Morbidity 
 
How does the intervention modify the progression of 
disease? 
Yes In patients with CHD, does the insertion of 
DES compared to BMS improve the 
recurrence of the target stenosis ? 
3 3 
D0006 Effectiveness Morbidity 
 
How does the intervention modify the progression of 
disease? 
Yes In patients with CHD, does the insertion of 
DES compared to BMS slow down the clinical 
progression of the disease?  
3 3 
D0006 Effectiveness Morbidity 
 
How does the intervention modify the progression of 
disease? 
Yes In patients with CHD, does the insertion of 
DES compared to BMS lower cardiac specific 
drug treatment?  
2 2 
D0006 Effectiveness Morbidity 
 
How does the intervention modify the progression of 
disease? 
Yes In patients with CHD, does the insertion of 
DES compared to BMS lower cardiac specific 
re-treatment, such as PCI or CABG?  
3 2 
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D0007 Effectiveness Morbidity 
 
How does the intervention modify the recurrence of 
symptoms and findings? 
Yes In patients with CHD, does the insertion of 
DES compared to BMS retard or even prevent 
the recurrence of cardiac specific symptoms 
(angina)? 
3 2 
D0008 Effectiveness Morbidity 
 
What is the morbidity related to the intervention? Yes In patients with CHD, does the insertion of 
DES compared to BMS reduce complications 
related to the intervention [safety]? 
3 3 
D0009 Effectiveness Morbidity 
 
What other treatments do patients need? Yes In patients with CHD, does the insertion of 
DES compared to BMS modify the need for 
other treatment? 
  
D0010 Effectiveness Morbidity 
 
How does the intervention modify the need for 
hospitalization? 
Yes In patients with CHD, does the insertion of 
DES compared to BMS lower the need for 
hospitalization for CHD? 
2 2 
D0011 Effectiveness Function / HRQL 
(Health-related quality 
of life)  
What is the effect of the intervention on global improvement 
of function?  
Yes In patients with CHD, does the insertion of 
DES compared to BMS leads to global 
improvement of function ?  
3 2 
D0012 Effectiveness Function / HRQL  
 
What is the effect of the intervention on health-related 
quality of life?  
Yes In patients with CHD, does the insertion of 
DES compared to BMS improve health-related 
quality of life?  
3 3 
D0013 Effectiveness Function / HRQL  
 
What is the effect of the intervention on disease specific 
quality of life? 
Yes In patients with CHD, does the insertion of 
DES compared to BMS improve cardiac 
specific quality of life? 
3 2 
D0014 Effectiveness Function / HRQL  
 
What is the effect of the intervention on return to work?  Yes In patients with CHD, does the insertion of 
DES compared to BMS affect return to work?  
2 2 
D0015 Effectiveness Function / HRQL  
 
What is the effect of the intervention on return to previous 
living conditions? 
Yes In patients with CHD, does the insertion of 
DES compared to BMS affect return to 
previous living conditions 
2 2 
D0016 Effectiveness Function / HRQL  
 
How does the intervention affect activities of daily living? Yes In patients with CHD, does the insertion of 
DES compared to BMS affect activities of daily 
living?  
2 3 
D0017 Effectiveness Patient satisfaction Was the intervention worth it? Yes Do patients with CHD feel that the insertion of 
DES compared to BMS was worth the effort, 
the anxiety and pain?  
3 2 
D0018 Effectiveness Patient satisfaction Would the patient be willing to have the intervention again? Yes Would patients with CHD who had DES rather 
than BMS inserted, be willing to select DES 
(rather than BMS) again ? 
3 2 
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Appendix A: HTA-reports, systematic reviews and meta-analyses 
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Costs and Economic Evaluation  
Pirjo Räsänen, Kersti Meiesaar, Monika Reesev, 
Irina Cleemput, Henrik Hauschildt Juhl and Harri Sintonen 
Introduction 
It has been shown that drug-eluting stents (DES) decrease angiographic restenosis rates and the 
subsequent need for repeat revascularisation procedures in the short to medium term as compared to 
BMS (Brophy, 2005). However DES is more costly than BMS. At the moment there is inconsistent 
evidence of whether DES would be a cost-effective option compared to BMS. 
 
In the economic evaluation part of this Core HTA, our aim is to assess the cost-effectiveness of 
DES as compared with BMS in patients with coronary heart disease who undergo percutaneous 
coronary intervention (PCI).  
 
The costs and economic evaluation domain consists of five topics: cost-effectiveness, resource 
utilisation, unit costs, indirect costs and outcomes/consequences. In each topic there are one or two 
issues, altogether six issues (Appendix 1). 
Methodology  
We have chosen the following framing of the economic analysis: 
 
Target population Patient with coronary artery disease 
 
Intervention Drug-eluting stents (DES) used during a percutaneous 
coronary intervention (PCI). 
 
Comparators Bare metal stents (BMS) used during a percutaneous coronary 
intervention (PCI). 
 
Outcomes Quality-adjusted life years (QALY) 
 
Time frame Two years from date of procedure 
 
Perspective Consequence and costs are assessed from the perspective of a 
hospital. 
 
To compare DES with BMS, the data have to be taken from several sources. In the previous work of 
FinOHTA (Kuukasjärvi et al. 2007), a systematic review of literature was conducted using 
electronic databases (Cochrane Database of Systematic Reviews; DARE, HTA, EED (NHS CRD); 
MEDLINE® In-Process, Other Non-Indexed Citations, MEDLINE®) from January 2004 to 
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January 2006. The following MeSH terms were used: Stents, Paclitaxel, Sirolimus, Costs and cost 
analysis, Stents/economics. References of the papers identified were checked. The review included 
economic evaluations alongside randomised controlled trials (RCT) or model-based cost-
effectiveness analyses comparing DES to BMS in patients with coronary artery disease. The 
methodological quality of the papers was assessed using Drummond's criteria.The systematic 
review identified 13 good quality economic evaluations that compared the DES to BMS. 
 
The perspective of the analysis is that of a single health care provider (hospital). A decision analysis 
model was built to evaluate the cost-utility of DES compared to BMS.  The model was developed 
using DATA software (TreeAge version Pro 2006). The model compares the costs and outcomes in 
terms of QALYs within a time horizon of two years. The probability of avoiding a reintervention is 
based on meta-analyses made in Norway in 2004 (NOKC 2004 ), and the risk of reintervention is 
based on the results by Brophy et al. (2005).  
 
A simplified presentation of the decision model is shown in Figure 1.  
 
 
Figure 1. Simplified decision tree: comparison of DES and BMS. 
The two initial branches of the decision tree represent a choice between BMS and DES for patients 
undergoing a PCI.  If the first stenting does not relieve the symptoms, then the treatment options are 
either a repeat intervention with the same type of stent, or coronary artery bypass graft surgery 
(CABG). A maximum of three revascularisations of both treatment scenarios are possible. The 
clinical pathway was confirmed through discussions with a cardiologist and a thoracic surgeon. The 
model was designed so that different countries can enter their own parameters. 
 
The cost data are based on direct hospital costs from the Cardiac Centre of Tampere University 
Hospital (in Finland) and are presented in euros and calculated for the year 2006. The outcomes 
include expected quality-adjusted life years (QALYs) during two years post initial PCI. The QALY 
calculation is based on earlier work on PCI and CABG patients' HRQoL (Kattainen et al. 2005). 
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The used HRQoL instrument was the generic 15D (Sintonen 2001; available at http//www.15D-
instrument.net/15D). No discounting of effects and costs was carried out, since the time horizon is 
relatively short. 
 
To account for uncertainty around the model input parameter values, one-way sensitivity analyses 
were carried out for costs and utility values. For further exploration of uncertainty probabilistic 
sensitivity analysis was used. The results are given using incremental cost-effectiveness ratios 
(ICER), mean incremental costs and effects, a cost-effectiveness plane, and cost-effectiveness 
acceptability curve. 
Assessment elements  
Resource utilisation 
What types of resources are used when delivering DES or BMS? 
The used resources and costs in this model are based on a price list from the Cardiac Centre of 
Tampere University Hospital. The relevant resources include: PCI, equipment used during the 
operation (including the stent) and length of stay in the hospital (overhead, staff and medical costs). 
Comment 
Due to perspective of analysis only resources used in hospital were considered. 
What amounts of resources are used when delivering DES or BMS? 
Results 
Following the model seven different resource use combinations are possible in both arms (Table 1). 
 
Table 1. Costs used in the decision tree model. 
 
DES BMS 
Amount Costs (€) Amount Costs (€) 
DES x1 4310 BMS x1 3260 
DES x2 8620 BMS x2 6520 
DES x3 12930 BMS x3 9780 
DES x4 17240 BMS x4 13040 
DES x1 + CABG 13434 BMS x1 + CABG 12384 
DES x2 + CABG 17744 BMS x2 + CABG 15644 
DES x3 + CABG 22054 BMS x3 + CABG 18904 
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Comment 
When looking at a single intervention, there are few differences in resource use between DES and 
BMS. In this draft, the data came from Finland; it is important to keep in mind that resource use 
may differ between countries. 
 
The results are based on the decision tree model, not on primary study. Therefore certain items of 
resources use were not available. 
Unit costs 
What are the unit costs of resources used when delivering DES or BMS? 
Results 
The average unit costs of DES and BMS are based on data from the Cardiac Centre of Tampere 
University Hospital for the year 2006 and are presented in euros.  
- BMS €3260 (including PCI, all needed materials and maximum two days in hospital) 
- DES €4310 (including PCI, all needed materials and maximum two days in hospital) 
- CABG €9124 (including operation, six days in hospital two days of them in intensive care unit) 
Comment 
Costs can vary markedly between different countries and are thus not transferable from one country 
to another. The ways of collecting cost information may also vary between countries: calculating all 
unit costs separately, using standard costs per procedure, or using diagnosis-related group (DRG) 
payments as the cost basis. In this analysis costs of hospital stay include overhead, staff and medical 
costs. There are differences in antithrombotic therapy after the stenting, which have not been 
considered in this study. 
Indirect costs 
What is the impact of DES and BMS on indirect costs? 
Comment 
We have chosen not to address indirect costs in this draft. It can be argued that there are no 
differences in indirect costs between DES and BMS. One could argue that the intervention with the 
most frequent reinterventions will have an impact on indirect costs. We need more information on 
the number of days in hospital and recovery at home to be able to calculate these costs. 
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Outcomes/consequences 
What are the incremental health-related quality of life effects of DES relative to 
BMS? 
Results 
The HRQoL utility scores used to estimate QALYs were measured by the 15D instrument 
(Kattainen et al. 2005). The utility scores were 0.730 (95 % CI 0.716 - 0.744) for situation before 
PCI and 0.824 (95 % CI 0.806 - 0.842) 6 months after. In the CABG group the HRQoL scores were 
0.752 (95 % CI 0.743 - 0.761) for situation before CABG and 0.858 (95 % CI 0.844 - 0.872) 6 
months after, respectively. In this decision tree model the utility scores were assumed to be the 
same in both branches. QALYs gained in different treatments options are presented in Table 3.   
The mean incremental QALYgained by DES was 0.00582 during the two-year time horizon. The 
probabilities of avoiding revacularisation were based on meta-analysis (NOCK 2004). 
 
Table 3. The QALY values 
 
Number of interventions QALYs 
DES or BMS x1 1,648 
DES or BMS x2 1,597 
DES or BMS x3 1,585 
DES or BMS x4 1,566 
DES or BMS x1 + CABG 1,577 
DES or BMS x2 + CABG 1,559 
DES or BMS x3 + CABG 1,550 
 
Comment 
Outcomes depend on the hospital environment, experience of the surgical team, and also selection 
of patients. In this draft, no comparison to a conservative treatment option was done, neither 
treatment effects of the high risk patients were evaluated. 
Incremental cost-effectiveness of the technology  
What is the incremental cost-effectiveness ratio for DES versus BMS? 
Results 
The ICER of DES versus BMS is about €100 000 per QALY. ICER for avoided revascularisation 
was approximately 4800 euros. Table 4 shows the costs and QALYs gained in different strategies 
based on the decision tree model. 
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Table 4. The cost-effectiveness results of DES vs. BMS 
 
Strategy Costs 
(€) 
Incremental costs QALY Incremental QALY C/E (€/QALY) ICER 
BMS 4003,3  1.63942  2442  
DES 4578,7 575,3 1.64524 0.00582 2783 98827 
 
To account for uncertainty both one-way and probabilistic sensitivity analyses were carried out. In 
the one-way sensitivity analyses the results turned out to be robust to changes in the parameter 
values except to changes in the cost difference between DES and BMS.  
 
In probabilistic sensitivity analysis of base case DES was almost in all simulated cases both more 
effective and costly (Quadrant II) and only in few cases less costly and more effective (Quadrant 
IV) (Figure 2).  
 
Figure 2. Cost-effectiveness plane.  
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At the threshold level of 50 000 euros per QALY gained the probability of DES (base case) being 
acceptable is 13 %, where the difference between DES and BMS probabilities of repeated 
intervention was 0.12 in favour of DES. When the difference was assumed to be 0.188 (DES high) 
and 0.062 (DES low), the probability of DES being acceptable was 71.7 % and 0.4 %, respectively. 
(Figure 3) 
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Figure 3. Cost-effectiveness acceptability curve for DES. 
 
Discussion 
It is important to keep in mind that in this analysis the cost and HRQoL values are based on Finnish 
data and therefore may not be directly transferable to other countries. However, the model 
constructed here can well be used by changing the input data to reflect the situation elsewhere. 
 
Due to lack of long-term HRQoL data, the model does not examine the cost-utility beyond two 
years.  As DES is quite a new technology, a long-term analysis would require more follow-up data 
on both effectiveness and costs. The strength of this economic analysis is that the HRQoL data were 
available from a real world patient population.  
 
The results of the systematic literature review showed that there are no concensus about cost-
effectiveness of DES vs. BMS. In two of included articles based on RCTs DES was found cost-
effective compared to BMS (Cohen 2004, van Hout 2005). In 6 studies it was concluded that DES 
might probably be a cost-effective strategy in some circumstances, but not as a single strategy 
(Bowen 2005, Brophy 2005, Kaiser 2005, Mittman 2005, MSAC 2005, Shivre 2005). Four studies 
concluded that DES is not cost-effective compared to BMS (Bagust 2005, Hill 2004, NOCK 2004, 
Oliva 2004). One study did not draw a clear conclusion (Kong 2004). The results of our simplified 
model indicate that the QALY gain is small and the incremental cost per extra QALY is high.  
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Assessment elements table 
ID Domain Topic Issue Relevance in the 
context of DES 
Yes/No 
Research question(s) in the context of DES 
or 
Comment (if regarded as a not relevant issue in this context) 
      
E0001 
Costs and economic 
evaluation 
Resource utilization  What types of resources are used when delivering the 
assessed technology and its comparators?  
 
yes What types of resources are used when delivering DES and 
BMS?  
 
E0002 
Costs and economic 
evaluation 
Resource utilization What amounts of resources are used when delivering the 
assessed technology and its comparators? 
yes What amounts of resources are used when delivering DES or 
BMS? 
 
E0003 
Costs and economic 
evaluation 
Unit costs What are the unit costs of the resources used when delivering 
the assessed technology and its comparators? 
yes What are the unit costs of resources used when delivering DES 
and BMS? 
E0004 
Costs and economic 
evaluation 
Indirect Costs What is the impact of the technology on indirect costs? 
 
No What is the impact of DES and BMS on indirect costs? 
E0005 
Costs and economic 
evaluation 
Outcomes/consequences What are the incremental effects of the technology relative to its 
comparator(s)? 
Yes What are the incremental health-related quality-of-life effects of 
DES relative to  BMS? 
E0006 
Costs and economic 
evaluation 
Incremental cost-effectiveness of the 
technology 
What is the incremental cost-effectiveness ratio? yes What is the incremental cost-effectiveness ratio for DES versus 
BMS? 
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Ethical analysis 
Dagmar Lühmann, Ilona Autti-Rämö, Björn Hofmann,  
Samuli Saarni, Marcial Garrido-Velasco, Marco Marchetti 
Introduction 
Ethical analysis within an HTA aims at analysing the moral questions raised by the technology 
itself and by the consequences of implementing / not implementing a health technology as well as 
ethical issues that are inherent in the HTA process. In principle, this maybe accomplished by 
systematically eliciting (by primary research or through literature and document analysis) values 
which are placed on a technology and / or its implementation by different stakeholders. These 
different values are then analysed for congruency and compatibility with each other as well as with 
prevalent morals in the respective societies. The results of the analyses should be integrated into the 
overall conclusions of the HTA report in such a way that they are helpful for decision-making. 
Ideally, ethical analysis should not be a „one session― task, but rather accompany and advise the 
whole HTA process from prioritising topics, defining research questions, choosing methodology to 
summarizing results and drawing conclusions.  
 
In some instances, for practical, resource or conceptual reasons this is not feasible (- for example in 
the ongoing assessment of drug eluting stents -). For these cases, in the HTA Core model a 
catalogue of questions, based primarily on the work of Hofmann (2005), was suggested that guides 
value analysis referring to the technology and its implementation as well as discussing compatibility 
and congruency with prevalent societal moral values. 
 
Methods 
The description of the stakeholder perspectives and the completion of the assessment elements are 
performed by using information from the ongoing assessment as well as data from the published 
literature. For time and resource reasons there was no opportunity to elicit primary information (e. 
g. patients perspectives on outcomes used in clinical trials). 
Literature searches 
A four part literature search was applied: 
1. Search for existing HTA reports in the CRD Databases: 28 references to relevant HTA reports 
were retrieved. Seven were not available in English or German language, two contained no 
comparison of DES and BMS, six were publications of protocols and two were not accessible. 
Altogether there were ten fulltext documents available in English language (see reference list). 
2. Database searches for articles on ―ethical‖ topics relating to drug eluting stents. The searches 
were performed in Pubmed as well as in two databases specified for Bioethics literature (BELIT 
and ETHMED) 
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a) a search strategy for Pubmed was constructed using a search module for ―ethics‖ literature as 
suggested by Droste et al., 2003 and combining it with a module of search terms for ―drug eluting 
stents‖. Furthermore the Pubmed subset ―bioethics‖ was searched using the single search term 
―stent‖. The Pubmed searches retrieved 60 references altogether. 
b) The BELIT database of the German Reference Center for ethics in the biosciences and the 
ETHMED database of the U.S. National Reference Center for Bioethics literature were searched 
using the single search term ―stent‖. 28 publications were retrieved from these two databases. 
3. Additional references were taken from reference lists of retrieved publications as well as recently 
published journal articles (e. g. debate on DES in The Lancet, Feb. 2007). 
4. Focussed searches relating to the specific issues were performed in Pubmed. 
 
Information selection 
HTA-reports: Screening the executive summaries and tables of content of the ten HTA reports 
revealed that except for the report from AETMIS (Brophy, 2004) none contained a section or 
chapter dealing with the ethical implications of drug eluting stents.  
Journal articles: The search strategies 1-4 yielded 88 references from scientific journals. Titles and 
Abstracts were screened, whether they contained information that may be useful to answer the 
research questions, with no regard to methodology of the information collection. 
38 references fulfilled the inclusion criterion and were further roughly categorized by topic in order 
to allocate them to the relevant issues: 
 
Topic Number of publications 
Informed Consent 12 
Recent publication on benefit / harm relationship 6 
Management of innovations 5 
Equity 4 
Quality of Life 3 
General ethical aspects 2 
Professional practice 2 
Role of Industry 2 
Legal aspects 1 
Off Label Use 1 
 
During working on the issues a further 14 publications were deleted from the list because they 
yielded no information of relevance. A list of all excluded publication with reasons for exclusion 
can be found in the appendix.   
 
Assessment of study / publication quality 
No assessment of methodological study quality was undertaken. 
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Assessment elements 
Going through the retrieved literature soon revealed that the following assessment elements of 
ethical analysis could not be answered in the suggested proceeding: desribing methodology, results 
and commenting. The answers themselves are rather discussions of the issue questions, which draw 
on information from the other chapters of the report as well as from statements and facts presented 
in the literature. The latter are given with their respective references. 
 
Principal questions about the ethical aspects of technology 
Are DES intended to be an innovative mode of care, an ”add on on” to a 
standard mode of care or a replacement of a standard? 
Results 
The application of Drug Eluting Stents (DES) is one form of percutaneous coronary intervention 
(PCI) for patients with specified forms of coronary artery disease (CAD). By supporting 
revascularisation of myocardial tissue it primarily aims at reducing CAD related morbidity and 
mortality. DES is a further development of the bare metal stent (BMS) technology by introducing 
the ―drug eluting‖ component, which, by inhibiting neointimal growth after the stenting procedure, 
is supposed to reduce the restenosis rates observed after bare metal stenting and thereby improve 
relevant outcomes (morbidity, mortality, Quality of life). In order to prevent in-stent thrombosis, 
dual antiplatelet therapy (ASS + Clopidogrel) is recommended by manufacturers for 3 months 
(sirolimus eluting stens) or 6 months (paclitaxel eluting stents) after the procedure (Maisel W, 
2007). Furthermore recommendations of manufacturers as well as the FDA limit the use of DES to 
patients with: 
 stable or instable angina, or silent but documented ischemia 
 with discrete and relatively short lesions (up to 28 mm for one stent, up to 30mm in the other)  
 in small native blood vessels (2.5 to 3.5 mm in diameter) (FDA statement, 14.9.2006). 
In that sense, DES is intended to be the replacement of a standard mode of care (BMS) for patients 
with the specified type of disease / lesions. 
 
Can DES challenge religious, cultural or moral convictions or beliefs of some 
groups or change current social arrangements? 
Results 
Since placement of DES requires dual anti-platelet therapy for (at least) three to six months after the 
procedure, it poses patients to an increased risk of bleeding. This may, for example in the case of 
emergency surgery, lead to the need for blood transfusion or application of other blood products. 
For some religious groups, e. g. Jehova‘s witnesses, this is unacceptable. Furthermore, within a 
country there may exist some religious or cultural groups which do not accept implantable devices 
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or devices that have drug eluting character. Clarification of these commitments may usually be 
performed during the informed consent procedure. 
 
What can be the hidden or unintended consequences of DES and its application 
to the different stakeholders? 
Results 
The intended use (in whom, how, with what benefits / harms to expect) of DES is specified by 
manufacturers and through documents (safety data, trial results) required and accepted as 
prerequisite for market admission by regulatory bodies (e. g. FDA, EMEA). Nevertheless, 
monitoring and registry data have shown, that at least 50% of the devices are being used ―off-label‖ 
in patients, that are not specified by the ―intended purpose‖ (e.g. Win et al., 2007; Beohar et al., 
2007, Zahn et al., 2004). As specified in these publications, patients treated off-label typically suffer 
from a more severe form of CHD than those specified in the intended purpose. At the same time, 
the data suggest that complication rates (esp. late stent thrombosis) maybe higher in this population 
and therefore yield a less favourable benefit / harm ratio. 
 
Autonomy 
Does the implementation or use of DES challenge patient autonomy? 
Results 
DES seems not to impose major challenges to patients‘ autonomy. A minor point might be, that in 
order to avoid stent thrombosis adherence to dual platelet therapy after the procedure is necessary 
for a yet to be specified time. Some patients might find the necessity to use a drug as interfering 
with their autonomy. This point may also be clarified during the informed consent procedure. 
 
Is DES used for patients that are especially vulnerable? 
Results 
In this issue ―vulnerability‖ means that patients in the situation of treatment do not have the full 
capabilities of decisionmaking, due to critical illness, age (children!) or mental disturbances. 
Cardiac patients may belong to this group when presenting in an emergency situation (acute cardiac 
syndromes: unstable angina, non-ST-elevation myocardial infarction, ST-elevation myocardial 
infarction).  
 
Although there is no direct evidence on decisionmaking capabilities concerning consenting to a 
treatment option, there is indirect evidence from research investigating consenting capabilities to be 
included into clinical trials while suffering from acute myocardial infarction. These results show, 
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that in the acute situation in many patients the capabilities of understanding complicated facts are 
very limited, and that there is a tendency towards the attitude that ―the doctor should decide‖ what 
should be done (Agard et al., 2001). It seems very doubtful, that in an acute situation all patients 
will be able to understand the different risk / benefit profiles of DES and BMS and make – together 
with the treating physician - an informed decision which procedure to prefer. This is even more 
problematic since the risk profile of DES seems to be more pronounced in high risk patients which 
therefore require more thorough explanations (Win et al., 2007). 
 
Does DES have special challenges/risks that the patient needs to be informed of? 
Results 
For a description of formal requirements of an ―informed consent‖ procedure see Chapter ―Legal 
Aspects‖. 
 
Recently published ―real life‖ data (Pfisterer et al., 2006; Lagerqvist et al., 2007) suggest, that stent 
thromboses as a possible late complication are seen more often in patients treated with DES as 
compared to patients treated with BMS. This especially holds for patients who discontinued ant-
platelet therapy early and for patients with advanced disease (Off-label patients). These are non-
controlled registry observations however. On the other hand, meta-analyses and medium-term 
clinical trial results demonstrate that the rate of late thromboses and especially deaths from the 
consequences are comparable (Mauri et al., 2007; Spaulding et al., 2007). Within the scientific 
community these results are discussed controversely because they might be afflicted with severe 
selection and ascertainment bias (RME, 2007). At the moment it seems not to be clear, what the 
long-term benefit / harm ratio for patients treated with DES rather than with BMS will be. This 
especially holds for Off-label patients with advanced disease for whom not even data from 
randomized controlled trials are available demonstrating short-term benefits. Estimation of benefit 
for this patient population is based on extrapolation of results from trials in less severely afflicted 
populations (Hodgson et al., 2004). 
 
Against this background all candidate DES patients need to be informed of the unclear long-term 
benefit / harm ratio of DES application as well as the necessity to take antiplatelet medication for a 
yet to be determined period of time. Off-label patients furthermore need to be informed that they 
will be undergoing a treatment that has for their indication not been tested in randomized controlled 
trial, and that expectations of benefit are derived from data observed in patients with lesser disease 
severity.  
 
As stated in the issue above, it seems doubtful that patients in an emergency situation will be able to 
comprehensively understand all implications of DES use. Even if it is legally acceptable and 
mandatory to initiate therapy in an emergency situation (see Chapter ―Legal aspects‖) it seems 
morally doubtful to apply DES instead of BMS in this type of situation. 
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Does the implementation of DES challenge or change professional roles? 
Results 
The off-label use of DES in current practice suggests that there is a discrepancy between regulatory 
statements and the value attributed to the technology by the professions. Indeed physicians' 
statements expressed the hope that DES ―… appear very effective in traditionally high-restenosis-
risk subgroups … and that their availability might eventually prompt expansion of the types of 
patients that could be treated with PCI…‖ At the same time it is stated ―… that it is important to 
note that no long-term controlled data currently exist for such applications …‖(Hodgson et al., 
2003). Implementation of DES is, as data from registries as well as utilization data demonstrate, 
readily accepted by the professions. On the other hand, concerns are expressed: 
– the reduction of bypass surgery and increase in stenting procedures (on unsecure scientific 
grounds) 
– the technical difficulties 
– economic / financial concerns leading to changes in practice patterns 
– lag behind competitors 
– malpractice litigations (restenosis after BMS). 
The Drug Eluting Stent Task Force of the Society for Cardiac Angiography and Interventions 
(Hodgson et al., 2004) outlines the conflict for the profession by stating that ―Concern about 
litigation and competitors' practices should not be reasons for using DESs. Evidence of benefit 
should be the primary consideration; where no data exist, a reasoned judgement must be made. In 
all cases, the potential benefit to patient is the foremost consideration.‖ 
 
 
Human Dignity 
Does the implementation or use of DES rather than BMS affect human dignity? 
Results 
There were no publications encountered in the literature searches that discussed violation of human 
dignity (challenging the intrinsic value of a person) in the context of DES implementation. In some 
guidelines (e. g. Canada: Heart and Stroke foundation, 2005; UK, NICE, 2003), for cost-
effectiveness reasons, the application of DES was suggested to be restricted to patients with high 
risk of restenosis (Groeneveld et al., 2007). This may exclude patients that, from a clinical point of 
view, still have a potential to benefit.  
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Does the implementation or use of DES rather than BMS affect human 
integrity? 
Results 
The characteristic that differentiates DES from BMS is the drug eluting component and the 
necessity for antiplatelet therapy after DES implantation. The latter might be a challenge to the self-
perception of some patients: the necessity to continue a medication may not be compatible with the 
hope to be ―cured‖ of the disease after the intervention. Hodgson et al., 2004 pointed out, that there 
is the widespread perception among CAD patients that placement of a (drug eluting) stent is 
regarded a cure of coronary artery disease rather than temporary relief of symtoms. 
 
Beneficence/ non-maleficence 
What are the benefits and harms for patients and what is the balance between 
the benefits and harms when implementing and when not implementing DES 
rather than BMS? 
Methods 
This issue does not directly apply to the comparison of DES vs. BMS because the technology has 
been implemented already. When pointing out consequences for patients, two types of patients must 
be distinguished: CAD patients, who are candidates for receiving DES and ―other‖ patients 
requiring other modes of health care. 
Results 
CAD patients: 
 
According to FDA approval and manufacturers advice (Cypher® and Taxus® stents) DES is 
licensed for use in specified patients only (see above, first issue), but as also stated above (third 
issue), international utilization data shows that more than 50% of DES are used ―off label‖.  
Probably suffering from the disease and the expectations towards the effects of a novel treatment is 
more pronounced in the second group.  
 
Evidence of short-term benefit may be taken from clinical trials comparing the efficacy of DES 
versus BMS in selected (on-label) patients. This evidence consistently demonstrates lower 
restenosis rates and reintervention rates in patients treated with DES compared to BMS. So far, 
there is no evidence that DES has superior effects on cardiovascular or overall mortality (see also 
Chapter ―Effectiveness‖ of this report). In cost-effectiveness models indirect evidence (composed of 
data on QoL impairment in patients suffering from restenosis after PCI and requiring reintervention 
and data on reduced reintervention rates after DES) is used to estimate gains in Quality of life after 
DES (Groeneveld et al., 2007). For off-label patients so far there is no direct evidence from 
randomized controlled trials demonstrating benefit of the procedure. Potential harms (late stent 
thrombosis, risk of bleeding complications) of the technology were discussed above, pointing out 
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that at the current state of knowledge, the benefit / harm ratio is not quite clear, especially not for 
patients treated off label. 
 
Other patient groups:  
 
In many health care systems within publicly funded health care human and money resources are 
budgeted for various specialities. Decision to implement a more costly intervention may ultimately 
lead to reallocation of resources within cardiac department or to allocation of resources from other 
patient groups to cardiac patients.  
The relation of benefits and harms of DES for patients may be summarized as follows: 
 
Stakeholder Benefits when 
proceeding with 
implementation 
Adverse 
consequences when 
proceeding  
Benefits when 
refraining from 
implementation 
Adverse 
consequences when 
refraining 
‖On label‖ CAD patients reduced rates of 
repeat 
revascularisation 
when compared to 
BMI (by 45-55%) 
unclear – possibly 
higher rates of late 
thrombosis;  
probability of 
bleeding 
complications due to 
antiplatelet therapy; 
in the case of 
emergency 
situations: loss of 
autonomy by having 
to make an informed 
decision while not 
being able to 
consider information 
offered. 
no side effects from 
antiplatelet 
medication; 
probability of 
surplus 
complications 
avoided 
Rates of 
revascularisation 
procedures won‘t be 
reduced 
‖Off label‖ CAD 
patients 
unclear – no RCT 
data available 
unclear – possibly 
even higher late 
thrombosis rates 
than in on-label 
patients 
probability of 
bleeding 
complications due to 
antiplatelet therapy 
no side effects from 
antiplatelet 
medication; 
probability of 
surplus 
complications 
avoided 
unclear 
Other cardiac patients unclear In some health care 
systems with closed 
budgets for 
specialties 
implementing the 
more costly DEM 
might diminish 
resources for other 
cardiac patients 
No additional 
constraints on 
budget 
unclear 
Other patients outside 
cardiology 
unclear In health care 
systems with closed 
overall budgets 
implementing the 
more costly DEM 
might diminish 
resources for other 
cardiac patients 
No additional 
constraints on 
budget 
unclear 
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Who will balance the risks and benefits of preferring DES over BMS in practice 
and how? 
Results 
After publication of the unfavourable registry data, regulatory bodies (e. g. FDA statement, 2006) 
and professional societies (e. g. Silber S for the German Cardiac Society, 2007) have published 
recommendations.  Given the widespread use and availability of DES, it is the individual physician 
who decides whether to prefer DES stenting over BMS stenting, after obtaining truly informed 
consent from the patient. In situations where there is no informed consent obtainable, the use of 
DES seems questionable. 
 
Effects of DES implementation on all patient groups have to be considered when making a decision 
whether to include DES into the benefit basket of payers. The decision varies, depending on 
organisation and financing of different health care systems. 
 
Can the implementation of DES rather than BMS harm any of the stakeholders? 
What are potential benefits and harms of implementing DES rather than BMS 
for other stakeholders? 
Results 
Beside patients the relevant stakeholder groups that may directly or indirectly benefit from the use 
of DES instead of BMS are care providers, the professions, payers, society and manufacturers. 
 
Providers (Hospitals etc):  
Implementing DES requires additional financial resources in comparison to BMS. How much and 
from whom, depend on the regulation of the hospital financing systems in the respective countries. 
A fee for service systems may offer the chance for extra profits for care providers; whereas in 
systems with flat rate hospital financing, DES might cause extra costs on health care providers (e. g. 
Kearney et al., 2006). Patients and society put high value on technically advanced medical 
technologies; therefore it is attractive for providers to advertise that patients receive the most 
innovative care in their facilities. 
 
Professions: 
DES has been readily accepted by the cardiologists; with special consideration to the favourable 
short term results, which, in the highly selected patients included in the randomized controlled 
trials, manifested as a markedly reduced number of reinterventions compared to bare metal stents. 
This has led in suggestions that every patient who needs stenting should receive drug eluting 
devices. The high costs of the procedure were regarded the only constraint from universal use 
(Faxon DP, 2004). Other representatives of the interventional cardiologist profession were cautious 
and expressed the need for long-term research results as well as systematic research in high-risk 
populations (Mitka M, 2004) before the uptake of the procedure into routine care. Mainly due to 
financial constraints uptake rates varied among countries with the highest seen in the United States 
and Switzerland (up to 90% of all stenting procedures). In countries with unclear reimbursement 
regulations the uptake rates have been lower. In Germany, where flat rate reimbursement plus extra 
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fees do not cover the costs of the procedure, uptake rates below 20% are reported for 2005 
(Grumann + Bode, 2005). 
 
After publication of long-term follow up data in 2006, which suggest an increase of late stent 
thrombosis in DES compared to BMS some professional societies recommended restrictions for the 
use of DES which immediately manifested in a sharp decrease of utilization rates (see Chapter 
―Current Use‖). 
 
From the profession of cardiac surgeons it is pointed out that the tendency towards increased use of 
PCI, including drug eluting stents, in patients with multivessel disease neglects the existing body of 
evidence that CABG in this particular patient group produces superior long-term results (Taggart 
DP, 2006). Furthermore, concerns are expressed that in patients with failed (multiple) stent 
implantations the options for surgical corrections are very limited (IRR, personal communication). 
 
Society: 
In health care systems, based on the idea of solidarity, one of the underlying principles for the 
provision of care is guaranteeing equal access to effective care for those in need. This, given limited 
resources to be spent on health care leads to the necessity of cost-effectiveness considerations and 
prioritisation. At the same time, strong beliefs are encountered among patients and general public, 
that the most modern and advanced technologies will yield optimal results, and that everyone has 
the right to receive them (Deyo R and Patrick DL, 2005). Concerning DES, study results and media 
responses elicited the belief that DES is the method of choice to treat coronary heart disease. 
Patients may perceive the failure to receive a drug eluting stent as a denial of the optimal chance to 
cure their heart disease (Hodgson et al., 2004). 
 
Manufacturers: 
There are a number of companies manufacturing DES. 
Manufacturers (first generation): 
 Boston Scientific: paclitaxel-eluting "Taxus"® stent 
 Johnson & Johnson (Cordis Corporation): sirolimus eluting "Cypher"® stent 
Manufacturers (second generation not approved in the US): e.g. 
 Medtronics: zotarolimus-eluting stent "Endeavour"® 
 Abbott: everolimus-eluting stent "Xience V"® 
 Conor Medsystems: paclitaxel-eluting stent "CoStar"® 
While the first generation stents are marketed world-wide, the second generation is, due to 
regulatory circumstances, not marketed in the US.  
 
Among the companies there is an ongoing competition for market shares while publication of 
unfavourable long-term results in fall 2006 led to sharply declining sales figures (Shuchman, 2007). 
Against this background an issue of concern could be that manufacturers are the sponsors of most 
ongoing trials as well as of most clinical registries and databases. 
 
The following table summarizes the most frequently mentioned consequences of DES 
implementation / non-implementation from the perspective of the different stakeholders: 
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Stakeholder Benefits when 
proceeding with 
implementation 
Adverse 
consequences when 
proceeding  
Benefits when 
refraining from 
implementation 
Adverse 
consequences when 
refraining 
Care providers  Gain in reputation for 
providing the most 
advanced care; 
In systems with fee for 
service reimbursement 
opportunity for financial 
gains; in systems with flat 
rate reimbursement 
indirect chance of 
financial gains through 
shifts away from more 
costly CABG prodedures 
(Hodgson et al., 2004) 
In systems with flat 
rate reimbursement 
additional costs for 
DES have to born by 
providers 
Opposite to 
‖benefis when 
proceeding with 
implementation‖ 
Opposite to ‖adverse 
effects when 
proceeding with 
implementation‖ 
Professions Gain in reputation for 
providing the most 
advanced care; 
Chance of iterative 
‖learning‖ by proceeding 
under trial and 
surveillance conditions 
performance‖ 
Cardiac surgeons: 
losing (CABG) 
patients. 
Interventional 
cardiologists: 
probability of 
malpractice litigations 
in off-label use; 
probability of doing 
harm to patients while 
proceeding with an 
intervention with 
unclear benefit / harm 
ratio 
Opposite to 
‖benefis when 
proceeding with 
implementation‖;  
Opposite to ‖adverse 
effects when 
proceeding with 
implementation‖ 
Payers Gain in reputation for 
providing the most 
advanced care; indirect 
financial gains when 
costly CABG procedures 
are avoided 
 
Have to bear 
additional costs for 
DES; limited 
resources may create 
the need to 
conceptualize 
measures for rationing 
/ prioritizing 
cost neutrality  Opposite to ‖adverse 
effects when 
proceeding with 
implementation‖ 
Society Gain in reputation for 
providing the most 
advanced care; 
Outside the private 
sector: having to bear 
the extra costs for the 
procedure. In societies 
with a strong private 
health care market: 
danger of enforcing 
‖two class health care‖ 
Opposite to 
‖benefis when 
proceeding with 
implementation‖;  
Opposite to ‖adverse 
effects when 
proceeding with 
implementation‖ 
Producers/Industry financial gains; ability to 
provide further data on 
‖real life use‖ by funding 
registries and data 
collections 
Proceeding with 
implementation of 
second and third 
generation DES in 
Europe may lead to 
competition for market 
shares, especially for 
manufacturers of first 
generation DES. 
Opposite to 
‖benefis when 
proceeding with 
implementation‖;  
Opposite to ‖adverse 
effects when 
proceeding with 
implementation‖ 
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Justice and Equity 
What are the consequences of implementing / not implementing DES on justice 
in the health care system? (Are principles of fairness, justness and solidarity 
respected?) 
Results 
This issue implies at least two types of considerations: 
The medical one is concerned with the principle, that technologies should be supplied to those who 
are in need of them in order to improve health. This concept of „need for a technology― implies that 
there is evidence, that use of the technology offers a net benefit (meaning that benefit outweighs 
harms), also in comparison to other available modes of care. Taken into consideration current 
knowledge, for DES it is unclear whether benefits outweigh harms. Up to now, an evidence-based 
decision whether a particular patient or a group of patients „need― DES instead of BMS can not be 
taken. Taking into consideration the widespread use and especially off-label use of DES the 
question arises whether for the implementation of DES fairness, justness and solidarity could also 
mean to efficiently protect patients in who harms might outweigh possible benefits from receiving 
the technology. 
 
In case we can in future determine a patient group in need of DES, economic considerations might 
impair the principles of fairness, justness and solidarity. The price of DES varies between countries 
but is generally higher than that of BMS (see also Chapter Costs and Economic Evaluations). By 
whom these extra costs are borne, depends on the reimbursement regulation of the respective 
countries. Taking into consideration the limited availability of resources for the health care sector it 
will be mandatory to implement transparent and fair allocation procedures along with the 
technology. 
 
How are technologies presenting with similar (ethical) problems as DES treated 
in the health care sector? 
Results 
The main moral problems around the DES result from the fact, that it is unclear whether in the long 
term net harm or net benefit will result from its implementation. This is especially a problem in the 
group of more severely ill patients that often present in an emergency situation, with temporarily 
limited decision making capacities and therefore constitute a particularly vulnerable population. 
For new technologies in some health care systems (e. g. Interventional Procedures Program, NICE, 
UK; Switzerland) it is an established procedure that  
 
1. the technology may only be applied under ―monitoring conditions‖, which could involve a 
clinical trial or establishment of a registry. It seems worthwhile to note here, that the monitoring 
condition should preferably be set up independent of funding from manufacturers in order to avoid 
―conflicts of interests‖ should unfavourable results arise. 
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2. implementation of an innovative technology requires thorough explanation of its developmental 
status as well as the scope of possible benefits and harms to the patients. Qualitative research found 
that the amount and precision of information that patients want to know before a cardiac 
intervention is very variable (Beresford et al., 2001). From an ethical point of view, it seems 
questionable to proceed with an innovative procedure in patients who are not able to or not want to 
consider the scope of possible benefits / harms of the respective treatment option.  
 
Are there any third parties involved when implementing DES rather than BMS? 
Comment 
Consequences of DES implementation for different stakeholders have been outlined in the 11th 
issue (Benefits and Harms for different stakeholders). 
Rights 
Does the implementation of DES rather than BMS affect the realisation of basic 
human rights?  
Results 
In the context of health care (treatment of an illness) the following human rights issues apply: 
 The human right to the highest attainable standard of physical and mental health, including 
reproductive and sexual health.  
 The human right to equal access to adequate health care and health-related services, regardless 
of sex, race, or other status. 
(The People's Movement for Human Rights Education; http://www.pdhre.org/rights/health.html) 
The ―adequacy‖ of applying DES rather than BMS in different patient groups has been discussed 
above (tenth issue, benefits and harms for patients) as well as aspects of distributive justice in issue 
twelve. 
 
Furthermore, there is an ongoing debate in the literature whether gender, age or social status limit 
access to adequate care, though no articles were found that directly apply to the topic of drug 
eluting stents. There is some evidence though, that advanced modes of care less often applied in 
elderly or female cardiac patients than younger (male) ones, despite equal evidence for 
effectiveness in clinical trials (e.g. Bond et al., 2003; Weisz et al., 2003; Avezum et al., 2005). 
These aspects should also be taken into consideration when establishing criteria / guidelines for the 
implementation of DES. 
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Legislation 
Is legislation to use DES rather than BMS fair and adequate? 
Results 
In Europe medical devices (Drug eluting stents falling into the device class MEDDEV III) may be 
marketed (and implemented) after receiving the CE conformity marking. CE conformity marking is 
issued when the safety of the device and its ability to fulfill the intended purpose are proven. CE 
marking does not require comprehensive evidence on its clinical effectiveness or long-term benefit / 
harm ratio. Coverage for DES procedures is regulated by national (in some countries even regional) 
law, in some countries with the possibility of „conditional coverage― linked to the generation of 
more clinical effectiveness and safety data (for an overview see the work of WP 7, EUNetHTA 
project). This legislation implies that innovative devices may be implemented which later prove to 
be ineffective or have an unfavourable benefit / harm ratio. From a moral point of view, the 
European legislation for medical devices by itself is not efficient to protect the best interest of the 
patients.  
 
Discussion 
From an ethical point of view in, decisionmaking on how to continue with the implementation of 
DES the following points should be taken into consideration: 
 
 Up to current knowledge, the relation of benefit and harm for patients receiving DES is not 
quite clear; this holds especially for patients treated off-label. A further source of risk and 
activity limitation is the necessity to take dual anti-platelet therapy for a still to be determined 
period of time. 
 In order to enable patients to make an autonomous informed decision whether or not to have 
treatment with DES, this situation has to be thoroughly explained. On the other hand, in the 
situation of decision patients ability to understand complicated information may be severely 
compromised by severity of illness. This again, holds especially for off-label patients, treated in 
an emergency situation. 
 From an overindividual perspective, there is clearly a need for more research data on 
effectiveness and safety of the intervention. These data should preferably be collected avoiding 
conflicts of interest for any of the stakeholders. 
 Although there are no clear data for DES, literature on the utilization of sophisticated cardiac 
procedures suggests, that patient characteristics like age and gender influence allocation. 
 In some health care systems the financing modalities (e.g. closed specialty or overall budgets) 
allow the introduction of a new costly technology only if resources are taken from another area 
of intervention / care. In order to help fair allocation of resources these mechanisms need to be 
made explicit. 
The European legislation for the market introduction of innovative medical devices seems not to be 
able to sufficiently protect patients from ineffective or harmful interventions.  
EUnetHTA WP4 - Core HTA on drug eluting stents (DES) 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
90 
References 
Available HTA-reports in English language 
Medical Services Advisory Committee. Drug-eluting stents. Systematic review.  2005.  
Mittmann N, Brown A, Seung SJ, Coyle D, Cohen E, Brophy J, et al. Drug Eluting Stents: An Economic Evaluation. 
Report.  2005.  
Mittmann N, Brown A, Seung SJ, Coyle D, Cohen E, Brophy J, et al. Economic evaluation of drug eluting stents. 
Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2005;61. 
Brophy J, Erickson L. An economic analysis of drug eluting coronary stents: a Quebec perspective. Report.  2004.  
Hill R, Bagust A, Bakhai A, Dickson R, Dundar Y, Haycox A. Coronary artery stents: a rapid systematic review and 
economic evaluation. Systematic review.  2004.  
Swedish Council on Technology Assessment in Health Care. Drug eluting stents in coronary arteries - early assessment 
briefs (Alert). Stockholm: Swedish Council on Technology Assessment in Health Care (SBU) 2004. 
Brophy J. An evaluation of drug eluting (coated) stents for percutaneous coronary interventions: what should their role 
be at the McGill University Health Centre (MUHC)? Systematic review.  2003.  
Institute for Clinical Systems Improvement. Drug-eluting stents for the prevention of restenosis in native coronary 
arteries. Bloomington, MN: Institute for Clinical Systems Improvement (ICSI) 2003. 
National Institute for Clinical Excellence. Guidance on the use of coronary artery stents. Systematic review.  2003.  
Garces K. Drug eluting stents: managing coronary artery stenosis following PTCA. Ottawa: Canadian 
Coordinating Office for Health Technology Assessment (CCOHTA) 2002;4. 
National Horizon Scanning Centre. Preventing restenosis after PTCA - horizon scanning review. Birmingham: National 
Horizon Scanning Centre (NHSC) 2001;7. 
Methodological and background information 
Deyo R, Patrick DL (2005) Medical Innovations and Amercial Culture. In: Hope or Hype. The obsession with medical 
advances and the high costs of false promises. AMACOM, New York, p.13-25 
Droste S, Gerhardus A, Kollek R (2003) Methoden zur Erfassung ethischer Aspekte und gesellschaftlicher 
Wertvorstellungen in Kurz-HTA-Berichten - eine internationale Bestandsaufnahme. DAHTA@DIMDI, Köln, 
ISBN 3-89906-730-4 
FDA statement on drug eluting stents (15.9.2006, 17.00 o‘clock). (http://www.fda.gov/cdrh/news/091406.html, 
accessed 28.5.2007) 
Hofmann B (2005) Towards a procedure for integrating moral issues in health technology assessment. International 
Journal for Technology Assessment in Health Care 21 (3): 312-318. 
Publications cited to answer the issues 
Agard A, Hermeren G, Herlitz J (2001) Patients' experiences of intervention trials on the treatment of myocardial 
infarction: is it time to adjust the informed consent procedure to the patient's capacity? Heart 86(6):632-7. 
Avezum A, Makdisse M, Spencer F, Gore JM, Fox KA, Montalescot G, Eagle KA, White K, Mehta RH, Knobel E, 
Collet JP; GRACE Investigators (2005) Impact of age on management and outcome of acute coronary syndrome: 
observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 149(1):67-73. 
EUnetHTA WP4 - Core HTA on drug eluting stents (DES) 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
91 
Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, 
Bennett CL, Williams DO (2007) Outcomes and complications associated with off-label and untested use of 
drug-eluting stents. JAMA 297(18):1992-2000.  
Beresford N, Seymour L, Vincent C, Moat N (2001) Risks of elective cardiac surgery: what do patients want to know? 
Heart 86(6):626-31. 
Bond M, Bowling A, McKee D, Kennelly M, Banning AP, Dudley N, et al (2003). Does ageism affect the management 
of ischaemic heart disease? J Health Serv Res Policy 8(1):40-7. 
Faxon DP (2004) Bringing Reality to Drug-Eluting Stents. Circulation 109;140-142 
Groeneveld PW, Suh JJ, Matta MA (2007) The costs and quality-of-life outcomes of drug-eluting coronary stents: a 
systematic review. J Interv Cardiol 20(1):1-9. 
Grumann T, Bode C (2005) Medikamente-freisetzende Stents: Welcher Koronarpatient profitiert? CME-Compact, June 
1st 2005, German Cardiac Society (www.dkg.org/cme) 
Heart and Stroke Foundation, Canada, (2005) Targeting new technologies – Who needs drug eluting stents? 
(http://ww2.heartandstroke.ca/Page.asp?PageID=33&ArticleID=4294&Src=news&From=SubCategory; accessed 
28.5.2007) 
Hodgson JM, Bottner RK, Klein LW, Walpole HT, Jr., Cohen DJ, Cutlip DE, et al. (2004) Drug-eluting stent task force: 
final report and recommendations of the working committees on cost-effectiveness/economics, access to care, 
and medicolegal issues. Catheter Cardiovasc Interv 62(1):1-17. 
Hodgson JM, King SB 3rd, Feldman T, Cowley MJ, Klein LW, Babb JD (2003) Society for Cardiac Angiography and 
Interventions.  SCAI statement on drug-eluting stents: practice and health care delivery implications. Catheter 
Cardiovasc Interv. 2003 Mar;58(3):397-9. 
Kearney P, Stokoe G, Breithardt G, Longson C, Marco J, Morgan J, et al. (2006) Improving patient access to novel 
medical technologies in Europe. Eur Heart J 27(7):882-5. 
Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L (2007) SCAAR Study Group.  Long-term 
outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356(10):1009-19. 
Maisel WH (2007) Unanswered questions--drug-eluting stents and the risk of late thrombosis. N Engl J Med 
356(10):981-4. 
Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE (2007) Stent thrombosis in randomized clinical 
trials of drug-eluting stents. N Engl J Med. 356(10):1020-9 
Mitka M (2004) Drug-eluting stents show promise: but experts warn against enthusiasm outpacing science. JAMA 
291(6):682-3. 
Pfisterer ME, Kaiser CA, Bader F, Brunner-La Rocca HP, Bonetti PO, Buser PT (2006) Late clinical events related to 
late stent thrombosis after stopping clopidogrel: prospective randomized comparison between drug-eluting versus 
bare-metal stenting. Program and abstracts from the American College of Cardiology 55th Annual Scientific 
Session; March 11-14, 2006; Atlanta, Georgia. Abstract 422-11 
RME (2007). Medikamenten-Stents: Neue Studien aber keine Antworten. Deutsches Ärzteblatt 2007 Feb 13. 
Shuchman M (2006) Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med 2006 
355(19):1949-52. 
Silber S (2007) Wirksamkeit und Sicherheit von Medikamentenfreisetzenden Koronarstents (DES) – ein 
Positionspapier der DGK. (http://www.aerzteblatt.de/v4/plus/down.asp?typ=PDF&id=1830, accessed 28.5.2007) 
EUnetHTA WP4 - Core HTA on drug eluting stents (DES) 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
92 
Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW (2007) A pooled analysis of data comparing sirolimus-
eluting stents with bare-metal stents. N Engl J Med. 356(10):989-97. 
Taggart DP. Thomas B (2006) Ferguson Lecture. Coronary artery bypass grafting is still the best treatment for 
multivessel and left main disease, but patients need to know. Ann Thorac Surg 2006 Dec;82(6):1966-75. 
Weisz D, Gusmano MK, Rodwin VG (2003) Gender and the treatment of heart disease in older persons in the United 
States, France, and England: a comparative, population-based view of a clinical phenomenon. Gend Med. 
1(1):29-40 
Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, 
Kleiman NS; EVENT Registry Investigators (2007)  Clinical outcomes and stent thrombosis following off-label 
use of drug-eluting stents. JAMA 297(18):2001-9. 
Zahn R, Hamm CW, Zeymer U et al, (2004) ―Real life‖ use of sirolimus-eluting coronay stents in Germany. Results 
from the prospective multi-centre German Cypher registry. Zeitschrift für Kardiologie 93:287-294. 
 
EUnetHTA WP4 - Core HTA on drug eluting stents (DES) 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
93 
APPENDIX 1: Assessment elements 
 
Domain  Topic  Issue  Relevance 
in the 
context of 
DES 
Yes/No 
Research Question in the context of DES Importance 
3=critical 
2=important 
1=optional  
Transferability 
3=complete 
2=partially 
1=not  
       
Ethical aspects  Principal 
questions about 
the ethical 
aspects of 
technology  
Is the 
technology 
intended to be 
an innovative 
mode of care, 
an "add on" to a 
standard mode 
of care or a 
replacement of 
a standard?  
Yes Are DES intended to be an innovative mode of care, an „add on― to a standard or 
replacement of a standard? 
3 3 
Ethical aspects  Principal 
questions about 
the ethical 
aspects of 
technology  
Can the 
technology 
challenge 
religious, 
cultural or 
moral 
convictions or 
beliefs of some 
groups or 
change current 
social 
arrangements? 
(Yes) Can DES challenge religious, cultural or moral convictions or beliefs of some groups or 
change current social arrangements? 
3 2 
Ethical aspects  Principal 
questions about 
the ethical 
aspects of 
technology 
What can be the 
hidden or 
unintended 
consequences 
of the 
technology and 
it‘s applications 
for different 
stakeholders. 
Yes Can DES challenge religious, cultural or moral convictions or beliefs of some groups or 
change current social arrangements? 
3 2 
Ethical aspects  Autonomy Does the 
implementation 
or use of the 
technology 
challenge 
patient 
(Yes) Does the implementation or use of DES challenge patient autonomy? 3 3 
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autonomy? 
Ethical aspects  Autonomy Is the 
technology 
used for 
patients that are 
especially 
vulnerable?  
Yes Is DES used for patients that are especially vulnerable? 3 3 
Ethical aspects  Autonomy Can the 
technology 
have special 
challenges/risk 
that the patient 
needs to be 
informed of?  
Yes Do DES have special challenges/risks that the patient needs to be informed of? 3 3 
Ethical aspects  Autonomy Does the 
implementation 
challenge or  
change 
professional 
roles? 
Yes Does the implementation challenge or change professional roles? 3 2 
Ethical aspects  Human Dignity 
 
Does the 
implementation 
or use of the 
technology 
affect human 
dignity? 
Yes Does the implementation or use of DES rather than BMS affect human dignity? 3 2 
Ethical aspects  Human 
integrity 
 
Does the 
implementation 
or use of the 
technology 
affect human 
integrity? 
Yes Does the implementation or use of DES rather than BMS affect human integrity? 
 
3 2 
Ethical aspects  Beneficence/ 
nonmaleficence 
What are the 
benefits and 
harms for 
patients, and 
what is the 
balance 
between the 
benefits and 
harms when 
implementing 
and when not 
implementing 
the technology?   
Who will 
balance the 
Yes What are the benefits and harms for patients and what is the balance between the benefits 
and harms when implementing and when not implementing DES rather than BMS? 
Who will balance the risks and benefits of preferring DES over BMS in practice and how? 
3 2 
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risks and 
benefits in 
practice and 
how? 
Ethical aspects  Beneficence/ 
nonmaleficence 
Can the 
technology 
harm any of the 
other 
stakeholders? 
What are the 
potential 
benefits and 
harms for other 
stakeholders, 
what is the 
balance 
between them? 
Who will 
balance the 
risks and 
benefits in 
practice and 
how? 
Yes Can the implementation of DES rather than BMS harm any of the stakeholders? What are 
potential benefits and harms of implenting DES rather than BMS for other stakeholders? 
3 2 
Ethical aspects  Justice and 
Equity 
What are the 
consequences 
of 
implementing / 
not 
implementing 
the technology 
on justice in the 
health care 
system? Are 
principles of 
fairness, 
justness and 
solidarity 
respected? 
Yes What are the consequences of implementing / not implementing DES on justice in the health 
care system? (Are principles of fairness, justness and solidarity respected?) 
3 2 
Ethical aspects Justice and 
Equity 
Are there any 
third parties 
involved when 
implementing 
the technology? 
(Yes) Are there any third parties involved when implementing DES rather than BMS? 3 2 
Ethical aspects  Justice and 
Equity 
How are 
technologies 
presenting with 
similar (ethical) 
Yes How are technologies presenting with similar (ethical) problems as DES treated in the 
health care sector? 
3 2 
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problems 
treated in health 
care system? 
Ethical aspects   Rights Does the 
implementation 
or use of the 
technology 
affect the 
realisation of 
basic human 
rights?  
(Yes) Does the implementation of DES rather than BMS affect the realisation of basic human 
rights? 
3 3 
Ethical aspects  Legislation Is legislation 
and regulation 
to use the 
technology fair 
and adequate? 
Yes Is legislation to use DES rather than BMS fair and adequate? 2 2 
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Assessment elements table 
ID Domain  Topic  Issue  Relevance in the 
context of DES 
Yes/No 
Research question(s) in the context of DES 
or 
Comment (if regarded as a not relevant issue in this context) 
      
F0001 Ethical aspects  Principal questions about the 
ethical aspects of technology  
Is the technology intended to be an innovative 
mode of care, an "add on" to a standard mode of 
care or a replacement of a standard?  
Yes Are DES intended to be an innovative mode of care, an „add on“ to a 
standard or replacement of a standard? 
F0002 Ethical aspects  Principal questions about the 
ethical aspects of technology  
Can the technology challenge religious, cultural or 
moral convictions or beliefs of some groups or 
change current social arrangements? 
(Yes) Can DES challenge religious, cultural or moral convictions or beliefs of 
some groups or change current social arrangements? 
F0003 Ethical aspects  Principal questions about the 
ethical aspects of technology 
What can be the hidden or unintended 
consequences of the technology and its 
applications for different stakeholders. 
Yes Can DES challenge religious, cultural or moral convictions or beliefs of 
some groups or change current social arrangements? 
F0004 Ethical aspects  Autonomy Does the implementation or use of the technology 
challenge patient autonomy? 
(Yes) Does the implementation or use of DES challenge patient autonomy? 
F0005 Ethical aspects  Autonomy Is the technology used for patients that are 
especially vulnerable?  
Yes Is DES used for patients that are especially vulnerable? 
F0006 Ethical aspects  Autonomy Can the technology entail special challenges/risk 
that the patient needs to be informed of?  
Yes Do DES have special challenges/risks that the patient needs to be 
informed of? 
F0007 Ethical aspects  Autonomy Does the implementation challenge or  change 
professional roles? 
Yes Does the implementation challenge or change professional roles? 
F0008 Ethical aspects  Human Dignity 
 
Does the implementation or use of the technology 
affect human dignity? 
Yes Does the implementation or use of DES rather than BMS affect human 
dignity? 
F0009 Ethical aspects  Human integrity 
 
Does the implementation or use of the technology 
affect human integrity? 
Yes Does the implementation or use of DES rather than BMS affect human 
integrity? 
 
F0010 Ethical aspects  Beneficence/ 
nonmaleficence 
What are the benefits and harms for patients, and 
what is the balance between the benefits and 
harms when implementing and when not 
implementing the technology?   Who will balance 
the risks and benefits in practice and how? 
Yes What are the benefits and harms for patients and what is the balance 
between the benefits and harms when implementing and when not 
implementing DES rather than BMS? 
Who will balance the risks and benefits of preferring DES over BMS in 
practice and how? 
F0011 Ethical aspects  Beneficence/ 
nonmaleficence 
Can the technology harm any other stakeholders? 
What are the potential benefits and harms for 
other stakeholders, what is the balance between 
them? Who will balance the risks and benefits in 
practice and how? 
Yes Can the implementation of DES rather than BMS harm any of the 
stakeholders? What are potential benefits and harms of implenting DES 
rather than BMS for other stakeholders? 
F0012 Ethical aspects  Justice and Equity What are the consequences of implementing / not 
implementing the technology on justice in the 
health care system? Are principles of fairness, 
justness and solidarity respected? 
Yes What are the consequences of implementing / not implementing DES on 
justice in the health care system? (Are principles of fairness, justness and 
solidarity respected?) 
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ID Domain  Topic  Issue  Relevance in the 
context of DES 
Yes/No 
Research question(s) in the context of DES 
or 
Comment (if regarded as a not relevant issue in this context) 
F0013 Ethical aspects Justice and Equity Are there any third parties involved when 
implementing the technology? 
(Yes) Are there any third parties involved when implementing DES rather than 
BMS? 
F0014 Ethical aspects  Justice and Equity How are technologies presenting with similar 
(ethical) problems treated in health care system? 
Yes How are technologies presenting with similar (ethical) problems as DES 
treated in the health care sector? 
F0015 Ethical aspects   Rights Does the implementation or use of the technology 
affect the realisation of basic human rights?  
(Yes) Does the implementation of DES rather than BMS affect the realisation of 
basic human rights? 
F0016 Ethical aspects  Legislation Is legislation and regulation to use the technology 
fair and adequate? 
Yes Is legislation to use DES rather than BMS fair and adequate? 
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Organisational Aspects 
Marco Marchetti, Marco Oradei, Mirella Corio, Carmen Furno, Matteo Ruggeri 
Introduction  
The organisational domain assesses what types of resources (material things, human skills and 
knowledge, money, etc) must be mobilised and organised when implementing a new technology, 
and what kinds of changes or consequences the use can cause in an organisation. In this core HTA 
the new technology is drug eluting stents (DES) and the objective is to assess the organizational 
effects of DES introduction compared to the use of traditional bare metal stents (BMS).  
From an organisational point of view,DES insertion does not represent a major innovation. 
Angioplastic procedures are not affected by the new device, unless stents are placed with ecoguide 
(IVUS, intra vascular ultrasound) or Optical Coherence Tomography (OCT), where extra skills are 
required from the professionals.  
Furthermore, depending on the kind of drug contained in the DES, patients may need antiplatelet 
therapy, which needs to be monitored. This therapy is longer than BMS post-surgery therapies. 
Methodology  
Organisational aspects are rarely analysed within clinical studies and HTA reports, so the analysis 
required several activities. Systematic review of the literature is crucial but not enough to answer 
the research questions of this domain. Therefore, in this study literature research represents the first 
step of analysis. The literature review includes grey literature and international guidelines. The 
search strategy is described in detail below. 
 
Literature search: 
Published literature was obtained by searching MEDLINE, CDSR (Cochrane Database of 
Systematic Reviews), CCRCT (Cochrane Central Register of Controlled Trials), and DARE 
(Database of Abstracts of Reviews of Effects), all by using EBSCO-HOST as search engine; and 
HTA Database CRD (Centre of Reviews and Dissemination). As the research objective is to 
compare the organizational effects of using drug-eluting stents (DES) compared to the traditional 
stent (BMS), the following keywords were used: ―Drug eluting stent‖ AND ―Organization*‖. Since 
the studies containing all of the keywords were found only from Medline, the search strategy was 
modified for the other databases, by using only "Drug eluting stent" as keyword. We limited our 
search results to studies on humans published in English between June 2002 (publishing date of the 
first randomized trial- RAVEL - on DES ) and March 2007. This search strategy (showed in detail 
in table 1) resulted in 212 studies and 16 HTA reports.  
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Table 1: Literature search strategy 
 
DATABASE LIMITS KEYWORDS RESULTS 
MEDLINE 
Human; English; 
2002+ 
―Drug eluting stent‖ 
AND ―Organization*‖ 
181 
DARE 
Human; English; 
2002+ 
―Drug eluting stent‖ 7 
CDSR - CCRCT 
Human; English; 
2002+ 
―Drug eluting stent‖ 24 
CRD 
Human; English; 
2002+ 
―Drug eluting stent‖ 16 
 
Selection criteria and method: 
A study was eligible for inclusion in the systematic review of organizational evaluation if it met 
each of the following inclusion criteria: 
 
 Included patients with coronary artery disease; 
 Compared: Drug Eluting Stent with Bare Metal Stent; 
 Analyzed and reported results of any of the following organizational topics: utilization, 
work processes, (de)centralization, staff, cooperation and communication, finances, 
management and controlling, stakeholders. 
 
Study selection was done in two stages: first the studies were screened based on title to remove 
duplicates. A total of 155 studies were found. Studies identified have been classified according to 
the study design. The studies were distributed in eight categories as follows: 
 HTA Reports: 16 
 Clinical Trials: 15 
 Meta-analysis: 6 
 Guidelines: 4 
 Reviews: 70 
 Comparative Studies: 30 
 Evaluation Studies: 2 
 Multicenter Studies: 12 
 
Two reviewers independently selected the relevant studies by reading the abstracts. A study was 
included if it provided useful information to answer the research questions. We identified 20 papers, 
reported in appendix 1, in the following categories: 
 HTA Reports: 2 
 Clinical Trials: 2 
 Meta-analysis: 0 
 Guidelines: 4 
 Reviews: 4 
 Comparative Studies: 5 
 Evaluation Studies: 2 
 Multicenter Studies: 1 
 
Figure 1 shows a QUORUM flowchart of study selection
1
.  
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Figure 1: Selection of studies for inclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quality assessment: 
Quality assessment using criteria for clinical effectiveness is not pertinent in the investigation of 
organizational aspects. We are currently not aware of suitable formal instruments or classifications 
using explicit quality criteria for articles looking at health care organisation.   
 
Integration of literature review: 
Since organisational aspects are rarely analysed within clinical studies, which represent the main 
part of the available content of the databases investigated, we have also integrated grey literature.  
Based on our review, some issues have not been analysed in literature. Therefore, no scientific 
evidence was found regarding those issues using our initial search. To complement our search, we 
reviewed also grey literature using a generic research engine (Google) and consulted websites of 
manufacturers, regulatory agencies, and health technology assessment agencies. Some issues 
required the analysis of guidelines established by national and international societies of cardiology 
(European Society of Cardiology, American College of Cardiology, American Heart Association, 
Society for Cardiac Angiography and Interventions). All papers on the Joint meeting of the 
European Society of Cardiology and World Heart Federation in Barcelona 2006 have been 
included. Futhermore, we have considered documents on DES approval, including 
recommendations by the US Food and Drug Administration (FDA) for marketing regulations and 
utilisation in USA, and guidelines by EMEA for regulations on marketing and utilisation in Europe. 
Since organisational aspects are strictly linked to their own context, it is useful to integrate results 
with the experience of clinical opinion leaders in this area. 
Potential studies 
identified from search 
 
228 
Excluded:  
 
73 duplicates 
Selected studies 
 
21 
Papers retrieved for 
further assessment 
 
155 
 
Excluded:  
 
134 not relevant for topics 
investigated in the 
organizational domain 
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Assessment elements  
Utilization  
How are DESs accepted by the organisation? 
Results  
Decisions on introducing new technology in health care organizations are very complex, because 
they are strongly linked to safety, clinical benefits, and economic aspects. In fact, considering the 
improvements in medical knowledge, the economic factors have become more and more 
determinat. So when a new technology is introduced in health care organizations it is necessary to 
consider the acceptance level of clinicians who are users of technology and also of budget managers 
who allocate the available resources. In the context of DES it is crucial to study the acceptance level 
of interventional cardiologists who perform angioplasty procedures, and also of budget managers.  
How are DESs accepted by interventional cardiologists of health care 
organizations?  
Methods 
Systematic literature review. We found additional information by internet search of grey literature. 
Results  
Compared to traditional Bare Metal Stents (BMS), Drug Eluting Stents (DES) do not require 
different implant procedures
2
. DES are functionally similar to their BMS predecessors. Inventory 
issues (shelf life, sterility, temperature sensitivity, etc.) should be easily addressed. 
Regarding the acceptance level of DES by interventional cardiologists, we observed original 
optimism following positive results of first clinical trials published. These studies showed 
significant reduction of restenosis.  
 
In this first phase, interventional cardiologists suggested wide utilization of DES. Since a meta-
analysis presented at the 2006 European Society of Cardiology Annual Meeting/World Congress of 
Cardiology meeting showed an increased risk of stent thrombosis and MI after 36 months in DES-
treated patients, the overall attitude among interventional cardiologists has become careful. The 
ACC.07/i2 Summit 2007 Joint Symposium: ―Drug- Eluting Stent Safety — Hype or Reality?‖ 
focused on reports published since findings of two studies indicated that the rates of death and 
nonfatal myocardial infarction were higher for DES than for BMS. 
This uncertainty over stent thrombosis with drug-eluting stents has led to a 20% drop in DES use in 
early 2007 in the US. Doctor Martin Leon (Columbia University, New York) presented the DES 
usage data Use of DES peaked in the US during the second half of 2006 at approximately 89%, but 
has dropped to 70% in early 2007. By contrast, DES usage has fluctuated in the UK and Europe but 
continues to hover just above 50% on average, while Japan has remained constant, at 72% for the 
past half year. Leon stressed the importance of careful patient selection; consideration of alternative 
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options (bare-metal stents, medical therapy), or CABG; clear communication of risks and benefits 
to patients; awareness of patients‘ pretreatment history; and optimal implantation techniques3.  
 
How are DESs accepted by financial management of health care organizations?  
Methods 
Systematic literature review. We found additional information by internet search of grey literature. 
 
Results 
In health care organisations, DES introduction can concern managers, because of their high cost 
may not be covered by reimbursement policies. For example, in several Italian Regions DES 
receive the same coverage as BMS, though the latter are much cheaper. The adoption levels
4 
of 
DES in the European countries range from less than 10% to more than 60%. This uptake is mainly 
constrained by reimbursement policies/incentives. Some regions contemplate the same coverage for 
both DES and BMS, even though DESs are more expensive than BMS. 
 
How do the patients accept DES?  
Methods 
Systematic literature review. We found additional information by internet search of grey literature. 
 
Results  
Some patients and patients‘ associations claim that DES should be implanted in every angioplasty 
intervention
5
. One reason for this is that patients form their own opinions of new technologies based 
on the information from producers‘ marketing campaigns and mass media. If they can access 
scientific literature on the specific technology, they may not fully understand it. 
 
Nowadays, media and advertising are the major sources of information
6
. Most patients do not have 
access or the necessary training to interpret information provided by scientific literature (HTA 
reports, articles, scientific papers). Given the overwhelmingly positive results of most of the DES 
studies reported in peer-reviewed journals and the media response to these results, it is not 
surprising that patients believe that DES should be used for all patients and for all indications. 
 
Moreover, an information bias was identified: scientific literature and mass media presented 
adverse effects with less emphasis (high risk of thrombosis related to DES insertion, revealed by 
BASKET Study - 2005) than the advantages of DES utilization (decreased risk of restenosis 
revealed in the first studies published).  
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Signs of changes in this trend are becoming evident, for example the controversies about safety and 
proper utilization of DES have been introduced in a popular Italian magazine ―Panorama‖, inviting 
patients to being more careful in DES implantations decision making
7
.  
 
What kind of technical problems can the implementation of DES produce?  
Results 
There are no specific technical problems in DES compared with BMS. 
Is DES use related with the adoption of new procedures or other instruments?  
Methods 
Systematic literature review. We found additional information by internet search of gray literature. 
Results 
Some papers underline the need to use intravascular ultrasound (IVUS) procedures in association 
with DES, in order to achieve a more correct placing for the stent8-9-10-11-12 . IVUS is recommended 
for at least 20% of stent implantations. Another technology was recently introduced in 
cardiovascular field: The Optical Coherence Tomography (OCT) is a new non-contact, light-based 
imaging modality providing in situ images of tissues at near histological resolution. As shown in 
various preclinical and clinical reports, OCT allows the identification of mural as well as luminal 
morphology including lumen dimensions, plaques, thrombi, dissections, tissue flaps as well as 
information on stent geometry, including apposition and symmetry
13-14
. 
Comment 
The high costs of the IVUS and OCT procedures are not included in the reimbursement provided by 
the public insurance systems in some European countries, so that hospitals are not encouraged to 
use this procedure.  
 
Work processes  
What kinds of changes are required in work processes when implementing 
DES?  
Methods 
Systematic literature review. Semi-structured interview with expert physicians in cardiology, 
purchase managers.  
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Results 
DES implantation, as compared with BMS, doesn‘t require adoption of new or different work 
processes. Nevertheless stent use (no matter if DES or traditional) depends on the context in which 
the interventional procedure is performed. Primary PTCAs should be performed within 1–2 hours 
(rescue angioplasty), or 20–30 minutes (primary angioplasty)15-16. Thus a hospital should guarantee 
surgical cardiology service on a 24-hour basis. Finally a high rate of effectiveness for DES is 
associated with a decrease of CABG procedures17-18, so that the organisational characteristics for 
heart surgical procedures could change. 
 
What kind of changes are required in patient path when implementing DES? 
Methods 
Systematic literature review. 
 
Results  
DES intervention techniques do not differ from coronary angioplasty (PTCA) with traditional stents 
(BMS). One of the main problems in BMS interventions is restenosis of the lesion treated. It occurs 
in a variable percentage of cases
19
 ( in about 20% of patients with simple lesions and more than 
50% of patients with more complex conditions), depending on patient characteristics, lesion treated 
and BMS used. DESs reduce restenosis, even though recent studies highlighted risks of late 
thrombosis, especially in patients implanted for off-label conditions. In order to reduce such risks, 
both FDA and NHS recommended therapy with aspirin and an antiplatelet drug (clopidogrel) for 12 
months after the implant. In case of BMS implant, the same therapy is recommended for only 4 
weeks
20-21-22
. Patient follow-up is not determined by type of stent implanted but is based on 
monitoring of cardiovascular disease, and occurs with.ambulatory access or hospital admission in 
cardiovascular department depending on diagnostic tool utilized (ECG, cardiomyography, or other). 
Comment 
Available scientific evidence is limited since studies didn‘t compare DES with the latest, technically 
improved BMS generation.  
What kind of changes can the implementation of DES generate in the quality of 
care ?  
Methods 
Systematic literature review. 
Results 
There are numerous definitions of quality in health care. The most widely quoted definition is that 
of the Institute of Medicine (Institute of Medicine in Washington, D.C., is part of the National 
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Academy of Sciences): ―Quality of care is the degree to which health services for individuals and 
populations increase the likelihood of desired health outcomes and are consistent with current 
professional knowledge23.‖ 
Quality of health care has several dimensions. Quite often reference is made to the following three 
elements of quality first proposed by Avedis Donabedian: structure, process, and outcome. Quality 
of health care related to the structure refers to the quality of the facilities and the environment in 
which health care is provided: buildings, equipment, degree of training of health care professionals 
and so on. Process quality refers to the correctness and appropriateness of the actual care that is 
provided: decisions concerning an indication to operate, how the operation was carried out, etc. 
Quality of health care outcomes refers to the actual result of care: improved health, patient 
satisfaction, reduced pain and so on.  
Therefore from an organisational perspective, DES seems not to influence process quality since the 
interventional procedure (implantation) remains the same as in BMS.  
Comment 
Relevant information about quality of care is provided in the domain about effectiveness. 
(De)centralization   
Where will DES be placed (primary - secondary - tertiary care)?  
Methods 
Systematic literature review. 
Results 
DES technology is used in a hospital-based surgical procedure (PTCA), so that the utilization 
context is the secondary or tertiary care. 
Comment 
A debate on hospital requirements to perform PTCA is ongoing. In particular in Zavala et al.24 and 
in Richardson et al.25 the more controversial issue is about the availability of cardiosurgery services. 
Thus, the structural requirements seem to overshadow  other requirements.  
 
How is accessibility taken into account?  
Methods 
Systematic literature review. 
 
EUnetHTA WP4 - Core HTA on drug eluting stents (DES) 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
113 
Results  
Introducing medical stents implies the same problems as introducing any new technologies in 
medicine: it is crucial to assess their impact on clinical practice in relation with the type of patients 
(compared to selected patients enrolled in clinical trials, ordinary patients may present 
heterogeneous clinical characteristics). DES dissemination in Europe varies from 14% (of total 
stents) in Germany to 65% in Portugal (2006)
4
. These differences can be partly explained by a lack 
of structured guidelines and by the high costs of the technology. The European Society of 
Cardiology organised a workshop involving clinicians, health economists and HTA experts, in order 
to discuss the equity of patient access to new technologies, including DES. The outcome of the 
meeting is published in the European Heart Journal. Participants concluded that the European 
guidelines have little practical influence, and that they should be systematically translated, 
explained, disseminated and updated by cardiologists. Also at national level the dissemination of 
DES is heterogeneous, while at a regional level there are some noteworthy experiences, such as the 
one of Emilia Romagna, where a committee of cardiologists developed its own guidelines, 
restraining the use of DES at 30% of the total PTCA procedures. This voluntary limit is based on 
future forecast of use according to patients' clinical characteristics. This shows that institutional 
decisions may influence patient access to the new technology.   
Comment 
Variations in using DES, both between and within health care organizations can occur due to 
different clinical opinions.  Such variability resulted in this experience in Emilia-Romagna
26
, a 
region of Italy with 4 million residents, where cardiac care is directed through a regional hub-and 
spoke model that includes both public and private facilities. Each centre (hub) is assigned a 
catchment area that includes a network of cardiology departments and wards (spokes). A regional 
commission of clinicians from both public and private hospitals defined guidelines on DES 
utilisation for the area and developed organizational and clinical appropriateness criteria. 
Nonetheless the 12 regional centres applied the guidelines very differently (see Figure below). 
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DES over- and underutilisation among cardiac 
Centres of Emilia Romagna 
 
 
 
 
 
 
 
 
 
Source : VARIOUS AUTHORS. Stent a rilascio di farmaco per gli interventi di angioplastica coronarica Impatto 
clinico ed economico. Dossier 91-2004 Agenzia Sanitaria Regionale Emilia Romagna. 
 
Unpublished data of an hospital with high intensive angioplasty activities highlights that in some 
cases cardiologists have different opinions in implanting a DES stent in single patients, with a range 
of variation from 20% to 40%.  
 
How can the organisation ensure the accessibility of DES? 
Methods 
Systematic literature review. 
 
Results  
Because of their high cost and unavailability of data regarding long term follow up, access to DES 
may be limited. Under current conditions, selective use of DES in high-risk patients seems the most 
acceptable strategy in terms of cost-effectiveness
27
. The main issue is the appropriate use of DES, in 
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order to submit eligible patients to the procedure, according to the guidelines developed. Therefore 
it becomes imperative to standardise processes, by defining shared health care profiles, which must 
be based on the same guidelines.   
What are the economies of scale in (de)centralization?  
Methods 
Systematic literature review. 
Results  
From the point of view of the organisations acquiring DES, it is possible to achieve economies of 
scale through centralised purchasing, as happens in two Italian regions (Emilia Romagna and 
Sicily). Price is negotiated between Regions and producers, and since products are purchased in big 
quantities, the prices are lower than to single centres. 
Staff   
What kinds of experts are involved in DES? What kind of training is needed?  
Methods 
Systematic literature review. Semi-structured interview with expert physicians in cardiology, 
purchase managers.  
Results 
Expertise for DES implantation is not much different from that needed for BMS, because the 
expertise and training are connected to the angioplasty procedure, regardless of stent type. If IVUS 
diagnostics are used, special training should be recommended. 
Comment 
The rate of IVUS utilisation is not equal worldwide. In USA IVUS was used in about 20% of 
patients during PTCA, while in Europe there was a relatively lower use of IVUS. 
What kind of incentive structures (financial, concerning career, work-processes 
etc.) might be established for staff when implementing DES?  
Methods 
Systematic literature review and a semitructured interview with physicians in an Italian Hospital. 
 
 
Results  
EUnetHTA WP4 - Core HTA on drug eluting stents (DES) 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
116 
 
The literature search highlighted a rising trend in DES use, also outside the indications in the 
guidelines established. Overuse in some American states may be explained with the fact that 
cardiologists receive 800$ for each DES implant
 28
, unlike in Italy. The research did not highlight 
forms of incentives, despite DES can be overused. An analysis of unpublished data of a hospital 
with high intensive angioplasty activity suggests that it is crucial to plan incentives for an 
appropriate DES use. Cardiologists must not only follow the agreed procedures, but also apply 
appropriate procedures to each patient depending on patient characteristics.  
What effect can DES have on job satisfaction?  
Methods 
Systematic literature review and a semitructured interview with physicians in Italian Hospitals. 
 
Results  
The literature search did not identify information on cardiologists‘ satisfaction in implanting DES. 
A survey submitted to 140 American cardiologists before DES approval highlighted an enthusiastic 
attitude of the specialists, who forecasted a significant use of DES in the next few years. This 
proves that a lack of data on long term follow up was not a restraint for cardiologists
29
. This attitude 
has been named "technological imperative" by Victor Fuchs
30
. 
 
Similar conclusions emerged in a study carried out in the Duke Hospital in 2004
31
. Cardiologists‘ 
initial enthusiasm decreased after the Barcelona International Meeting in 2006, where studies were 
presented, which demonstrated a major risk of late thrombosis in patients implanted with DES. 
BASKET-LATE study monitored more than 826 patients (545 treated with DES and 281 with 
BMS) for an 18-month follow-up period
32
.  
 
The risk of thrombosis and other adverse events increased in patients implanted with DES stents, 
who stopped using clopidogrel. An internal audit in an Italian hospital showed doctors would be 
much more satisfied, if they could use new technologies with the procedure, such as IVUS or OCT. 
Furthermore, using new technologies can be an opportunity to carry out clinical studies, produce 
new publications and increase professional prestige of both cardiologists and the organisation. 
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Figure 1: Rate of late-stent thrombosis (adaptation from Basket –Late study) 
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Figure 2: Outcomes related to late-stent thrombosis (adaptation from Basket –Late study) 
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How will know-how of a new technology be spread out among the staff?  
Methods 
A semistructured interview has been made whith opinion leaders in interventional cardiology 
 
Results  
An interview to the specialists pinpointed that DES implants do not require additional know-how 
with respect to BMS (traditional technology). On the other hand, it may become necessary to 
acquire new competencies if DES implants are performed with technologies such IVUS and OCT.  
 
Co-operation and communication 
What kind of coordination and communication of activities does DES require?  
Methods 
A semistructured interview has been made whith opinion leaders in interventional cardiology. 
Results  
DES stents do not require any additional forms of communication and cooperation between hospital 
units, neither outpatient services nor hospital structures, because implant procedures are the same as 
for BMS (traditional technology). 
 
What kind of information is given to the patients about the DES?  
Methods 
Systematic literature review. 
Results  
There is the clinical priority to provide patients (and often their relatives) with adequate information 
about the proposed procedure, in order to let them appropriately decide whether to continue the 
procedure or not. It is crucial that they understand
 
the whole procedure and the risks involved, as 
well as all other treatment options available. In seeking patient
 
consent, legislation is similar in 
cardiological and other medical procedures
33
. 
 
Generally speaking, when informed consent is required, some recommendations must be followed. 
For example in Italy, guidelines from the Ministry of Health are as follows:  
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1. To make sure that in the text to be signed by patients the information is concise, simple and 
understandable, without specific medical words;  
2. to accompany written text with exhaustive and detailed explanations; and 
3. if possible, to involve the general practitioner
 34
. 
 
A literature search on international websites confirms that much information is available for 
patients, provided by the manufacturers (Boston Scientific
35
 and Cordis
36
), and institutions, (i.e. 
information provided to patients by Queensland Government or by UK National Health Service)
37
. 
 
However such information should be provided by cardiologists who perform the procedure.   
 
For a fully informed consent of the patient, the format designed by Queensland Government, 
requires that the doctor explains to the patient his/her medical conditions and the procedure to 
follow, in order to make the patient aware of the risks involved, both general and specific, and the 
possible outcomes. The doctor should also present other therapeutic options and their risks and 
introduce the prognosis and the risks of not following the procedure
38
. An FDA report outlines that 
patients do not receive adequate informed consent after diagnosis and before the intervention
39
.  
How is the information controlled in integrated patient path with respect to 
DES?  
Methods 
Systematic literature review. 
Results 
The literature search did not find guidelines or recommendations about the timing for 
communication and about who is in charge of giving the correct information to patients. 
Several studies underline the importance of having an adequate communication level between 
physicians and patients. In particular a case study on 199 patients40 examined the outcome of 
improved communication aimed at empowering patients to be more effective participants in 
rehabilitation after surgery. In the intervention group, hospital stay was shorter (by 1 day), 
incidence of post-surgery tachyarrhythmia was reduced (by 15%), transfer to less intensive care 
levels was faster and patient ratings for communicative quality of care by doctors and nurses were 
improved. 
Comment 
The personnel in charge of informing patients should be predefined. Information should preferably 
be provided by the cardiologist in charge of the patient, in order to provide enough time to 
understand and decide. This issue has some common areas with the ―ethics‖ domain. 
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Finances  
What kinds of investments are needed (material or premises)? 
Methods 
A semistructured interview has been made whith purchasing managers who prepare all purchase 
orders. 
Results  
Introduction of DES doesn‘t require changes in investments as compared to BMS. 
 
How does the costs of DES influence to the purchasing decision? 
Methods 
A semistructured interview has been made whith budget managers and opinion leaders in 
interventional cardiology. 
Results  
Since DES are high cost tecnhologies, the purchasing decisions are influenced by budget constraint. 
It is possible that purchasing managers of health care organizations can acquire fewer DESs than 
required by users. A negotiation between clinicians and budget managers may be needed to obtain a 
correct trade-off between clinical and budget needs.  
Is the number of DESs purchased influenced by cost?  
Methods 
Systematic literature review. Semi-structured interviews conducted with cardiologists, regional 
policy makers, hospital general management, and purchasers in Italian context. We found additional 
information by internet search of gray literature. 
 
Results 
The new technology costs are higher than the traditional ones
25-41-42-43
. This difference varies across 
countries and in most cases DES technology costs twice the traditional BMS. Financing systems 
can limit the use of DES. For example, until 2006 in Italy44 the reimbursement system (based on 
DRG) paid hospitals for a stent implantation the same amount of money for DES and for the 
traditional BMS, as a consequence DES use was not encouraged. Some Italian regions applied 
different reimbursement for DES. Since 2006 a new specific DRG was applied at a national level. 
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Comment 
This issue has some overlapping areas with the domain ―Costs and economic evaluation‖ 
 
Which organizations participate in payment arrangements (investments and 
running costs)?  
Methods 
Systematic literature review. 
 
Results  
Within the Italian Health Service, investments in new technologies are made directly by hospitals. 
Because of the high costs of DES, some Italian Regions have attempted to decrease costs through 
forms of centralised purchasing.  
 
What is the relevance of DES (in financial matters) to other activities of the 
hospital?  
Methods 
A semistructured interview has been made with opinion leaders in interventional cardiology 
 
Results  
Within the organizations which operate with fixed annual budgets, the number of procedures with 
DES, (three times more expensive than BMS), highly impact the allocation of available resources.  
 
DES impact on overall expenditure for PTCA with stent insertion could increase from 20% to 300% 
assuming DES utilization from 10% to 80% correspondingly on overall of stent insertions. The 10% 
- 80% range represents the EU countries' variation range in stent implantation.   
 
What is the likely budget impact of DES for the government?  
 
Methods 
Systematic literature review. 
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Results  
As all innovative technologies, also DES have both an economic and a clinical impact. An Italian 
region (Sicily) assessed the economic impact of introducing DES in health organizations, local 
hospitals, and the Regional Health Service. 
Five main changes were observed:  
1. The costs of PTCA increased (DES are more expensive than BMS); 
2. The number of PTCAs increased, because the number of patients treated as an alternative to 
bypass operations increased; 
3. The number of bypass operations decreased. From the analysis made by Boston Scientific, 
using GISE 2001 data, with respect to PTCA and  hospital discharge records 2001, it 
emerged that PTCA/CABG ratio in Sicily is 2.26 and was lower than regional best 
performers (Piemonte 3.31, Toscana 3.14, Veneto 2.85). Therefore, Sicily Region can 
optimise its  PTCA/CABG ratio in favour of PTCA; 
4. The number of reinterventions decreased, since restenosis rates decreased; 
5. The social advantages of reintroducing patients in working environments, without a need for 
rehabilitation or convalescence (general post-bypass time of rehabilitation is 2 months, post-
PTCA 3-7 days). 
Similar conclusions have been drawn by NHS R&D HTA Programme, which in the report 
Coronary artery stents: rapid systematic review & economic evaluation, in 2003 forecast an 
increasing impact of total costs for NHS, due to three main factors: 
1. increasing DES costs,  
2. DES target population (DES are cost effective for patients at high risk of restenosis), and 
3. offset costs level, which comes from reducing needs for revascularization, associated with 
the use of DES.  
Moreover, the final impact of sirolimus-eluting stents on Canadian Health Care budget, even 
after allowing for savings from a reduction in repeated revascularizations, may reach $35 
million in Quebec only, and $75 million in Canada. Therefore, this single technology may 
consume up to 4% of the $2.1 billion of the funds provided by federal and provincial 
governments per year. 
 
Management and control 
Who sets the overall objectives and goals athe the national, regional and 
organisational levels? Who follows the achievement of goals? Who makes the 
decisions of investments of DES? 
Methods 
Analysis of selected studies 
 
Results  
Recommendations on DES utilization have been established by regulatory authorities (FDA) and by 
scientific societies (ESC European society of cardiology, ACC/AHA American College of 
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Cardiology, American Heart Association). Examples of a systematic implementation on a regional 
bases of monitoring and management system on DES utilization come from in two Italian regions 
(Emilia Romagna and Sicily), where regional registers have been established. 
Investment decision on DES utilization can be related to two levels of decision making: 
 Macro level: government authorities can support the diffusion of DES trough favourable 
reimbursement system. For example in some cases a specific DRG on DES insertion has 
been established. 
 Meso level: in health care organizations there may be a trade-off between physicians' 
needs, favouring DES introduction, and budget constraint. Thus investment on DES can 
be influenced by budget negotiations between management and physicians. 
Who decides which patients receive DES treatment and on what basis?  
Methods 
Analysis of selected studies 
Results 
Cardiologists, on the basis of a diagnostic exam (coronary angiography), should be the main 
decision makers for a stent implantation procedure. They should decide this based on the kind of 
lesion and its length. Patients with diabetes, in whom restenosis is more frequent, should be usually 
treated with DES. 
 
Who will handle management and information responsibility? 
Results  
Data for formulating recommendations on the use of DES, are managed, assessed and disseminated 
in guidelines produced by clinical scientific societies or HTA agencies. Moreover, several 
regulatory authorities (FDA, NICE) have given recommendations on DES appropriate utilization.   
 
What management competences are needed at all levels? 
Results  
DES management requires: 
 Clinical skill to manage DES in clinical practice;  
 Multidisciplinary competence for assessment activities (clinical, economical and 
organizational skills are required).   
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Who is responsible for sanctioning at all levels? 
Results  
In European public health care systems sanctioning usually is linked to denied funding. So the 
responsibility is committed to governmental authorities. 
 
Stakeholders 
How will the other interest groups of DES be taken into account in the planning 
/ implementation of the new technology?  
Methods 
Systematic literature review. 
 
Results  
Different stakeholders‘ perspectives on introducing DES have been summarized (Regulatory 
Authority, Healthcare Organization, Patients Organization, and Pharmaceutical Industry). 
 
 
Regulatory Authorities are responsible for regulating both the introduction of new technologies 
(through approval procedures) and their use, by monitoring adverse events related to them.  
With regard to monitoring activities, on the basis of the results of recent studies, (where the follow 
up time of patients enrolled was longer than in the previous studies, an higher risk of late trombosis, 
in case of off label DES, was highlighted), FDA recommends the use of  DES only for approved 
indications (not off-label use)
46
.  In Europe, the European Society of Cardiology (ESC) provided 
guidelines for DES utilization
8
. In Italy, in particular, the Emilia Romagna Committee limited DES 
utilisation to patients with specific clinical characteristics (diabetes, specified length and width of 
lesions)
25
. 
National/Regional government: In health systems where interventions are reimbursed according 
to agreed rates, policymakers‘ decisions (at national/regional level) on DES and BMS rates highly 
influence stent utilization (incentive – disincentive) 49. 
In Italy most Regional Health Services do not specify diagnosis-related groups (DRGs) for DES; 
DES are reimbursed at the same rates of traditional stents, even though they are more expensive. 
This discourages DES utilisation in hospitals
25
.  
In USA, new DRGs for DES with (DRG 526) and without (DRG 527) acute myocardial infarction, 
have been created by the Centers for Medicare and Medicaid Services, but these DRGs may not be 
sufficient to cover the acquisition costs of the DES compared with the DRGs for bare metal stents 
(DRGs 516 and 517)
 50
. 
Patient Perspective: Most patients do not have the training necessary to interpret this level of 
scientific data and must base their assessment on other sources. In the modern era, the media and 
direct patient advertising provide the major sources of this information. Given the positive results of 
most DES studies reported in peer-reviewed journals and the media response to these results, it is 
EUnetHTA WP4 - Core HTA on drug eluting stents (DES) 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
125 
not surprising that patients believe that DES should be used for all patients and for all indications. 
In conclusion, from the patient‘s perspective, optimal utilization is nearly 100%. This is based on 
the belief that the DES is equally beneficial in all settings and that it provides a lasting cure rather 
than a treatment for symptoms.  
A literature search highlighted that government authorities, in developing recommendations on the 
appropriate use of devices, involve patient representatives. 
In USA, in the FDA Patient Representative Program, the Patient Representative's role is to provide 
the advisory committee and FDA insight on issues, problems, and questions pertinent to the 
viewpoint of patients and family members living with a specific serious or life-threatening disease. 
Representatives serve as voting or non-voting members of the advisory committee
51
. 
In UK, The Patient and Public Involvement Programme (PPIP) at NICE is dedicated to developing 
and supporting opportunities to involve patients, in shaping NICE policy
52
.  
Also in Canada COMPUS (Canadian Optimal Medication Prescribing & Utilization Service) 
gathers information from different stakeholders, including patients and consumers, health care 
providers and pharmaceutical manufacturers
53
. 
Discussion  
The objective of organizational domain was to assess what kinds of resources (material things, 
human skills and knowledge, money, etc) need to be mobilised and organised when implementing 
DES procedure, and what kinds of changes or consequences the use can further cause in the 
organisation. The investigation of DES impact on management and structure of organization was 
very complex, because organisational aspects are rarely analysed within clinical studies and HTA 
reports. A traditional systematic literature review was not completely suitable to obtain full 
information on organisational aspects, and it was necessary complete the search with analysis of 
other sources.  
It is the opinion of the authors that lack of information on organizational aspects means there were 
no relevant changes depending on type of stent used. In fact the patient path is determined by type 
of procedures (bypass or angioplasty). 
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Appendix 1 - Characteristics of studies included in systematic review 
 
Study Authors Source Study design Inclusion criteria 
A randomized comparison of a sirolimus-
eluting stent with a standard stent for 
coronary revascularization.  
Morice M: et al. 
N Engl J Med. 2002 Jun 6; 
346 (23):1773-80. 
Clinical trial Relevant for  utilization topic 
DRUG-ELUTING STENT TASK FORCE: 
Final Report and Recommendations of the 
Working Committees on Cost 
Effectiveness/Economics, Access to Care, 
and Medicolegal Issues,  
Hodgson John McB. et 
al. 
Catheterization and 
cardiovascular interventions, 
2004: 62: 1-17 
Review Relevant  to utilization topic 
Cost-effectiveness of drug-eluting coronary 
stents in Quebec, Canada.  
Brophy J.M. et al. 
Int. J. Of Technology 
Assessment In Health Care 
21:3, 2005 
Comparative study Relevant to utilization topic 
Economic Evaluation of Drug Eluting 
Stents. 
Various Authors 
CCOHTA, Technology 
report. Issue 53. February 
2005. 
Health Technology 
Assessment report  
Relevant  to utilization topic 
Guidelines for Percutaneous Coronary 
Interventions: The Task Force for 
Percutaneous Coronary Interventions of the 
European Society of Cardiology. 
Sigmund Silber, et al. 
  Eur Heart J 2005 26: 804-
847. 
Guideline Relevant o utilization topic 
TASK FORCE MEMBERS: 
ACC/AHA/SCAI 2005 Guideline Update for 
Percutaneous Coronary Intervention—
Summary Article A Report of the American 
College of Cardiology/American Heart 
Association . 
Elliott M. Antman et al. 
Circulation. 2006; 113:156-
175. 
Guideline Relevant to utilization topic 
TASK FORCE MEMBERS: ACC/AHA 
Guidelines for Percutaneous Coronary 
Intervention (Revision of the 1993 PTCA 
Guidelines)  
Sidney C. Smith et al. 
Circulation 2001;103;3019-
3041 
Guideline Relevant to utilization topic 
Relationship between Procedure Indications 
and Outcomes of Percutaneous Coronary 
Interventions by American College of 
Cardiology/American Heart Association 
Task Force Guidelines.  
H. Vernon Anderson et 
al. 
Circulation 2005;112;2786-
2791 
Guideline Relevant to utilization topic 
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Optical Coherence Tomography (OCT). 
Potential of a new high-resolution 
intracoronary imaging technique.  
Gerckens
 
U. et al. 
Herz. 2003 Sep;28(6):496-
500 
Comparative study Relevant to utilization topic 
Drug-Eluting Stents and the Future of 
Coronary Artery Bypass Surgery: Facts and 
Fiction, 
Shahzad G. Raja 
Ann Thorac Surg 
2006;81:1162–71 
Review Relevant  to work process topic 
Stent Thrombosis Redux — The FDA 
Perspective, 987. 
Farb A. et al. 
N Engl J Med 2007  356;10: 
984- 
Review Relevant to work process topic 
Final Appraisal Determination, Coronary 
artery stents, available on  
Various Authors 
NATIONAL INSTITUTE 
FOR CLINICAL 
EXCELLENCE 
Health Technology 
Assessment report  
Relevant to work process topic 
Safety of elective--including "high risk"--
percutaneous coronary interventions without 
on-site cardiac surgery. 
Zavala A. E. et al. 
Am Heart J. 2004 Oct; 
148(4):676-83. 
Multi centre study   Relevant to work process topic 
Management of acute coronary occlusion 
during percutaneous transluminal coronary 
angioplasty: experience of complications in 
a hospital without on site facilities for 
cardiac surgery.  
Richardson SG. Et al. 
BMJ. 1990 Feb 10; 
300(6721):355-8. 
Comparative study Relevant to work process topic 
Effect of Hospital ownership status and 
payment structure on the adoption and use of 
drug-eluting stents for percutaneus coronary 
interventions. 
Grilli R. et al. CMAJ 2007, 16; 176-185. Comparative study Relevant f to (De)centralization topic 
Coronary artery stents: rapid systematic 
review & economic evaluation, 
Various Authors. NICE Review Relevant to Staff  topic 
Economic impact of Drug eluting stents on 
Hospital Systems: a disease-state model. 
Kong D.F. et al. 
Am Heart Journal; 2004; 147 
(3): 449-56. 
Evaluation study Relevant to Staff  topic 
Consent in cardiology: there may be trouble 
ahead? 
Curzen N. et al. Heart 2005;91;977-980 Evaluation study 
Relevant to Cooperation and 
communication topic 
Does physician–patient communication that 
aims at empowering patients improve 
clinical outcome? A case study.  
Trummer U. et al. 
Patient Education and 
Counselling 61 300 (2006) 
299–306. 
Clinical trial  
Relevant to Cooperation and 
communication topic 
Economics of Sirolimus-Eluting Stents: 
Drug-Eluting Stents Have Really Arrived 
Weintraub S. W. 
Circulation 2004;110;472-
474 
Comparative study Relevant to Stakeholder topic 
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Appendix 2 - Characteristics of references of grey literature used 
 
Reference Authors Source Publication Types  Inclusion criteria 
American College of cardiology, 
Scientific session news. I2 summit 
2007.  
Various Authors http://www.acc07.acc.org/ssn/Sun_SSN.pdf 
Newsletter of  ACC 07 
Scientific session 
Relevant to utilization 
topic 
Improving patient access to novel 
medical technologies in Europe.  
Kerney P. et al l. Eur Heart Journal, 2006 Apr;27(7):882-5 Congresses 
Relevant  to utilization 
topic 
Can we afford to eliminate restenosis? 
Can we afford not to?  
Greenberg D. et al. Am Coll Cardiol 2004; 43: 513-518. Comment 
Relevant  to utilization 
topic 
Processo agli stent.  Codignola A. Panorama 2007 (18): 221. Comment 
Relevant  to utilization 
topic 
Stent a rilascio di farmaco per gli 
interventi di angioplastica coronarica 
Impatto clinico ed economico.  
Various Authors 
Dossier 91-2004 Agenzia Sanitaria Regionale 
Emilia romagna 
http://asr.regione.emilia-romagna.it/ 
Dossier 
Relevant  to utilization 
topic 
Cost effectiveness of eluting stents 
versus other treatments ― 
M. Oradei, C. 
Marano, M. 
Marchetti. 
HTA annual meeting 2004, Krakov June 2004,  Oral Presentation 
Relevant to utilization 
topic 
Stent a rilascio di farmaco: dai risultati 
degli studi clinici ai modelli di impatto 
economico-sanitario nella realtà 
italiana. 
Sangiorgi et al. Ital Heart J Suppl 2005; 6: 145-156. Evaluation study 
Relevant to utilization 
topic 
Primary coronary intervention in acute 
myocardial infarction,  
Kim C. X. et al Ital Heart J 2004; 5 (Suppl 6): 76S-82S) Evaluation study 
Relevant to work process 
topic 
Medicare: A Strategy for Quality 
Assurance.  
Lohr KN 
Volume I. Institute of Medicine. Washington, 
DC: National Academy Press; 1990 
Books 
Relevant  to work process 
topic 
Stent coronarici a rilascio di farmaco,  Various Authors 
Ministero della salute CUD ( Commissione Unica 
Dispositivi, 
Dossier 
Relevant  to work process 
topic 
Guideline for the use of clopidogrel in 
combination with aspirin in Coronary 
Heart Disease (CHD) 
Various Authors 
NHS Bedfordshire and Hertfordshire Cardiac 
Network, 
Dossier 
Relevant  to work process 
topic 
DMS Project discovers excessive 
surgery rates 
Blodget K, The darmount.com news comment 
Relevant  to work process 
topic 
Who shall live? Health economics and Fuchs, V.R  Basic Books, (1974), New York Books  Relevant to 
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social choice.  (De)centralization topic 
BASKET-LATE: Late Clinical Events 
Related to Late Stent Thrombosis After 
Stopping Clopidogrel: Drug-Eluting vs 
Bare-Metal Stenting:  
Gruberg L. http://www.medscape.com/viewarticle/ Comment  
Relevant to 
(De)centralization topic 
Sperimentazione controllata e 
randomizzata (RCT)  
Various Authors Bollettino di informazione sui farmac Comment Relevant to Staff  topic 
TAXUS® Express2™ Paclitaxel-Eluting 
Coronary Stent System.  
Various Author Boston scientific. Patient information guide 
Relevant to Cooperation 
and communication topic 
CYPHER® Sirolimus-eluting Coronary 
Stent, 
Various Author Cordis (Johnson & Johnson). Patient information guide 
Relevant to Cooperation 
and communication topic 
Recovering from coronary angioplasty 
and stent insertion,  
Various Authors NHS trusts. Trust New Castle  Patient information guide 
Relevant to Cooperation 
and communication topic 
Protecting Patients Through Informed 
Consent and Appropriate Therapy.  
Grover F. 
http://www.fda.gov/ohrms/dockets/AC/06/slides/
2006-4253oph2_22_Grover.pdf 
Oral presentation  
Relevant to Cooperation 
and communication topic 
TAXUS®  FDA approval  Various Authors http://www.fda.gov /cdrh/pdf3/POO0026a.pdf FDA approval  
Relevant to Stakeholder 
topic 
CYPHER® FDA approval  Various Authors http://www.fda.gov /cdrh/pdf3/ PO30025a.pdf FDA approval  
Relevant to Stakeholder 
topic 
Boston Scientific Becomes Only 
Company With Two Drug-eluting Stent 
Platforms 
Various Authors 
www.medicalnewstoday.com/medicalnews.php?n
ewsid=54565  
News  
Relevant to Stakeholder 
topic 
Medtronic stent begins FDA pre-market 
approval process 
Various Authors 
www.bizjournals.com/phoenix/stories/2005/10/1
0/daily1.html 
 
News  
Relevant to Stakeholder 
topic 
Update to FDA Statement on Coronary 
Drug-Eluting Stents 
Various Authors http://www.fda.gov/cdrh/news/010407.htmll Appraisal  
Relevant to Stakeholder 
topic 
FDA Patient Representative Program,  Various Authors http://www.fda.gov/oashi/patrep/patientrep.htmll Appraisal 
Relevant to Stakeholder 
topic 
NICE Patient and Public Involvement 
Programme  
Various Authors  www.nice.org.uk/page.aspx?o=PatientPublic Guideline  
Relevant to Stakeholder 
topic 
CADTH COMPUS (Canadian Optimal 
Medication Prescribing & Utilization 
Service). 
Various Authors 
http://www.cadth.ca/index.php/en/compus/about/
procedures 
Guideline  
Relevant to Stakeholder 
topic 
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APPENDIX 3: Table template for translating assessment elements 
 
 
Domain Topic Issue Relevance in the context of DES 
Yes/No 
Research question(s) in the context of DES Importance 
3=critical 
2=important 
1=optional 
Transfera-bility 
3=complete 
2=partially 
1=not 
       
Organisational 
aspects 
Utilization 
How is the new technology 
accepted by the organisation? 
YES 
How are DES accepted by interventional 
cardiologists of health 
care organizations? 
 
3,2,2,3,2,2,3 
 
2 
3,1,2,2,2,2,2 
 
2 
Organisational 
aspects 
Utilization 
How is the new technology 
accepted by the organisation? 
YES 
How are DES accepted by Financial 
Management of Health 
Care Organizations of 
health care 
organizations? 
 
3,2,2,3,2,2,3 
 
2 
3,1,2,2,2,2,2 
 
2 
Organisational 
aspects 
Utilization 
How do the patients accept the new 
technology? 
YES  
3,2,2,3,2,2,2 
 
2 
3,1,2,2,2,2,2 
 
2 
Organisational 
aspects 
Utilization 
What kind of technical problems 
can the implementation of a new 
technology produce? 
YES 
Are the DES use related with the adoption of 
new procedures or other 
instruments? 
1,2,3,3,3,2,3 
 
3 
3,3,2,3,2,1,2 
 
2 
Organisational 
aspects 
Work processes 
What kinds of changes are required 
in the work processes when 
implementing new technology?  
NO because DES implantation compared with 
BMS doesn’t need the adoption of new or 
different work processes. 
 
2,3,3,3,3,2,3 
 
3 
3,1,2,2,2,2,2 
 
2 
Organisational 
aspects 
Work processes 
What kinds of changes are required 
in the patient path when 
implementing new technology? 
No because DES interventions techniques do not 
differ from coronary angioplasty (PTCA) with 
traditional stents (BMS).  
 
1,2,3,2,3,2,2 
 
2 
 
2,1,2,2,2,1,2 
 
2 
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Organisational 
aspects 
Work processes 
What kind of changes can the 
implementation of a new 
technology generate in the quality 
of care?  
NO because DES does not influence the quality 
of process since the interventional procedure 
(implantation) still remains the same. 
 
3,2,3,2,3,2,3 
 
3 
2,2,2,2,2,2,2 
 
2 
Organisational 
aspects 
(De)centralisation 
Where will the new technology be 
placed (primary - secondary - 
tertiary care)?  
YES  
3,3,3,3,3,2,3 
 
3 
1,2,1,2,2,2,2 
 
2 
Organisational 
aspects 
(De)centralisation How is the accessibility taken into 
account? 
 
How can the organisation ensure 
the accessibility of a new 
technology? 
YES  
 2,3,2,3,2,2,3 
 
2 
2,1,2,1,1,1,1 
 
1 
Organisational 
aspects 
(De)centralisation What are the economies of scale 
and quality of scale of the 
(de)centralisation? 
YES 
 1,1,2,2,2,2,2 
 
2 
3,1,1,1,1,1,1 
 
1 
Organisational  Staff What kinds of experts are involved 
in the new technology? What kind 
of training is needed? 
NO  because Expertise for DES implantation is 
not much different from the one needed for the 
BMS 
 3,3,3,3,3,3,3 
 
3 
2,2,2,2,2,2,2 
 
2 
Organisational  Staff What kind of incentive structures 
(financial, career-wise, work-
process-wise, treatment-wise etc.) 
might be established for staff when 
implementing a new technology?  
YES 
 3,3,1,2,2,1,2 
 
2 
3,2,1,2,2,1,1 
 
2 
Organisational 
aspects 
Staff What kind of meaning can a new 
technology have in relation to job 
satisfaction? 
YES 
 1,1,1,1,1,1,1 
 
1 
2,1,2,1,2,1,1 
 
2 
Organisational 
aspects 
Staff How will know-how of a new 
technology be spread out among 
the staff? 
NO because DES implant doesn’t need further 
know how with respect to BMS  
 2,2,2,2,2,2,2 
 
2 
3,2,2,2,2,2,2 
 
2 
Organisational 
aspects 
Co-operation and 
communication  
What kind of co-ordination and 
communication of activities does 
the new technology require? 
NO because DES doesn’t require any additional 
forms of cooperation and communication between 
hospital units.  
 2,2,2,3,2,2,2 
 
2 
3,2,2,2,2,2,2 
 
2 
Organisational 
aspects 
Co-operation and 
communication  
What kind of information is given to 
the patients about the new 
technology? 
YES 
 1,3,3,2,2,2,3 
 
2 
3,2,2,2,2,2,2 
 
2 
Organisational 
aspects 
Co-operation and 
communication  
How is the information controlled in 
integrated patient path with respect 
to a new technology? 
YES 
 3,3,3,3,3,3,3 
 
3 
3,3,2,3,2,2,2 
 
2 
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Organisational 
aspects 
Finances What kinds of investments are 
needed (material or premises)?  
NO because Introduction of DES doesn’t require 
changes in investments matter compared to BMS. 
 3 2 
Organisational 
aspects 
Finances How does the costs of the new 
technology influence to the 
purchasing decision? 
YES 
 2 2 
Organisational 
aspects 
Finances How does the costs of the new 
technology influence to the 
purchasing decision? YES 
Is number of DES purchased influenced by 
their higher costs? 
2 2 
Organisational 
aspects 
Finances Which organisations participate in 
the payment arrangements 
(investments and running costs)? 
YES 
 1,2,2,2,2,1,2 
 
2 
2,2,1,1,1,1,1 
 
1 
Organisational 
aspects 
Finances What kind of relevance has the new 
technology (in financial matter) to 
other activities of the hospital? 
YES 
 1,2,2,2,2,2,2 
2 
2,2,1,1,1,1,1 
1 
Organisational 
aspects 
Finances What is the likely budget impact of 
the technology for the government? YES 
. 
 
 
3 
 
1 
Organisational 
aspects 
Management and 
controlling 
Who makes the overall objectives 
in national / regional / 
organisational level? Who is setting 
goals? Who will follow up on goal 
achievement? Who makes the 
decisions of investments of a new 
technology? 
YES 
 2,2,2,2,2,2 
 
2 
1,1,1,1,1,1 
 
1 
Organisational 
aspects 
Management and 
controlling 
Who decides which patients are to 
undergo a treatment and on what 
basis?  
YES 
 2,3,2,3,3,3 
 
3 
2,2,2,2,2,1 
 
2 
Organisational 
aspects 
Management and 
controlling 
Who will handle management, 
responsibility and evaluation of 
information? 
YES 
 1,3,2,2,3,3 
 
3 
1,1,1,1,1,1 
 
1 
 
Organisational 
aspects 
Management and 
controlling 
What management competences 
are needed at all levels? YES 
 2,2,2,2,2,2 
 
2 
3,2,2,22,1 
 
2 
Organisational 
aspects 
Management and 
controlling 
Who is responsible for sanctioning 
at all levels? YES 
 1,1,1,1,1,1 
 
1 
1,1,1,1,1,1 
 
1 
Organisational 
aspects 
Stakeholders How will the other interest groups of 
the new technology be taken into 
account in the planning / 
implementation of the new 
YES 
 1,3,3,2,3,2,3 
 
3 
2,1,1,1,1,1,2 
 
1 
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technology? 
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Social aspects 
Heidi Anttila, Juha Koivisto, Päivi Reiman-Möttönen, Ilona Autti-Rämö, et al.  
 
Introduction  
Coronary disorders can not be cured by any current treatment. Regardless of the chosen treatment 
(e.g. revascularisation with DES or BMS or treatment with drugs) the coronary disease progresses 
individually. Also patients' commitment to changes in life-style may have a major effect on the 
outcome. The symptoms of coronary disease requiring medical intervention can thus reoccur. In 
many cases repeated interventions (re-stenting or coronary by-pass surgery) may be required.  
 
The social consequences of using DES or BMS can be expected to be the same for both 
technologies, as the only difference between these two technologies lies in the addition of drug to 
the stent. Thus we analyzed the social consequences of using any type of stent: drug eluting stents 
(DES) or bare metal stents (BMS). 
Methodology  
We conducted a literature search to find systematic reviews or primary studies on social issues 
related to the use of stents. We decided to include every empirical study that concerns some of the 
social issues and analysed what kind of information the studies provide concerning issues defined 
according to the translation model.  
 
In addition, to explore the differencies between DES and BMS, we consulted a content expert in 
thoracic and cardiovascular surgery (Pekka Kuukasjärvi, senior medical officer, Finohta). In a two 
hour interview the expert was asked to evaluate the consequences and differencies of using DESs 
compared to BMSs in relation to social issues. One researcher wrote down his answers.   
 
Translating the issues to study questions 
 
The two main questions in the social analysis are:  
1) What kind of resources (people, support, money etc.) must be mobilized and organized when 
using DES or BMS after the hospital stay in order to produce satisfactory results.   
Issues: 
 Support needed by the patient (from health care professionals, family and other related 
people, and services, systems and polices) 
 Arrangements needed at work place, at home or in any daily acitivites   
 
2) What kind of changes or consequences can the use of DES or BMS produce in the various life 
spheres of patients/citizens?  
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Issues:  
 Access to health care 
 Working life  
 Economy of a citizen 
 Family life 
 Social relations 
 Attitudes and self-conception 
 
We translated the issues to specific study questions simply by changing the word "technology" in 
the issues to "DES or BMS" (Appendix A).  
 
Locating and selecting the studies 
 
We searched systematic reviews and empirical studies from databases of  
1) social sciences: Sociological Abstracts, Social Services Abstracts, Social Care on line/Caredata, 
SocINDEX,  
2) medicine: Medline, EBM-databases (Cochrane, DARE, ACP Journal Club), Cinahl, Medic, 
SweMed+ ;  
3) other databases: Assia, Ageline, PsycINFO, ERIC, Academic Search Elite, and  
4) full text databases: Sage premier, SpringerLink, Blackwell Synergy, Science direct from the time 
of their inception to to March 2007.   
 
Innformation scientists at STAKES planned the literature searches for the various databases. The 
following search terms were used for searches in Medline: stent$, coronary stenosis, transluminal, 
percutaneous, coronary, coronary disease, coronary artery bypass, myocardial infarction,  
coronar$, angioplasty, heart, cardiac$, cardiol$, myocardi$, social welfare, social work, social 
security, social support, social, socio$, societal$, health services accessibility, access$, health 
resources, health priorities, patient selection, candidate$,  resource$, equit$, unequit$, allocate$, 
reallocate$, gender, age factors, professional-family ralations, professional-patient relations, 
family relations, famil$, patient$, nurse$, doctor$, physician$, staff$, personnel, relations$, work 
capacity evaluation, work simplification,  work$, job$, profession, return$, capacity$, facit$, 
ability$, workload, rehabilitation, vocational, attitude to health, patient$, attitude$, belie$, expect$, 
percept$, perceive$, experience$, asaptation, psychological, orientation, self concept, self efficacy, 
cope, soping, empowerment, social adjustment. In the other databases the search term was "stent*" 
in keywords or free text. The search strategies are attached (to be added in appendix B). 
 
Studies were eligible if they: 
 included patients with coronary artery disease, 
 investigated stents (drug-eluting sirolimus or paclitaxel stents or BMS or other type of 
stents) 
 consider patients outside the treating hospital (before or after hospital stay)  
 analyzed and reported results of any of the following social issues: access to health care, 
patient group selection, support, working life, economy of the citizen, family life, social life, 
values, attitudes, self-concept 
 study designs: systematic reviews or any kind of empirical studies that studied some of the 
social issues 
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Two researches (HA, PRM) separately screened all search results by titles and abstracts to select the 
articles to be ordered. One researcher (JK) evaluated the full text articles for inclusion criteria. 
Unclear cases were discussed and solved in consensus by the three reasearchrs.     
Assessing study quality 
 
There are several different models for assessing the quality of empirical studies other than 
randomized controlled trials. Due to time limits we were not able to assess study quality. 
 
Collecting data from individual studies 
 
The following study characteristics will be tabulated of the empirical studies:  
 Publication details: authors, year, social issue,  
 Nature of the study: aims/objectives of the study, user/carer involvement in the 
design/conduct of study, country, site (setting, key characteristics of the context), details of 
theory/conceptual model,  study type and design, study date and duration, 
sampling/recruitment, methods of data collection, data collector, used research tools (if any),  
analysis methods 
 Participant characteristics: gender, age, ethnicity, types of practitioners, policy makers or 
patients 
 Features of the studied intervention (when applicable):  aim of the intervention, country, 
location/setting, intervention process (description of how the intervention/servise was 
delivered) and 
 Outcomes and results: outcome measures, details of findings, strengths/limitations of the 
study, author's conclusions.   
 
Presenting and analyzing results 
 
We made a narrative synthesis and analysed the results with the help of the themes that arose from 
the selected studies.  
 
The literature searches yielded 1300 references; of wich 32 were ordered for closer consideration of 
the inclusion criteria (Figure 1). Eigth full text articles were not obtained until week 21 in May 2007 
and thus had to be excluded. Sixteen studies were excluded by the full text as they did not address 
the social domain issues (appendix C). Eight studies were included, and they were categorized to 
the social issues as follows: access to health care (n=2), support (n=5), working life (n=1) (1-8). 
Full details of the included studies are in appendix D. No studies were identified on the other issues. 
Thus the analysis of these issues is based on the expert interview only, which addressed solely the 
differencies between BMS and DES.  
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Figure 1: Selection of studies for inclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment elements 
Access to health care 
What kind of changes can the implementation of DES or BMS produce in the 
access to health care? 
Results 
We identified two studies focusing on patients' access to health care. Bond et al. (1) analysed equity 
in access by age group to cardiac procedures. The observational study was based on a retrospective 
case note analysis of 712 patients (388 males, 324 females) with diagnosed cardiovascular disease. 
Eligible patients were inpatients with a cardiac ICD-code (120-25) recorded on the patient 
administration system covering ischaemic heart disease, acute myocardial infarction or angina 
Search results:  
 
1300 
 
1268 excluded by titles 
and abstracts 
Included studies: 
 
8 
Full texts retrieved for 
further assessment: 
 
32 
 
Excluded:  
 16 not relevant for 
social domain issues 
 8 full text not obtained 
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pectoris (n=447) and a sample of 265 cardiac outpatient attendees. The analysis tracked each case 
backwards and forwards by 12 months from patient's study entry date. The primary outcome was 
weather the patient received the targeted interventions, e.g. exercise tolerance testing, cardiac 
catheterisation and angiography or revascularisation when indicated.  
 
Forty eight percent of the study patients were under 65 years, 31% were between 65- 75 years, 10% 
between 75-80 years and 11% over 80 years. The analysis showed that older hospital patients with 
ischemic heart disease, and with indication for further investigation, were less likely to be referred 
for exercise tolerance tests and cardiac catheterisation and angiography than younger people.  This 
was independent of both the gender and the severity of condition. The patients who underwent 
cardiac catheterisation and angiography were analysed in relation to their subsequent receipt of 
revascularisation. Of the 107 patients 31% were referred for revascularisation. Of these patients 
27% were under 65 years and 34% between 65-75 years. Two of the four people aged over 75 years 
underwent revascularisation. 
 
Rates of indicated interventions were relatively low for all the age groups, and lowest for the oldest 
patients. The patients did not appear to be discriminated in receiving the indicated treatments, 
except in the case of revascularisation, where older patients were more likely to be filtered out at the 
investigation stage. The study population was limited only to one district hospital in eastern 
London.  There might also be some underestimation of the denominator population due to lack of 
information how many patients with cardiac problems were not given a cardiac diagnosis on death 
and discharge.  
 
Rao et al. (2) study focused on the use of DES in clinical practice. The multicenter data from the 
ACC-NCDR registry included the information of 408,033 percutaneous coronary intervention 
procedures. Of those, 353,242 procedures (86.6%) involved stent placement. The initial part of the 
study examined the use of the Cypher stent. After the Taxus stent became available, the later part of 
the study examined the use of either stent.  The primary outcomes were the occurrence of in-
hospital mortality, adjusted in hospital mortality, post procedure MI, unplanned coronary artery 
bypass grafting and procedural success. 
 
During the study period of 21 months the proportion of procedures using DES increased from 
19.7% to 78.2%. There were significant patient-level and hospital-level differences in DES use. 
Although DES use increased in all patient groups and hospital types, adoption was slower among 
older patients and those without health insurance. There was a progressive decrease in the odds of 
DES use as age increased. White race, female sex, presence of insurance, diabetes mellitus, PCI of 
de novo lesion, PCI at a suburban hospital and PCI at a high volume center were significant 
predictors of DES use. To determine if the differences persisted after the introduction of the Taxus 
stent, the analysis was repeated after dividing the study period into 2 phases: before and after the 
availability of the Taxus stent. The same patient, clinical, and hospital characteristics were 
associated with DES use in both phases. The adjusted odds ratios and 95% confidence intervals 
were nearly identical in both phases. The analysis of data demonstrates that there was rationing of 
DES to certain patients subgroups. Non white patients and patients without health insurance appear 
to be much less likely to receive DES. The use of DES was higher at high-volume hospitals than at 
low-volume hospitals. These patterns persisted even after the introduction of a second DES product.   
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Expert interview:  
At this moment the clinical criteria for implementing BMS or DES are the same. Based on the 
effectiveness and cost-effectiveness studies we need to have clear indications for the use of DES.  
The consequences of patient selection for stents need to be evaluated.  
 
The cost of DES is ca. 1.5 times the cost of BMS. The decision to use DES instead of BMS will 
require a budget increase as the amount of patients needing stents remains the same. This will have 
major consequences on the reallocation of resources. The major question here is whether these 
resources will be taken from other patient groups in the cardiac unit or from any other patient group 
within the health care. At the end the funding of other interventional approaches (e.g. preventive 
measures) might be challenged. In the long run the costs may be balanced if the need of 
reoperations decreases when using DES. The major issue would then be how the released resources 
would be used. Will those be reallocated to areas that suffered when implementing DES or will it be 
kept within coronary units. How open and transparent these decisions are made will have 
consequences with relation to the public opinion. 
 
An increase in the use of DES may lead to limiting resources available for coronary patients who do 
not fulfil the criteria for these stents. It is most probable that patients needing a stent will receive it. 
The consequent limitation in resources (personal money) may also affect other patient groups. 
Comment 
The change in the available resources could produce changes in the access to health care that may 
differ between organisations. 
Support 
What kind of services, systems and policies do the patients with DES or BMS 
need after the hospital stay?   
Results 
We identified two studies adressing patient service needs after the hospital stay. Caulin-Glaser et al. 
(3) assessed gender differences for in-hospital secondary prevention instruction and physician 
referral to cardiac rehabilitation (CR).  A matched case, observational survey design was used to 
assess the referral for phase II outpatient cardiac rehabilitation based on gender at the hospital 
and/or follow-up physician visit after a cardiac revascularization procedure. Study subjects 
consisted of 80 patients (40 men, 40 women) who had been revascularized (50% balloon anglo-
plasty/coronary stenting, and 50% CABG). No patient had previously undergone a revascularization 
procedure.  The patients were 45 years old or older and English speaking, and geographically 
distributed throughout New Heaven County. They completed a survey addressing information and 
referral to cardiac rehabilitation during their hospitalization and at the follow-up physician office 
visit.  
 
The study results inform that women were less likely to be instructed on secondary prevention 
strategies and CR or referral to CR compared to men despite being matched for age and undergoing 
the same procedure. The data demonstrate a gender difference in hospital teaching and referral 
information for CR after revascularization. The instruction of patients concerning secondary 
prevention and CR postrevascularization procedure is poor. Within that group, women were far less 
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likely to have CR discussed or referrals made by healthcare professionals. The study demonstrates 
that all healthcare providers need education on the comprehensive nature and benefits of cardiac 
rehabilitation , with a particular emphasis on women. 
 
Edelman et al. (4) reports a qualitative analysis on the feedback provided by cardiac disease patients 
who attended a group cognitive behaviour therapy (CBT). The aims of the program were to reduce 
anxiety, depression and hostility. Eligible participants were males who had undergone stent surgery 
at one of the two major hospitals in Sydney. The participants were randomized to either a group 
CBT intervention or a "standard care" control group.  Participants attended eight weekly group 
sessions, with 6 to 10 patients per group. The groups were led by a clinical psychologist. Evaluation 
of the program was mostly positive; mean scores (out of 5) on the questions "How much did you 
enjoy the program?", how helpful did you find the program?", and "How well did the leader 
facilitate the group?" were 4.73, 4.45, and 4.79 respectively. Ninety-six percent of the responses 
were above the indifference point (of 3). However, the intervention process was not followed, 
evaluted and analysed. Thus the results give only scarce knowledge of the functioning of the group 
CBT program. 
 
An interesting finding of the study was that the value that participants placed upon interacting with 
other patients who had had similar experiences with cardiac disease. This was the aspect of the 
program that most participants enjoyed. It was also nominated frequently as a perceived benefit of 
the program. This finding suggests that while the content of a structured group CBT program is 
often perceived as beneficial, the social environment in which it is delivered may be the most highly 
valued aspect of the intervention. The findings call for studies that analyse the interaction of peers 
and the meaning of support from peers after the in-hospital time. 
 
Expert interview: No major difference. After implanting DES the need for antithrombotic 
prophylaxis is slightly longer. DES requires a higher resource allocation. 
What kinds of support do the patients with DES or BMS need from health 
professionals after the hospital stay? 
Results 
We identified three studies addressing patients' needs from health professionals. Higgins et al. (5) 
described participants' perceptions of recovery after angioplasty. Coronary angioplasty and stent 
placement is associated with short hospital days. Patients are expected to recover at home, alone, 
following limited care time with nurses. The study used a grounded theory design. Data were 
gathered from semi-structured, taped interviews designed to explore the recovery experiences of 
coronary angioplasty patients. The participants were eight men and three women. Selection criteria 
included men and women over the age of 18 from all cultural groups who could communicate in 
English. Participants, who resided in the Australian metropolitan area and had undergone elective 
PTCA, were selected.  
 
The study results describe the recovery phase. Awareness of problems in the recovery phase was 
associated with 'relief from chest pain' for most participants. In contrast, anxiety continued and was 
associated with 'uncertainty over future health'. Participants described coping responses of 'taking 
control of their life again' by undertaking both physical and psychological strategies. Finally, the 
situation was appraised to be either a 'good' or a 'bad' recovery. This appraisal was based on 
considerations of the absence of chest pain, improvement in well-being and energy levels. The 
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results of this study highlight patients' concerns and support the need for greater emphasis on their 
psychosocial needs. This care must be provided within the time constraints of short hospital stays. 
Nurses must also consider providing support to patients in the pre-admission and recover phases. 
Nurses have the potential to extend their support to the post discharge recovery phase. Participants 
in the study felt that psychological support was very important. This may be achieved by follow-up 
calls by nurses, or establishing phone help so that the patient could call and discuss any feelings or 
concerns. It could also provide an avenue for families to gain access to nursing support.  
 
In another report Higgins et al. (6) provided insight into the same patients' perceptions of their 
experiences during the admission phase of the angioplasty process. The results indicate that the 
admission period before the PTCA may be anxiety provoking. Data analysis revealed three major 
categories: awareness of the problem or situation, coping responses and appraisal of the situation. 
The patients were described to go through a problem solving process in response to the perceived 
health threat. Continuing chest pain and fear of the unknown were identified as themes within the 
first category. Anxiety was reported in relation to fear of the unknown and was experienced also 
those patients who had earlier experience with angioplasty. Only three participants reported little 
anxiety. 
 
The coping responses included acquiring knowledge of the angioplasty, confidence in the skill of 
the doctor, support from family and gearing up psychologically. Doctors were perceived the most 
important source of information. Some patients were disappointed with the reliance on pamphlets 
rather than human interaction with nurses. Information from experienced patients who had 
undergone the angioplasty was perceived valuable. Support from family members was identified 
important coping mechanism during the whole angioplasty process. Patients' appraisal of their 
situation and decisions to go ahead with or delay the procedure seemed to be based on the success 
of the coping responses. Participants' experiences indicate that psychosocial aspects of nursing care 
are an important component of the care of angioplasty patients and provide information in order to 
change and advance nursing practises. 
 
Eastwood (7) described the rationale and influences behind the decisions of four male patients to 
change or not to change their risk factor behaviour three months after a percutaneous transluminal 
coronary angioplasty/intracoronary stent procedure. Three months period was thought to be long 
enough to allow patients to either incorporate rehabilitative changes into their lifestyles or to return 
to pre-procedure behaviour.  The data was collected by single semi-structured interview. The 
participants in the study were English-speaking males who had not previously had cardiac surgery 
or been involved with a cardiac rehabilitation program. 
 
Of the four participants, only one had implemented a noticeable degree of lifestyle pattern change 
following the procedure. The results suggested that psychological, social, family-related and work-
related issues had impact on decisions concerning possible lifestyle pattern change. Some of the 
patients viewed that the procedure had fixed their health problem and were unaware of the need to 
change and maintain new lifestyle patterns in order to prevent future cardiac complications. The 
short period of hospitalization was also thought to have impact on dismissing the severity of their 
cardiac condition. Two participants emphasize the value of the family members receiving 
counselling to improve their understanding about patient's condition. The ability to maintain 
exercise routines was affected by the nature of the work, work rosters and inflexible work 
schedules. The benefits regarding working life were increased feelings of self-worth, renewed 
ability to socialize and the feeling of a return to normality. 
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Despite the information concerning the benefits of lifestyle change being received during 
hospitalization there was a reluctance to attend cardiac rehabilitation program activities. Two out of 
four patients believed that the information they received and their own knowledge base was 
sufficient to maintain healthy lifestyle. Only one of the four participants took part in structured 
cardiac rehabilitation. He also showed the greatest awareness of cardiac risk factors and 
implemented the greater degree of lifestyle pattern change. The nurses, who spend the greatest 
amount of time with patients during the hospitalization period, are in an important position to 
provide relevant information concerning healthy lifestyle patterns.  Because of the small sample 
size and the descriptive methodology generalisation of the study results is not possible.  
 
Expert interview: Some people having an implanted stent may have psychological problems due to 
fear of complications. The fears may slightly vary as the side-effect profiles are slightly different 
between DES and BMS. After implanting DES the need for antithrombotic prophylaxis is longer.  
What kind of physical and emotional support do the patients with DES or BMS 
need from family or other related people?  
Results 
No studies were identified in the literature search.  
 
Expert interview:  
No difference between DES and BMS. The patients with DES and BMS probably need as much and 
the same type of help and support from family or other related people. 
Working life 
What kind of arrangements does the use of DES or BMS require at the 
workplace? 
Results 
No studies were identified in the literature search.  
 
Expert interview:  
The use of a stent itself does not require reorganization or adjustments at work - the primary 
disease/s (coronary disorder) and the requirements of the work are the major limiting factors in 
working capacity. What about differences in side-effects and medication? If stents (DES or BMS) 
reduce the symptoms of cardiovascular disease (e.g. the grade of angina) an improvement in 
working capacity can be expected. Thus previous adaptations at workplace may no longer be 
necessary. 
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What kind of changes in the working capacity/life can the implementation of 
DES or BMS mean for the patients?   
Results 
We identified one study addressing working life after stent installation. Abbas et al. (8) conducted 
an analysis of the frequency and variables associated with early (after 1 month) and late (after 6 
months) return to work after percutaneous coronary intervention for acute myocardial infarction. 
The patients (n=450) had been randomized in the Stent Primary Angioplasty in Myocardial 
Infarction trial. The international study compared primary angioplasty with and without stenting 
with a heparin-coated Palmaz-Schatz stent in patients who had electrocardiographic or angiographic 
evidence of AMI. This study examines the demographic, clinical, and angiographic characteristics 
of patients who returned to employment 1 and 6 months after percutaneous coronary intervention 
for AMI. The frequency and variables associated with return to work at 1 and 6 months were 
analyzed.  
 
Of 450 patients who were employed before the acute myocardial infarction, 230 (51%) returned to 
work within 1 month with no increases in in-hospital and 1-or 6-month event rates compared with 
those who did not return to work. Predictors of early return to work were employment in the United 
States, no history of smoking, and single-vessel coronary disease. At 6 months, 353 of 435 patients 
(78%) had returned to work; and predictors of late return to work were employment in the United 
States and absence of angina.  
 
The study suggests that regional differences play an important role in determining return to work 
after percutaneous coronary intervention for AMI. Being a US employee was the single most 
important predictor of early (1 month) and late (6 months) resumption of employment. Early return 
to work was also determined by the number of narrowed coronary arteries and history of tobacco 
use but appeared to have no adverse effect on rates of mortality, stroke, or reinfarction at 6 months. 
By 6 months, >75% of the patients had returned to work and they were less likely to complain on 
angina. However, even in patients who remained unemployed, symptoms were mild in most of 
them (only 3.8% had class 3 to 4 angina). In addition, with no difference in clinical events in the 
previous 6 months, regional and geographic influences seem to supersede functional class and 
clinical events in determining late return to employment. 
 
The study highlights the importance of regional rather than clinical factors in determining 
reemployment after percutaneous coronary intervention for AMI. The reason for this is unclear but 
definitely reflects geographic, ethnic, and regional influences on return to employment after AMI. 
However, the qualitative analysis of recovery and return process is missing from the study, thus 
the results give only scarce knowledge of return process.  
 
Expert interview: After BMS there is a higher risk for the need of reoperations, preceded by signs of 
angina pectoris. DES might thus allow a slightly higher probability of better working capacity. The 
mortality data shows, however, a slightly higher mortality 2 to 3 years after implanting DES. 
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Economy of a citizen 
What effect can the implementation of DES or BMS have on patients' economy? 
Results 
No studies were identified in the literature search.  
 
Expert interview:  
The patients' costs of implanting a BMS or DES may vary depending on the social security system 
of the country and cost-sharing policies. The length of hospital stay and sick leave are the same for 
both stent types. The costs of medication after implementing DES are slightly higher due to longer 
prophylactic antithrombotic medication. The differences in need of reoperations and complication 
rate may cause different economic burden favouring the use of DES as compared to other 
therapeutic alternatives. 
Family life 
What kind of special arrangements does the use of DES or BMS require at 
home?  
Results 
No studies were identified in the literature search.  
 
Expert interview: BMS or DES do not require special rearrangements at home; no difference 
between the stents. 
Social relations 
What kind of changes can the use of DES or BMS produce to the patients' social 
relations?   
Results 
No studies were identified in the literature search.  
 
Expert interview: No big difference between BMS and DES.  The stents allow normal social life. 
The coronary symptoms decrease similarly after both treatments (DES and BMS). However, after 
DES the symptoms reoccur slightly later and every tenth DES patient increases their movement 
capacity more than BMS patients. 
Comment 
Life-style changes recommended are related to coronary disease regardless of therapeutical 
approach. 
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Attitudes and self-conception 
What kind of changes can the implementation of DES or BMS produce in the 
patients' or other peoples's attitudes and patients self-conception? 
Results 
 
No studies were identified in the literature search.  
 
Expert interview: As DES are more expensive than BMS, patients receiving BMS might think that 
they are not "worthy" of receiving DES.  In contrast to open heart surgery (scar) the stents are 
invisible and a person with a stent is not recognized as "heart diseased". It is well known that new 
and advanced technologies can have a substantial symbolic value. To the extent that the difference 
between BMS and DES are known to patients, the latter can turn out to have a higher social status 
than the former. As new technology is sometimes promoted by producers and health care 
professionals as ―advanced methods‖ and ―high-tech‖, other kinds of technology can come to 
symbolize ―low-tech‖ or low standard treatment.  
 
Discussion 
We evaluated the social aspects of revascularization treatment in patients with coronary disease. A 
comprehensive literature search identified only eight studies addressing social issues. The identified 
studies focus on the following four issues: access to health care; support from services, systems and 
policies; support from health professionals; and working life. No studies were identified on support 
from family or other related people, working capacity, arrangements needed at workplace or home, 
patients' economy, social relations, and attitudes and self-perception. However, due to tight time 
constraints of the project, a few studies that possibly address social aspects could not be retrieved in 
time. These studies may reveal additional social aspects, and they will be evaluated for inclusion 
criteria later. 
 
This analysis has some limitations. It is possible, that we have not identified all existing qualitative 
studies in the search. As these studies often describe local circumstances they have a scarce 
international interest and are thus usually published only in each country's own language. Locating 
these studies would require searching national databases and interpretation of the studies would 
require versatile language skills. Even then the transferability of these studies may be questionable. 
Another limitation of our analysis is that we did not conduct any quality assessment of the included 
studies. The study methods were of such variety that no single quality assessment approach could 
be applied. The study designs and characteristics are described and their limitations are discussed in 
the data extraction sheets.  
 
The identified eigth studies differed in design, size and patient characteristics: retrospective analysis 
of case notes (n=712, ischemic heart disease, acute myocardial infarction, angina pectoris) (1), 
register data (n=408,033, of which 86.6% stent patients) (2), matched case observational survey 
(n=80, of which 50% balloon/stent patients) (3), randomised controlled trial (n=38, cardiac disease) 
(4), qualitative study with grounded theory design (n=11, angioplasty patients) (5,6), semi-
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structured interview (n=4, PTCA/stent patients) (7), regression analysis of RCT patients (n=470, 
percutaneous coronary intervention patients) (8).  
 
Our results on coronary patients' access to health care services are based on two studies (1,2).  
In one British hospital most patients seemed to receive the indicated cardiac intervention, except 
some older people, who were filtered out already at the investigation stage (1).  One American 
register study (2) revealed rationing of DES (both Cypher and Taxus stents) to certain patients 
subgroups. Non-white patients and patients without health insurance were less likely to receive 
DES. Also the use of DES was higher at high-volume hospitals than at low-volume hospitals. These 
findings may not be transfereble to other settings, as different countries may have different service 
access limits for the coronary artery patients.  
 
Two studies assessed patients views on support needed from services, systems and policies (3,4). 
According to the results of an American survey, women are less likely than men to have cardiac 
rehabilitation discussed and referred by health professionals (3). An Australian randomised 
controlled trial found that group cognitive behaviour therapy, that provides interaction with peers, 
may help the cardiac patients to reduce anxiety, depression and hostility compared to no such 
therapy (4). Three studies were found on patients' support needs from health professionals (5-7). 
According to an Australian qualitative study on patients' needs after a stenting procedure, more 
psychological support after hospital stay may be needed e.g. in form of follow-up calls by nurses 
(5). The same patients experienced that the admission period before the PTCA may be anxiety 
provoking. Their coping responses included acquiring knowledge of the angioplasty, confidence in 
the skill of the doctor, support from family and gearing up psychologically (6). Another Australian 
small study suggested that psychological, social, family-related and work-related issues have impact 
on the patients' decisions concerning possible lifestyle pattern change (7). Thus, there are some 
findings of various patient needs before and after the hospital stay. However, no studies exist on 
how these needs could be met in these patients, except the only cognitive behaviour therapy 
intervention study.   
 
One study was classified to the issues of working life (8). This American study reveals that regional 
rather than clinical factors determine reemployment after percutaneous coronary intervention for 
AMI. The reason remains unclear, but results reflect geographic, ethnic, and regional influences on 
return to employment after AMI. These environmental factors may be caused from formal or 
informal structures, services or systems in the community or society. No studies were found on 
what kind of services related to the work environment e.g. on the arrangements needed for working 
place to help the patients' reemployment after the revascularization.  
 
None of the studies were made according to the translational model, i.e. analyzed and evaluated the 
actual use processes of the technology in question where different resources needed are mobilized 
and that may produce further changes in the different life spheres of the patients. Thus, this analysis 
tells a little of the patients' life when returning home from hospital after a revascularization 
treatment. Future research may provide more information on the patients' resource needs before and 
after the hospital stay, as well as on the consequences of use of stents to patients' family life, social 
relations, attitudes and self-conception.  
 
In conclusion, the included studies highlight some Australian, British and American patients' needs 
with coronary artery disease. Based on this literature review we have no information on what kind 
of community activities, or services would be needed and no information of informal social 
networks, attitudes and ideologies of the patients.  Disability after a revascularization procedure at 
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hospital can be characterized as a complex relationship between an individuals health condition, 
personal and environmental factors. Different sociomaterial networks may mould the same 
individual with a coronary artery disease very differently. The local sociomaterial conditions hinder 
patients' performance either by creating barriers, or it does not provide facilitators. Future studies 
should focus on patients' needs in different settings and evaluate what kind of services could be 
helpful to meet these needs.  
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Assessment elements table 
 
Domain Topic Issue Relevance in the 
context of DES 
Yes/No 
Research question(s) in the context of DES Importance 
3=critical 
2=important 
1=optional 
Transferability 
3=complete 
2=partially 
1=not 
       
Social aspects Access to health care What kind of changes can the implementation of the 
technology produce in the access to health care? 
Yes What kind of changes can the implementation of DES or BMS 
produce in the access to health care? 
3 2 
Social aspects Support What kind of services, systems and policies should be 
organized to support the use of the technology after the 
hospital stay? 
Yes What kind of services, systems and policies do the patients with 
DES or BMS need after the hospital stay?   
2 1 
Social aspects Support  What kind of support is needed from the health 
professionals when using the technology or as a 
consequence of using the technology? 
Yes What kinds of support do the patients with DES or BMS need from 
the health professionals after the hospital stay? 
2 2 
Social aspects Support   What kind of physical and emotional support for the use of 
technology is needed from family or other related people? 
Yes What kind of physical and emotional support do the patients with 
DES or BMS need from family or other related people?  
2 2 
Social aspects Working life What kind of arrangements does the implementation of 
the technology require at the workplace? 
No What kind of arrangements does the use of DES or BMS require at 
the workplace? 
2 2 
Social aspects Working life What kind of changes can the implementation of the 
technology mean in the working capacity/life of a person?  
Yes What kind of changes in the working capacity/life can the 
implementation of DES or BMS mean for the patients?   
3 2 
Social aspects Economy of a citizen What effect can the implementation of the technology 
have on patients' economy? 
 
Yes What effect can the implementation of DES or BMS have on 
patients' economy? 
 
2 1 
Social aspects Family life What kind of special arrangements does the use of the 
technology require at home?  
Yes What kind of special arrangements does the use of DES or BMS 
require at home?  
2 2 
Social aspects Social relations What kind of changes can the use of the technology 
produce to patient’s social relations?  
Yes What kind of changes can the use of DES or BMS produce to the 
patients' social relations?   
2 2 
Social aspects Attitudes and self-
conception 
What kind of changes can the implementation of the 
technology produce in patients' or other people's attitudes 
and patients self-conception?   
Yes What kind of changes can the implementation of DES or BMS 
produce in patients and other peoples's attitudes and patients' self-
conception? 
2 2 
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Appendix B: Search strategies 
 
Database 
 
Search strategy 
  
CINAHL 1    exp Stents/ (1888) 
2    stent$.tw. (1695) 
3    1 or 2 (2226) 
4    exp coronary disease/ or exp myocardial infarction/ (18068) 
5    exp angioplasty, transluminal, percutaneous coronary/ or exp coronary artery bypass/ (4514) 
6    (coronar$ or angioplasty or stenosis or restenosis).mp. or (heart$ or cardiol$ or myocardia$ or cardiac).ti. (41559) 
7    4 or 5 or 6 (44791) 
8    3 and 7 (1506) 
9    exp social attitudes/ or exp "economic and social security"/ or exp social environment/ or exp social work/ or exp 
social change/ or exp social class/ or exp sociological theory/ or exp social values/ or exp social welfare/ (33200) 
10    (social$ or socio$ or societal or communit$).tw. (92674) 
11    9 or 10 (115703) 
12    8 and 11 (7) 
13    exp HEALTH SERVICES ACCESSIBILITY/ (15023) 
14    access$.mp. [mp=title, subject heading word, abstract, instrumentation] (37246) 
15    exp HEALTH RESOURCE UTILIZATION/ (4057) 
16    Patient Selection/ (3874) 
17    candidate$.tw. (2826) 
18    resource$.tw. (25404) 
19    13 or 14 or 15 or 16 or 17 or 18 (68248) 
20    (equit$ or unequit$ or allocat$ or reallocat$ or gender).mp. [mp=title, subject heading word, abstract, 
instrumentation] (24227) 
21    *age factors/ or minority groups/ or race factors/ or sex factors/ (32991) 
22    20 or 21 (50203) 
23    19 and 22 (7009) 
24    8 and 23 (5) 
25    exp professional-client relations/ or exp professional-family relations/ or exp family relations/ or exp patient-
family relations/ (20368) 
26    ((famil$ or patient$ or nurse$ or physician$ or staff or personal) adj2 relation$).mp. [mp=title, subject heading 
word, abstract, instrumentation] (49646) 
27    25 or 26 (58131) 
28    8 and 27 (1) 
29    Job Re-Entry/ (1903) 
30    ((return$ or capacit$ or abilit$) adj2 (work$ or job? or profession)).mp. [mp=title, subject heading word, abstract, 
instrumentation] (2315) 
31    29 or 30 (3517) 
32    8 and 31 (1) 
33    patient attitude.mp. [mp=title, subject heading word, abstract, instrumentation] (6654) 
34    ((experienc$ or belief$ or expect$ or perception$) adj2 patient$).mp. [mp=title, subject heading word, abstract, 
instrumentation] (9773) 
35    (experienc$ adj2 (thrombo$ or restenosis)).mp. [mp=title, subject heading word, abstract, instrumentation] (27) 
36    34 not 35 (9765) 
37    33 or 36 (15603) 
38    8 and 37 (14) 
39    Coping/ (9296) 
40    exp self concept/ or self-efficacy/ (11196) 
41    (cope or coping or self concept or self efficacy or empowerment).mp. [mp=title, subject heading word, abstract, 
instrumentation] (30549) 
42    39 or 40 or 41 (31934) 
43    8 and 42 (3) 
44    SOCIAL ADJUSTMENT/ or (workplace adj 2 adjustment$).mp. (971) 
45    8 and 44 (0) 
46    12 or 24 or 28 or 32 or 38 or 43 or 45 (27) 
47    from 46 keep 1-27 (27) 
Cochrane #1 (coronary disease):ti,ab,kw and (stents):ti,ab,kw 635  
#2 (patient experiences):ti,ab,kw or (patient selection):ti,ab,kw or (social support):ti,ab,kw or (interpersonal 
relations):ti,ab,kw or (workplace adjustments):ti,ab,kw or (empowerment):ti,ab,kw 23851 #3 (#1 AND #2) 36  
Medline 1    Stents/ (26118) 
2    stent$.ab,ti. (29887) 
3    1 or 2 (34891) 
4    exp Coronary Stenosis/ or exp Angioplasty, Transluminal, Percutaneous Coronary/ or exp Coronary Disease/ or 
exp Coronary Artery Bypass/ (186544) 
5    exp Myocardial Infarction/ (111880) 
6    (coronar$ or angioplasty).ab,ti. (211835) 
7    (heart$ or cardiac or cardiol$ or myocardi$).ab,ti. (718999) 
8    4 or 5 or 6 or 7 (853983) 
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9    3 and 8 (15988) 
10    exp Social Welfare/ or exp Social Work/ or exp Social Security/ or Social Support/ (93021) 
11    (social or socio$ or societal$).ab,ti. (215374) 
12    10 or 11 (282195) 
13    9 and 12 (40) 
14    Health Services Accessibility/ (27386) 
15    access$.ab,ti. (145576) 
16    Health Resources/ or Health Priorities/ (11803) 
17    Patient Selection/ (26984) 
18    candidate$.ab,ti. (76822) 
19    resource$.ab,ti. (75268) 
20    14 or 15 or 16 or 17 or 18 or 19 (336355) 
21    (equit$ or unequit$ or allocat$ or reallocat$ or gender).ab,ti. (117814) 
22    *Age Factors/ (3186) 
23    exp Minority Groups/ or exp Ethnic Groups/ (75436) 
24    Sex Factors/ (152559) 
25    22 or 23 or 24 (223581) 
26    20 and 25 (9593) 
27    9 and 26 (10) 
28    professional-family relations/ or exp professional-patient relations/ (93061) 
29    exp Family Relations/ (48913) 
30    ((famil$ or patient$ or nurse$ or doctor$ or physician$ or staff$ or personnel) adj2 relation$).ab,ti. (17422) 
31    28 or 29 or 30 (149955) 
32    9 and 31 (14) 
33    Work Capacity Evaluation/ or Work Simplification/ (4543) 
34    (work$ or job$ or profession).ab,ti. (508620) 
35    (return$ or capacit$ or facilit$ or abilit$).ab,ti. (840710) 
36    34 and 35 (65568) 
37    Workload/ (8784) 
38    Rehabilitation, Vocational/ (7105) 
39    37 or 38 (15856) 
40    33 or 36 or 39 (82198) 
41    9 and 40 (32) 
42    *Attitude to Health/ (24573) 
43    (patient$ adj2 (attitude$ or belie$ or expect$ or percept$ or perceiv$ or experience$)).ab,ti. (43727) 
44    (experience$ adj2 (restenosis or thrombo$)).mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] (515) 
45    43 not 44 (43608) 
46    42 or 45 (66615) 
47    9 and 46 (196) 
48    adaptation, psychological/ or orientation/ (66167) 
49    self concept/ or self efficacy/ (34520) 
50    (cope or coping or self concept or self efficacy or empowerment).ab,ti. (36100) 
51    48 or 49 or 50 (115616) 
52    9 and 51 (6) 
53    Social Adjustment/ (17084) 
54    9 and 53 (0) 
55    13 or 27 or 32 or 41 or 47 or 52 (290) 
Medic/Helecon stent* 
ASSIA/CSA Illumina stent* in keywords 
ERIC/CSA Illumina stent* in keywords 
Sociological Abstracts/CSA 
Illumina 
stent* in keywords 
Social Services 
Abstracts/CSA Illumina 
stent* in keywords 
Social Care Online/ SCIE stent* in free text 
PsycINFO/EBSCOHost stent* in Keywords not (stent in Author field or stentor in Keywords) 
Academic Search 
Elite/EBSCOHost 
(stents in subject terms) and (coronary* or arterial* or heart* or cardiol* or myocard*)) and (economic* or financ* or 
cost' or resource*) 
Academic Search 
Elite/EBSCOHost 
(stents in subject terms) and (coronary* or arterial* or heart* or  cardiol* or myocard*)) and (access* or patient 
selection or candidate*) 
Academic Search 
Elite/EBSCOHost 
(stents in subject terms) and (coronary* or arterial* or heart* or cardiol* or myocard*)) and (work* or occupation or 
capacity*) 
Academic Search 
Elite/EBSCOHost 
(stents in subject terms) and (coronary* or arterial* or heart* or cardiol* or myocard*)) and (support* or aid* or auxiliar 
or help* or guidance*) 
Academic Search 
Elite/EBSCOHost 
(stents in default fields) and (coronary* or arterial* or heart* or cardiol* or myocard*)) and (socio* or social*) 
SocINDEX with Full 
Text/EBSCOHost 
stent* in deafault fields 
Sage Premier/Sage 
Publications 
(stent or stents or stenting) in keywords 
SpringerLink/Springer (stent or stents or stenting) in summary 
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Publishing 
Blackwell Synergy/Blacwell 
Publishing 
(drug-eluting stent and bare-metal stent) in all fields 
Science Direct/Elsevier "drug-eluting stent" and "bare-metal stent" and (socio or social) 
Science Direct/Elsevier "drug-eluting stent" and "bare-metal stent" and not (socio or social) 
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Appendix C: Excluded studies (n=24) 
 
Database  Year  First author Title Reason for exclusion 
     
PsycInfo via EBSCOHost  2006 Peterson, JC Living with heart disease after angioplasty. Dissertation 
Abstracts International: Section B: The Sciences and 
Engineering 66(10-B):5671, 2006 
Full text not obtained 
PsycInfo via EBSCOHost  2002 Larney, L Do depression, anxiety, hostility, coping style and 
dispositional outlook predict adherence to prescribed 
rehabilitation program and recovery outcomes for cardiac 
rehabilitation outpatients? Dissertation Abstracts 
International: Section B: The Sciences and Engineering 
62(7-B):3382, 2002 
Full text not obtained 
PsycInfo via EBSCOHost  2000 Deaner, SL Depressive symptoms and problem solving as predictors of 
adherence to the cardiac medical regimen. Dissertation 
Abstracts International: Section B: The Sciences and 
Engineering 60(8-B):4214, 2000 
Full text not obtained 
Ovid MEDLINE(R) 2005 Korzeniowska
-Kubacka, I 
Cardiological rehabilitation -- a chance of returning to work 
(Review) [Polish]. Medyzyna Pracy 56(4):325-7, 2005 
Full text not obtained 
Ovid MEDLINE(R) 2002 de la Rosa, A Nurses' participation in heart rehabilitation (review) 
[Spanish]. Archivos de Cardiologia de Mexico 72 Suppl 
1:S247-53, 2002 
Full text not obtained 
ERIC via CSA Illumina 2004 Cujec, B The effect of age upon care and outcomes in patients 
hospitalized for congestive heart failure in Alberta. Canadian 
Journal on Aging 23(3):255-267, 2004 
Full text not obtained 
EBSCOHost Academic 
Search Elite 
2006 Floyd, KC Age-based differencies of percutaneous coronary 
intervention in the drug-eluting stent era. J Int Cardiol 
19(5):381-387, 2006 
Full text not obtained 
SocINDEX with Full Text 1999 Charlson, ME Improving health behaviour & outcomes after angioplasty 
(project (RCT), Medicine Weill Medical College of Cornell 
University, New York, US).  
Full text not obtained 
PsycInfo via EBSCOhost                                                   2006 Pedersen, SS Anxiety enhances the detrimental effect of depressive 
symptoms on health status following percutaneous coronary 
intervention. J Psychosomatic Research 61(6):783-789, 
2006 
Examines whether anxiety has 
incremental value to depressive 
symptoms in predicting health status in 
patients undergoing PCI 
PsycInfo via EBSCOHost  2006 Pedersen, SS Risk factors for impaired health status differ in women and 
men treated with percutaneous coronary intervention in the 
drug-eluting stent era. J Psychosomatic Research 61(1):11-
17, 2006 
Compares women's and men's health 
status 6 and 12 months post-PCI 
PsycInfo via EBSCOHost  2006 Trummer, UF Does physician-patient communication that aims at 
empowering patients improve clinical outcome? A case 
study. Patient Education & Counselling 61(2):299-306, 2006 
Organizational domain, staff training and 
reorganization of communication 
PsycInfo via EBSCOHost  2000 Ladwig, K-H Gender differences in emotional disability and negative 
health perception in cardiac patients 6 months after stent 
implantation. Journal of Psychosomatic Research 48(4-
5):501-8, 2000 
Effectiveness -domain 
PsycInfo via EBSCOHost  2005 Lehrner, J Neuropsychosocial outcome 6 months after unilateral carotid 
stenting. Journal of Clinical and Experimental 
neuropsychology 27(7):859-866, 2005 
Examines neuropsychological outcomes 
after stenting, effectiveness domain 
PsycInfo via EBSCOHost  2003 Sirois, BC  Biomedical and psychological predictors of anginal 
frequency in patients following angioplasty with and without 
coronary stenting. Journal of Behavioral Medicine 26(6):535-
551, 2003. 
Examines the contribution of biomedical 
and psychological variables in the report 
of anginal frequency at 6-week and 12 -
month follow-up in patients who received 
angioplasty with or without stent 
Ovid MEDLINE(R)  2006 Denollet, J Social inhibition modulates the effect of negative emotions 
on cardiac prognosis following percutaneous coronary 
intervention in the drug-eluting stent era. Eur Heart J 
27(2):171-7, 2006 
Examines whether social inhibition 
(inhibited self-expression in social 
interaction) modulates the effect of 
negative emotions in clinical outcome 
following PCI  
Ovid MEDLINE ® 1999 Eeckhout, E Indications for intracoronary stent placement: the European 
view. Working Group on Coronary Circulation of the 
European Society of Gardiology. Eur Heart J 20(14):1014-9, 
1999 
Analyses indications for stent placement, 
clinical, no social dimension 
Ovid MEDLINE ® 1995 Rothlisberger, 
C 
Coronary interventions in Europe 1992. The working group 
on coronary circulation of the European Society of 
Cardiology. Eur Heart J 16(7):922-9, 1995 
Organizational domain, studies the 
amount etc. of coronary interventions in 
European countries 
ASSIA/CSA Illumina 2006 Grilli, R Managing the introduction of expensive medical procedures: Organizational issue 
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use of a registry. Journal of Health Services Research & 
Policy 11(2):89-93, 2006 
ERIC via CSA Illumina 2005 Straube, BM How changes in the Medicare coverage process have 
facilitated the spread of new technologies. Health Affairs 
24(1): 5314-5316, 2005 
Organizational issue 
SocINDEX with Full Text 2000 Mehilli, J Differences in prognostic factors and outcomes between 
women and men undergoing coronary artery stenting. JAMA 
284(14):1799-1806, 2000 
Examines whether there are sex-based 
differences in prognostic factors and in 
early and late outcomes among CAD 
patients undergoing coronary stent 
placement 
SocINDEX with Full Text 2006 Hashimoto, H The diffusion of medical technology, local conditions, and 
technology re-intervention: a comparative case study on 
coronary stenting. Health Policy 79(2-3):221-230, 2006 
Examines the diffusion/implementation 
of medical technology; organizational 
domain 
CINAHL 2006 Shim, JK Risk, life extension and the pursuit of medical possibility. 
Sociol Health Illn 28(4):479-502, 2006 
Focus is not on the  CM issues 
Cochrane 1999 Stables RH Design of the 'Stent or Surgery' trial (SoS): a randomized 
controlled trial to compare coronary artery bypass grafting 
with percutaneous transluminal coronary angioplasty and 
primary stent implantation in patients with multi-vessel 
coronary artery disease 
Effectiveness domain, trial design 
presentation 
Cochrane 2007 Dawn, AJ Gender-based outcomes in percutaneous coronary 
intervention with drug-eluting stents 
Clinical effectiveness, gender 
differencies 
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Appendix D: Chracteristics of the included studies (n=8) 
 
First author, year  
 
Bond M et al. (2003) 
  
Issue Access to health care: 
Nature of the study: 
aims/objectives, user/carer 
involvement in the design/conduct 
of study, country, site (setting, key 
characteristics of the context), 
details of theory/conceptual model.  
Objectives:To analyse equity in access by age group to procedures with documented benefits in all age groups: 
exercise testing, coronary angiography, revascularisation (percutaneous transluminal coronary angioplasty/stent 
insertion and coronary artery bypass graft surgery) and receipt of thrombolysis, where indicated 
Country: Great Britain 
Site: A district hospital in the eastern part of outer London. Primarily responsible for the provision of district hospital 
services for over 700 000 people. 
Methods: study type and design, 
study date and duration, 
sampling/recruitment, methods of 
data collection, data collector, used 
research tools (if any),  analysis 
methods 
 
Study type and design: An observational study based on a case note analysis of a 12-month census of all inpatients 
(elective and emergency, survivors and deceased) with a cardiac ICD-10 code (120-25) recorded on the patient 
administration system (PAS) covering ischaemic heart disease, acute myocardial  infarction or angina pectoris 
(n=447), and a sample of 265 cardiac outpatient attenders (new episodes who attended in date order as recorded on 
the PAS), attending cardiology clinics (out of the total of 1304 outpatients) 
Study date and duration:From 1 April 1996 to 31 March 1998, 24 months 
 
Sampling/recruitment: Patients were eligible for inclusion in the study if they were admitted or first attended (new 
episodes) the study hospital between 1 April 1996 and 31 March 1997 
 
Methods of data collection: 
- the notes of the outpatient sample were hand-searched from hospital case notes, the total number of case notes 
included in the study was 712 
- the data included: specialty, date of birth, sex, symptoms, diagnoses, results of all recorded tests and 
investigations, interventions, severity and pattern of disease, co-morbidity, indications for and contraindications to 
investigations/treatment 
- repeat tracings of eligible case notes were conducted over 12-month period 
  
Analysis methods: Retrospective case note analysis, tracking each case backwards and forwards  by 12 months 
from the patient's date of entry to the study 
Bivariate analyses included χ²-tests for trends. Interactions between potentially predictive variables were tested using 
logistic regression analysis (odds ratios). Age and gender were entered as independent variables in the models on 
the grounds of theoretical significance. The data for inpatients and outpatients were analysed separately, but as the 
results were similar they are presented together.  
Participant characteristics: gender, 
age, ethnicity, types of 
practitioners, policy makers or 
patients 
Gender: Males: 55 % of the study patients, (n=388), Females: 45 % of the study patients,  (n=324) 
Age: 
- 48 % (n=342) under 65 years 
- 31 % (n=217)  between 65 and 75 years 
- 10 % (n=74) between 75-80 years 
- 11 % (n=79) 80+ years  
Thirty-seven per cent (n=265) of all study patients entered through cardiology outpatients, the remaining 635 (n=447) 
were elective (n=107) or emergency (n=340) admissions. Sixty-two per cent of cases (n=443) had a primary 
diagnosis of ischaemic heart disese and 38% (n=269) had a primary diagnosis of AMI 
Features the studied intervention 
(when applicable)   
NA 
Outcomes and results: outcome 
measures, details of findings, 
strengths/limitations of the study, 
author's conclusions. 
Outcome measures: 
- weather the patient received the targeted interventions when indicated (based on tight internationally approved 
criteria for intervention, and taking into consideration documented contraindications) 
 
Details of findings: 
Analysis of 712 case notes showed that older hospital patients with ischemic heart disease, and with indication for 
further investigation, were less likely than younger people to be referred for exercise tolerance tests and cardiac 
catheterisation and angiography. This was independent of both gender and severity of condition. Older patients did 
not appear to be discriminated against in relation to receipt of indicated treatments (revascularisation or 
thrombolysis), although, in the case of revascularisation, older patients were more likely to have been filtered out at 
the investigation stage (catheterisation and angiography), so selection bias partly explains this finding. 
 
Author's conclusions: 
The current findings from a single hospital are comparable with the results from a broader study of equity to access 
by age to cardiological interventions in another district hospital in the same region. It appears that age per se causes 
older cardiac hospital patients to be treated differently. 
The rates of indicated interventions were relatively low for all age groups, with older patients' rates of intervention the 
lowest of all.  
Reviewers' comments: e.g. 
remarks of quality issues 
Limitations of the study: 
- the possibility that there may have been some underestimation of the denominator population: it is not known how 
many patients with cardiac problems were not given a cardiac ICD code on death or discharge and were thus not 
selected for study 
- this investigation was limited to hospital patients, who represent a relatively small proportion of patients with 
ischemic heart disease.  
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Publication details: First author, 
year  
Rao SV et al. (2006)  
  
Issue Access to health care: 
- limited availability of the stents due to uneven distribution across the country 
- high cost of DES when compared with BMS 
- hospital-level characteristics (significantly lower proportion of nonteaching hospitals, low- and medium-volume 
hospitals, rural hospitals, government hospitals) 
 
Patient group selection: 
- technology diffusion as it relates to innovative medical devices; initial underuse in certain patient groups 
- black patients less likely to receive DES in 2003 (demographic characteristics) 
- significantly lower proportion of male patients (demographic characteristics) 
- lower proportion of patients older than 70 years (demographic characteristics) 
- lower proportion of patients without insurance (socioeconomic characteristics) 
Nature of the study: aims/objectives, 
user/carer involvement in the 
design/conduct of study, country, site 
(setting, key characteristics of the 
context), details of theory/conceptual 
model.  
Objective:To determine  patterns and outcomes of drug-eluting stents (DES) use in clinical practice (= to examine 
the use of DES in clinical practice) 
 
Country: USA 
 
Site:- Multicenter data, PCI procedures at 383 sites 
Methods: study type and design, 
study date and duration, 
sampling/recruitment, methods of data 
collection, data collector, used 
research tools (if any),  analysis 
methods 
Study type and design: 
- data from the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) 
- the initial part of the study examined the use of the Cypher stent (the first phase was the period between the 
second quarter of 2003 when the Cypher became available and the end of 2003) 
- in March 2004 the Taxus stent became available and the later part of the study examined the use of either stent 
(the second phase was the period between the first quarter of 2004 and the fourth quarter of 2004) 
 
Date and duration: from April 2003 to December 2004 
 
Sampling/recruitment: 408,033 percutaneous coronary intervention (PCI) procedures. Of those, 353,242 
procedures (86.6%) involved stent placement. 
 
Methods of data collection:- data from the registry 
 
Used research tools: 
- categorical variables were compared with the χ² test  
- continuous variables were compared with the nonparametric Kruskal-Wallis test  
- predictors of DES use were determined by using multivariate logistic regression. Candidate variables: patient 
level variables, e.g. demographics and medical history, hospital level variables, e.g. PCI volume and teaching 
affiliation, clinical characteristics, e.g. presence of shock, prior coronary artery bypass surgery (CABG) and acute 
myocardial infarction (MI)  
 
Analysis methods: 
- first the proportion of procedures that involved placement of a BMS, a DES, or both were determined 
- the proportion of procedures that involved the placement of at least 1 DES during each quarter after the market 
availability of DES were determined 
- second the comparison of baseline characteristics between the patients who received only a BMS with those 
who received at least 1 DES 
- predictors of DES use were determined 
To determine the impact of introduction of the Taxus stent on patterns of DES use, the analysis was repeated 
after dividing the study period into 2 phases. 
Multivariate predictors of DES use were determined separately for each phase to see if patient, clinical, or hospital 
characteristics associated with DES use changed after availability of the Taxus stent. 
Participant characteristics: gender, 
age, ethnicity, types of practitioners, 
policy makers or patients 
Gender:males, females 
Age: from <50 y to >70 y  
Ethnicity:white, nonwhite 
Types of practitioners, policy makers or patients: 
subgroup: patients with diabetes mellitus 
Features the studied intervention 
(when applicable)  
NA 
Outcomes and results: outcome 
measures, details of findings, 
strengths/limitations of the study, 
author's conclusions.   
 
Outcome measures: 
The primary outcomes considered were 
- the occurrence of inhospital mortality 
- adjusted inhospital mortality (expressed as observed mortality/expected mortality multiplied by the overall 
mortality rate) 
- postprocedure MI 
- unplanned coronary artery bypass grafting 
-  procedural success  
 
Details of findings: 
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Adoption of DES 
- placement of only a BMS in 127,973 procedures (31.4%) 
- placement of only a DES in 207,733 procedures (50.7%) 
- use of both BMS and DES in 18,536 procedures (4.5%) 
Therefore 225,269 procedures (55.2%) involved the placement of at least 1 DES. The rate of DES use over the 
study period increased from 19.7% of cases in the second quarter of 2003 to 78.2% of cases in the fourth quarter 
of 2004. 
Once available, the use of Taxus stent was higher than that of the Cypher stent throughout the study period.  
 
Patient and hospital characteristics by stent type  
- significant differences between procedures during which at least 1 DES was used (n = 225,269)  compared with 
procedures were a DES was not used (n = 127,973) 
- a significantly lower proportion of male patients (?), patients older than 70 years and patients without insurance 
represented in the DES procedures 
- a significantly lower proportion of nonteaching hospitals, low- and medium-volume hospitals, rural hospitals, and 
government hospitals using DES  
 
Predictors of DES use 
- there was a progressive decrease in the odds of DES use as age increased 
- white race, female sex (?), presence of insurance, diabetes mellitus, PCI of de novo lesion, PCI at a suburban 
hospital and PCI at a high volume center  were significant predictors of DES use. To determine if the differences 
persisted after the introduction of the Taxus stent, the analysis was repeated after dividing the study period into 2 
phases: before and after the availability of the Taxus stent. The same patient, clinical, and hospital characteristics 
listed above were associated with DES use in both phases. The adjusted odds ratios and 95% confidence 
intervals were nearly identical in both phases.  
 
Outcomes 
- procedural outcomes (procedural success, unplanned CABG, postprocedure MI) and inhospital mortality were 
excellent regardless of the stent type 
- outcomes with either DES platform were slightly better than those with BMS 
 
Limitations 
- lack of the detailed angiographic data that could have influenced the choice of stent used 
- the researchers did not compare restenosis rates or subacute thrombosis rates among patients who did and did 
not receive DES 
- the analyses were observational, and the trends identified could be influenced by unmeasured patient, 
angiographic, or hospital level characteristics  
 
Author's conclusions:  
The analysis of a large multicenter PCI data demonstrates that there was rationing of DES to certain patients 
subgroups. In particular, nonwhite patients and patients without health insurance appear to be much less likely to 
receive DES. DES use was higher at high-volume hospitals. These patterns persisted even after the commercial 
introduction of a second DES product.   
Reviewers' comments: e.g. remarks of 
quality issues 
 
 
 
In the results concerning patient characteristics the authors state there were a significantly lower proportion of 
male patients represented in the DES procedures. The authors' also state female sex was one of the significant 
predictors of DES use. However, in table 1, the numbers (percentages) regarding patient level characteristics 
show higher proportion of male patients in both BMS and DES groups. 
 
 
First author, year  
 
Caulin-Glaser T et al. (2001)  
  
Issue Support : services, systems and policied needed after hospital stay  
Nature of the study: aims/objectives, 
user/carer involvement in the 
design/conduct of study, country, site 
(setting, key characteristics of the 
context), details of theory/conceptual 
model.   
 
Objectives:  
The main objectives of the study were to assess whether gender differences exist for in-hospital secondary 
prevention instruction and physician referral to cardiac rehabilitation after coronary revascularization procedure in 
patients with cardiovascular disease controlling for age and cardiac procedure. 
Country, site: 
Yale New Haven Hospital during 1997 and 1998. 
Methods: study type and design, 
study date and duration, 
sampling/recruitment, methods of data 
collection, data collector, used 
research tools (if any),  analysis 
methods 
 
Design: 
A matched case, observational survey design was used to assess the referral for phase II outpatient cardiac 
rehabilitation based on gender at the hospital and/or follow-up physician visit after a cardiac revascularization 
procedure.  
Sample: 
Study subjects consisted of 80 patients (40 men, 40 women) who had been revascularized (balloon anglo-plasty, 
coronary stenting, and CABG). No patient had previously undergone a revascularization procedure. Fifty percent 
of the patients had undergone revascularization by balloon angioplasty/stent, 50 percent had undergone 
coronary bypass strategy. The patients were 45 years old or older and English speaking. Respondents 
completed a survey addressing information and referral to cardiac rehabilitation during their hospitalization and at 
the follow-up physician office visit. Respondents were geographically distributed throughout New Heaven 
County; based on the address zip codes, it was determined that a CR program was within reasonable distance to 
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all participants in the study. In the population, 87% of the men and 95% of the women were Caucasian; African 
Americans comprised the remainder of the group.  
Data analysis: 
Descriptive statistics were utilized to summarize data obtained from chart reviews. In order to control for the 
matching criteria, the Extended Mantel-Haenszel procedure was employed. 
Participant characteristics: gender, 
age, ethnicity, types of practitioners, 
policy makers or patients 
See above. 
Features the studied intervention 
(when applicable)  
NA 
Outcomes and results: outcome 
measures, details of findings, 
strengths/limitations of the study, 
author's conclusions.  
Patient questionnaires were employed to evaluate teaching of patients on secondary prevention and the referral 
patterns of patients to CR. CR instruction included indication for referral program components (such as 
education, exercise, and behaviour/life-style modification, written literature and the names of the local programs.  
Subjects were asked if they received any information (written or verbal) about secondary prevention of 
cardiovascular disease and CR while hospitalized and/or at the follow-up physician visit. Questions addressed 
information provided by medical personnel, including nurses, CR representatives, medical house staff, cardiology 
fellows, and attending physicians. The subjects were also asked about potential factors which would have 
influenced their decision to participate; these factors included (1) written information on CR, (2) 
physician/healthcare provider encouragement to participate, (3) family and/or friend encouragement to 
participate, and (4) insurance coverage. In addition, factors which may have influenced referral patterns include 
hypertension, diabetes mellitus, and prolonged hospitalization after cardiac procedure due to medical or surgical 
complications were examined. 
Results: 
Women were less likely to be instructed on secondary prevention strategies and CR or referral to CR compared 
to men despite being matched for age and undergoing the same procedure. The data demonstrate a gender 
difference in hospital teaching and referral information for CR after revascularization. 
Conclusion: 
The instruction of patients concerning secondary prevention and CR postrevascularization procedure is poor. 
Within that group, women were far less likely to have CR discussed or referrals made by healthcare 
professionals. This study demonstrates the need for education initiatives of all healthcare providers on the 
comprehensive nature and benefits of CR in the secondary prevention of cardiovascular disease, with a 
particular emphasis on women. 
Reviewers' comments: e.g. remarks of 
quality issues 
In the boundary of organizational and social domains. 
 
First author, year 
  
Edelman S et al. (2003)  
  
Issue Support: : services, systems and policied needed after hospital stay  
Nature of the study: aims/objectives, 
user/carer involvement in the 
design/conduct of study, country, site 
(setting, key characteristics of the 
context), details of theory/conceptual 
model.   
 
Aims/objectives: 
- the study reports a qualitative analysis on the feedback provided by cardiac disease  patients who attended a 
group CBT program as part of an ongoing study examining psychological and health outcomes of the intervention; 
associations between patients' qualitative evaluations and changes in scores on anxiety, depression, and hostility 
are also reported  
Country: 
- Australia, Sydney. 
Methods: study type and design, 
study date and duration, 
sampling/recruitment, methods of data 
collection, data collector, used 
research tools (if any),  analysis 
methods 
 
Study type, recruitment, methods: 
- participants were randomized to either a group CBT intervention or a "standard care" control group 
- in order to reduce the interval between recruitment and intervention, additional patients who met all eligibility 
criteria, except that they had had previous cardiac surgery, were invited to participate as "fillers". 38 patients had 
completed the program, of whom 13 were randomized to the intervention and 25 were fillers. 
- anxiety and depression were measured using the Hospital Anxiety and Depression Scale; hostility was 
measured using the Hostility Scale  
- the program evaluation included six items; the first three were five-point Likert scale items asking the degree to 
which participants had enjoyed the program and found it helpful, and how well the leader had facilitated the group; 
the next three items were open-ended, asking participants to describe any specific benefits that they experienced 
as a result of doing the program, any aspects of the program that they had particularly liked or found helpful, and 
any aspects of the program that they did not like or ways in which the program could be improved 
- Relationships between measured variables and evaluations were tested using repeated measures ANOVA 
analyses. 
Participant characteristics: gender, 
age, ethnicity, types of practitioners, 
policy makers or patients 
Eligible participants were males who had undergone stent surgery (mechanical expansion of a partially blocked 
cardiac artery) at one of the two major hospitals in Sydney.  
Features the studied intervention 
(when applicable):  aim of the 
intervention, intervention process 
(description of how was the 
intervention/service delivered) 
 
Participants attended eight weekly group sessions, with 6 to 10 patients per group. The groups were led by a 
clinical psychologist. A participants' manual was provided, with supplementary handouts being added each 
session. The first tour of each session involved a discussion of homework. Participants were asked to record any 
stressful situations that occured during each week and to identify their accompanying thoughts, feelings, and 
beliefs. Subsequently, they learned how to identify and reframe maladaptive cognitions, and they were asked to 
write down "disputing statements" and "positive actions" as part of their homework. In the second half of each 
session, the group leader provided a didactic presentation (10-15 minutes) on the week's topic. This was followed 
by exercises and discussion aimed at encouraging participants to learn and apply the skills being taught. The 
theoretical component of each session included training in the principles of Cognitive Behaviour Therapy and 
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information on particular topics. Weekly topics included an introduction to CBT, managing anxiety, depression and 
anger, effective communication,  relationships, life-style, and goal-setting.   
Outcomes and results: outcome 
measures, details of findings, 
strengths/limitations of the study, 
author's conclusions.   
 
Items I to 3, Program assessment: 
- evaluation of the program was mostly positive; mean scores (out of 5) on the questions "How much did you 
enjoy the program?", how helpful did you find the program?", and "How well did the leader facilitate the group?" 
were 4.73, 4.45, and 4.79 respectively. Ninety-six percent of the responses were above the indifference point (of 
3). 
Item 4: Specific benefits experienced from doing the program:  
-  the classification frequency for the category "Learning new skills" was 62% (based on weighted percentage of 
responses), for "Change in thinking" 22%, for "Disclose/share 18%, for "Improved function" 15%, and for "Feel 
better" 15%. The less frequent categorization was "Reduced anxiety/depression 6%. 
Item 5: Positive aspects of the program: 
- the most frequently nominated category was "Disclose/share" which was cited in 44% of evaluations, "Program 
contents" in 19%, "Useful information" in 12,5%, "Thought provoking" in 12,5%  "Social interaction" in 10%, and 
"Method of delivery" in 6%. 
- pre/post changes were evident ffor anxiety, hostility, but not for depression; these changes cannot be interpreted 
as due to the intervention on the basis of the participant sample alone. 
- an interesting finding was the value that participants placed upon interacting with other patients who had had 
similar experiences with cardiac disease. This was the aspect of the program that most participants enjoyed. It 
was also nominated frequently as a perceived benefit of the program. This finding suggests that while the content 
of a structured group CBT program is often perceived as beneficial, the social environment in which it is delivered 
may be the most highly valued aspect of the intervention. 
Reviewers' comments: e.g. remarks of 
quality issues 
 
 
First author, year 
  
Higgins M et al. (2000)  
  
Issue Support from the health professionals 
Nature of the study: aims/objectives, 
user/carer involvement in the 
design/conduct of study, country, site 
(setting, key characteristics of the 
context), details of theory/conceptual 
model. 
Objectives: 
Coronary angioplasty and stent placement is associated with short hospital days. Patients are expected to recover 
at home, alone, following limited care time with nurses. The purpose of this study was to describe participants' 
perceptions of recovery after angioplasty. 
Country: Australia 
Theory: qualitative techniques of grounded theory (see above). 
Methods: study type and design, 
study date and duration, 
sampling/recruitment, methods of data 
collection, data collector, used 
research tools (if any),  analysis 
methods 
Study design: 
The study used a grounded theory design. Data were gathered from semi-structured, taped interviews designed to 
explore the recovery experiences of coronary angioplasty patients. The purpose of the grounded theory is to 
understand the concerns, actions and behaviours of a group of individuals and, through their own language, 
explain those patterns of behaviour at a higher level of abstraction or theory. In-depth interviewing is an 
appropriate method to gain access to the individual's language and interpretations of social reality. 
Data collection: 
The semi-structured interviews allowed the researcher to clarify issues and gain further explanations and 
information during each interview. In this way, data saturation could be achieved. The interviews were taped and 
transcribed verbatim, therefore enhancing accuracy and validity of the interview data. The researcher verified 
each tape recording against the transcript to ensure it was an accurate record of the interview. All participants 
were assigned a code number and pseudonyms in order to preserve anonymity. 
Data analysis: 
The constant comparative method was utilized during the concurrent data collection and analysis to identify and 
develope recurrent themes and ideas. The aim was to generate theoretical constructs that, along with codes, 
categories and their properties, formed a theory that encompassed as much behavioural variation as possible. By 
constantly comparing codes and categories, the researcher identified patterns, similarities and differences. 
Comparing for similarities enabled the basic properties of a category to be defined, while differences enabled 
boundaries and relationships between categories to be clarified. These categories were further broken down, 
conceptualized and put back together in new ways through grounded theory techniques including open and axial 
coding procedures and memoing. 
   The outcomes of the continuing analysis suggested additional questions to be asked at the upcoming 
interviews. In this way theoretical sampling of data was achieved through directed questioning. This process 
enabled constant comparison of patient perceptions to either strengthen or challenge the emerging categories. 
The constant comparative method also uncovered a depth of range and variation within the categories. By the 
time the last of 11 interviews were analysed, no new information was identified that that did not fit within the 
previously identified and defined categories. Thus the data was dense, rich and fully saturated.  
Participant characteristics: gender, 
age, ethnicity, types of practitioners, 
policy makers or patients 
The participants included eight men and three women. Selection criteria included men and women over the age of 
18 from all cultural groups who could communicate in English. Participants who resided in the metropolitan area 
and had undergone elective PTCA were selected. Those patients undergoing emergency coronary angioplasty in 
the setting of acute myocardial infarction were excluded, as their recovery patterns were different to that of 
elective angioplasty patients and included a longer hospitalisation 
and a graded cardiac mobilisation. 
Features the studied intervention 
(when applicable) 
NA 
Outcomes and results: outcome 
measures, details of findings, 
strengths/limitations of the study, 
Results: 
Data analysis revealed three major categories: awareness of the problem, coping responses and appraisal of the 
situation. These were linked via a problem solving process. In step one, the problem was identified. In step two, 
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author's conclusions. 
 
coping responses were taken up to try and solve the problem. In step three, the results of the coping responses 
were appraised and evaluated. These categories were further defined by four phases identified as: pre-admission, 
admission, during the angioplasty and recovery. 
   The results describe the recovery phase. Awareness of the problem in the recovery phase was associated with 
'relief fron chest pain' for most participants. In contrast, anxiety continued and was associated with 'uncertainty 
over future health'. Participants described coping responses of 'taking control of their life again' by undertaking 
both physical and psychological strategies. Finally, the situation was appraised to be either a 'good' or a 'bad' 
recovery. This appraisal was based on such considerations as the absence of chest pain, improvement in well-
being and energy elvels. The results of this study highlight patients' concerns and support the need for greater 
emphasis on their psychosocial needs. This care must be provided within the time constraints of short hospital 
stays. Nurses must also consider providing support to patients in the pre-admission and recover phases. 
Implications for nursing practice: 
Nurses have the potential to extend their support to the post discharge recovery phase. Participants in the study 
identified that psychological support was very important. This may be achieved by follow up calls by nurses, or 
establishing phone help that the patient could call to discuss any feelings or concerns. It could also provide an 
avenue for families to gain access to nursing support. 
Limitations of the study: 
Several potential limitations of the study were identified. First, the researcher did not contact the participants after 
the interview transcript was complete in order to validate interpretation of the data. Second, the interviews were 
contacted 4 weeks following PTCA, therefore the participants were requested to recall past events. A number of 
staged interviews whilst the participants were experiencing recovery may have identified different perceptions. 
Third, the current study was small and specific to the first month following angioplasty. Thus the process 
described cannot be generalised to include recovery events occurring later than one month after PTCA.  
Reviewers' comments: e.g. remarks of 
quality issues 
 
 
 
First author, year  Higgins M et al. (2001)  
 
  
Issue Support from health care professionals 
Nature of the study: aims/objectives, 
user/carer involvement in the 
design/conduct of study, country, site 
(setting, key characteristics of the 
context), details of theory/conceptual 
model.   
Objectives: 
To describe participants' experiences of preparing for angioplasty in situations where patients undergo a short 
stay admission with limited care time with nurses 
User involvement in the conduct of study: 
Eleven patients were interviewed for the study 
Setting: 
The participants were selected from the cardiology and intensive units of a private metropolitan hospital. The 
hospital Ethics Committee granted ethical approval. 
Methods: study type and design, 
study date and duration, 
sampling/recruitment, methods of data 
collection, data collector, used 
research tools (if any),  analysis 
methods 
 
Study type and design: 
Qualitative study using techniques of grounded theory. 
Sampling: 
People from all cultural groups who could communicate in understandable English, were over the age of 18 and 
were scheduled for elective angioplasty were eligible for the study. 
Methods of data collection: 
A single, tape-recorded, semi-structured interview one month after discharge from hospital. Interviews took place 
at participants' homes. 
Analysis methods: 
The grounded theory techniques were used: theoretical sampling, open and axial coding, the constant 
comparative method. 
Participant characteristics: gender, 
age, ethnicity, types of practitioners, 
policy makers or patients 
 
Gender: Eight men, three women 
Ethnicity: Not specified  
Types of patients: Patients prior to percutaneous transluminal coronary angioplasty (PTCA) and intracoronary 
stent placement 
Features the studied intervention 
(when applicable):  aim of the 
intervention, intervention process 
(description of how was the 
intervention/service delivered) 
 
The aim of the study is to describe patients' experiences before the PTCA procedure (during admission to hospital 
and preparation for the angioplasty). The potential participants were given a study description sheet and consent 
form prior the procedure. The interviews took place 1 month after the angioplasty procedure date and were 
conducted at patients' homes. The tapes were transcribed and data analysis was reviewed by research 
colleagues. During data collection and analysis the constant comparative method was used to identify different 
themes. The open coding was used to assign a code to each theme and the codes were clustered into categories. 
Axial coding was used to connect the categories.   
Outcomes and results: outcome 
measures, details of findings, 
strengths/limitations of the study, 
author's conclusions.   
 
Details of findings: 
Three major categories were identified: awareness of the problem or situation, coping responses and appraisal of 
the situation. Continuing chest pain and fear of the unknown were identified as themes within the category of 
awareness of the problem. Anxiety was related to fear of unknown and was identified as a central theme. Anxiety 
was expressed also by those patients who had previous experience with angioplasty. Three participants reported 
little anxiety. 
The coping responses included acquiring knowledge of the angioplasty, confidence in the skill of the doctor, 
support from family and gearing up psychologically. The patients received information from doctors, pamphlets 
and experienced patients. The doctor was perceived the most important source of information but also other 
patients experiences were thought to be valuable. Some of the patients perceived the written material helpful but 
others were disappointed and preferred human interaction. Support from family members was an important coping 
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mechanism during the whole angioplasty process. Patients' appraisal of their situation and their decisions to go 
ahead with or delay the procedure seemed to be based on the success of the coping responses. The common 
perception was that the admission phase was anxiety provoking. 
Limitations of the study: 
The small sample size limits generalisability of the result to other population. The interview was conducted one 
month after the procedure and participants were recall past events.  
Author's conclusions: 
The concepts that emerged from the study provide the potential for changes to nursing practice and further 
research. The time before the angioplasty was experienced anxiety provoking by most of the patients. In contrast, 
the high turnover nature of the angioplasty care may cause that nurses view the procedure as a mechanised and 
routine process. The patients' perceptions indicated that psychological aspects of nursing care are important 
components of nursing practice for the angioplasty patients.  
Reviewers' comments: e.g. remarks of 
quality issues 
 
 
 
First author, year 
  
Eastwood GM (2001)  
  
Issue Support from health professionals 
Nature of the study: aims/objectives, 
user/carer involvement in the 
design/conduct of study, country, site 
(setting, key characteristics of the 
context), details of theory/conceptual 
model.  
Objectives: 
What are the rationale and influences behind the decisions of patients to change/not to change their lifestyle 
patterns 3 months after a percutaneous transluminal coronary angioplasty/intracoronary stent procedure 
User involvement in the conduct of study: 
Data collected by interview from the patients 
Country:Autralia 
Methods: study type and design, 
study date and duration, 
sampling/recruitment, methods of data 
collection, data collector, used 
research tools (if any),  analysis 
methods 
Study type and design:Descriptive study utilized naturalistic inquiry approach with the implementation of semi-
structured interview  
Study date and duration: 
A single interview with each participant three months after  PTCA/intracoronary stent procedure 
Sampling/recruitment: 
-Identification of potential participants via regular telephone and personal consultations with the cardiac unit 
coordinator. Consent from the cardiologist responsible for performing the procedure  
-Non-probability purposive sampling. A sample of four male participants who had undergone a PTCA/stent 
procedure for the first time  
- The patients approached by the researcher within the first 36 h following their procedure and ask their interest to 
participate in the study (plain language statement and consent form) 
Methods of data collection: 
Semi-structured interview schedule 
Data collector:Not specified  
Research tools:Semi-structured interview, audio-taped, transcribed verbatim 
Analysis methods: The material of interviews was read, re-read and listened to several times, in sequential order, 
in order to make the researcher familiar with the collected data and recognise emergent themes. A copy of 
transcript was sent to each participant to verify the accuracy, interpretation and use of quotations 
Participant characteristics: gender, 
age, ethnicity, types of practitioners, 
policy makers or patients 
Gender:Males 
Age:Not specified 
Ethnicity:Not specified 
Types of patients:Inclusion criteria: No a serious co-morbid medical diagnosis, no major complication as a result 
of the procedure, English-speaking, males, no previous cardiac surgery or involved with a cardiac rehabilitation 
program 
Features the studied intervention 
(when applicable):  
NA 
Outcomes and results: outcome 
measures, details of findings, 
strengths/limitations of the study, 
author's conclusions.   
 
Details of findings: 
The results suggested that a positive psychological health perspective, family considerations, return to work 
issues together with a reluctance to participate in cardiac rehabilitation program activities had impact on patients' 
decision to change/not to change their lifestyle patterns after the procedure: 
-The renewed feelings of well-being, improved quality of life and enhanced physiological outcomes are a 
consequence of the PCTA/stent procedure. Some of the patients viewed that the procedure has 'fixed' the 
problem which made apparent that they were unconcerned or unaware of the need to change their lifestyle 
patterns in order to prevent future cardiac complications. The short period of hospitalization was thought to be 
another influential factor (three out of the four patients dismiss the significance of their cardiac condition).   
- The results suggested that participants with dependants (children, elderly relatives) were affected in their ability 
to instigate change or maintain existing lifestyle patterns. Two participants highlighted the need for and potential 
value of the family members receiving counselling to promote better understanding of patients' situation.  
- The ability to maintain exercise routines was affected by the nature of the work, work rosters and inflexible work 
schedules. The benefits regarding working life were increased feelings of self-worth, renewed ability to socialize 
and the feeling of a return to normality. 
- Despite the information concerning the benefits of lifestyle change being received during hospitalization there 
was a reluctance to attend cardiac rehabilitation program activities. Two out of four patients believed that the 
information they received and their own knowledge base was sufficient to maintain healthy lifestyle. 
- The one patient who took part in structured cardiac rehabilitation showed the greatest awareness of cardiac risk 
factors and implemented the greater degree of lifestyle pattern change. 
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Limitation of the study:  
Due to methodology and a small sample size, the ability to extrapolate the findings of the study to the greater 
population of PTCA/stent patients is not possible. 
Due to only one interview it is not possible to detect the long-term influences on lifestyle pattern change. 
 
Author's conclusions:   
The study gave insight into and understanding of the influences affecting lifestyle pattern change. That change is 
dependent on the individual's psychological, social, familial and work-related circumstances. Nurses spend the 
greatest amount of time with PTCA/stent patients during hospitalization and have best opportunity to provide 
relevant information in order to influence the decisions concerning lifestyle pattern change.   
Reviewers' comments: e.g. remarks of 
quality issues 
 
 
First author, year  
 
Abbas AE. et al. (2004)  
  
Issue Working life; meaning of implementation of the technology for the patient's working life 
Nature of the study: aims/objectives, 
user/carer involvement in the 
design/conduct of study, country, site 
(setting, key characteristics of the 
context), details of theory/conceptual 
model. 
Aims: 
The study conducted an analysis of the frequency and variables associated with early (after 1 month) and late 
(after 6 months) return to work after percutaneous coronary intervention for acute myocardial infarction in patients 
who had been randomized in the Stent Primary Angioplasty in Myocardial Infarction trial. The study examines the 
demographic, clinical, and angiographic characteristics of patients who returned to employment 1 and 6 months 
after percutaneous coronary intervention for AMI: 
Methods: study type and design, 
study date and duration, 
sampling/recruitment, methods of data 
collection, data collector, used 
research tools (if any),  analysis 
methods 
 
The frequency and variables associated with return to work at 1 and 6 months were analyzed. Categorical 
variables were analyzed with the chi-square test, when appropriate. Fisher's exact test, and continuous variables 
were examined with Wilcoxon's rank test. A p values <0,05 was considered statistically significant. We compared 
demographics, clinical presentation, angiographic findings, procedural success, anginal index at 1 month, and in-
hospital and 1-month events of patients who returned to work at 1 month with those of patients who did not. We 
also compared 6-month clinical outcomes to determine the safety of early return to employment. In addition, we 
compared the anginal index and 6-month outcomes in patients who returned to work at 6-months with those in 
patients who did not.  
   A step-down multivariate logistic regression analysis was completed to determine the best predictors of 
returning to work at 1 and 6 months. Included in the first step for return to work at 1 month were age >70 years, 
gender, employment, in the US versus employment elsewhere, multivessel disease, smoking history, final percent 
stenosis, in-hospital events, 1-month events, lowest systolic blood pressure during hospitalization, and angina at 1 
month. Included in the first step for return to work at 6 months were age >70 years, gender, US versus non-US 
employee, multivessel disease, smoking history, 6-month events, aand presence of angina at 6 months. The least 
significant variable was dropped at each step until only those with a p value <0,05 remained in the final mode. 
Participant characteristics: gender, 
age, ethnicity, types of practitioners, 
policy makers or patients 
An analysis was done of all patients (450) who had been randomized in the Stent Primary Angioplasty in 
Myocardial Infarction study. The international study compared primary angioplasty with and without stenting with a 
heparin-coated Palmaz-Schatz stent in patients who had electrocardiographic or angiographic evidence of AMI. 
Features the studied intervention 
(when applicable):  
NA 
Outcomes and results: outcome 
measures, details of findings, 
strengths/limitations of the study, 
author's conclusions.   
 
Results: 
Of 450 patients who were employed before the acute myocardial infarction, 230 (51%) returned to work within 1 
month with no increases in in-hospital and 1-or 6-month event rates compared with those who did not return to 
work. Multivariate analysis showed that predictors of early return to work were employment in the United States, 
no history of smoking, and single-vessel coronary disease. At 6 months, 353 of 435 patients (78%) had returned 
to work, and multivariate analysis showed that predictors of late return to work were employment in the United 
States and absence of angina.  
 
The study suggests that regional differences play an important role in determining return to work after 
percutaneous coronary intervention for AMI: Being a US employee was the single most important predictor of 
early (1 month) and alte (6 months) resumption of employment. Early return to work was also determined by the 
number of narrowed coronary arteries and history of tobacco use but appeared to have no adverse effect on rates 
of mortality, stroke, or reinfarction at 6 months. By 6 months, >75% of the patients had returned to work and they 
were less likely to complain on angina. However, even in patients who remained unemployed, symptoms were 
mild in most of them (only 3,8% had class 3 to 4 angina). In addition, with no difference in clinical events in the 
previous 6 months, regional and geographic influences seem to supersede functional class and clinical events in 
determining late return to employment. 
 
The study highlights the importance of regional rather than clinical factors in determining reemployment after 
percutaneous coronary intervention for AMI. The reason for this is unclear but definitely reflects geographic, 
ethnic, and regional influences on return to employment after AMI: 
Reviewers' comments: e.g. remarks of 
quality issues 
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Legal Aspects 
Marco Marchetti, Marco Oradei, Mirella Corio, Carmen Furno, Matteo Ruggeri 
Introduction  
In this HTA domain will be discussed some legal issues related to DES technology. Some legal 
issues are directly related to the patient and his/her basic rights, such as autonomy, informed 
consent, privacy and confidentiality. Other issues are linked to the technology, such as 
authorisations, patents/licenses, acquisition process, price and reimbursement regulations, product 
safety, guarantee and liability. European directions do not include specific instructions for DES, but 
regulate the general devices sector (i.e. CE certification for new devices). DES can not be 
considered as a new experimental technology; therefore some questions of this domain are not 
relevant. 
 
One of the legal aspect linked to DES utilization it is a possible increase of litigation cases, either 
when a DES was not implanted and restenosis occurred, or conversely, if a complication occurred 
after DES implantation for an unapproved indication. 
 
Questions proposed in this domain partly overlap those in the other domains (i.e social, 
organizational, ethical, economic domains).  
 
Methodology  
 
According to the guidelines provided by the Corel Model, legal sources were analysed at different 
levels.   
– European Council Level (i.e. Convention on Human Rights and Biomedicine and European 
Human Rights Convention) 
– EU level (medical devices guidelines) 
– National level  
– Documentation provided by DES producers. 
 
Articles have been searched on medical-legal specialised reviews and ad hoc researches have been 
made on both generic (e.g. Google) and specialised (e.g. Pubmed) search engines. 
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Assessment elements 
Autonomy of the patient  
Is the patient competent to make his/her own health care decisions? 
Methods 
Analysis of legal sources at the different levels (European and National) and research of articles on 
scientific journals.  
Results 
Patient‘s capacity to make informed decisions on their health is connected to the type of 
information received and the way it is transferred. The Convention for the protection of Human 
Rights and Biomedicine (Oviedo 1997), agreed by all States member of European Community, 
encloses regulations on informed consent, by establishing that each person must give his/her own 
consent to be submitted to health care treatments(art. 5)
1
.  
  
Consent must be personal, expressed, specific, actual, revocable, and informed. Without adequate 
information, no form of consent, even if undersigned, is valid by laws. If the patient is a minor, the 
consent is automatically delegated to his/her own parents. The minor has the right to be informed 
and to express his/her wishes, which must be taken into consideration. If the patient is a major, but 
he/she is incapable to decide, his/her legal tutor is responsible for giving consent, even though 
he/she has the right to be informed and his/her will must be taken into consideration.  
 
The three steps of informed consent:  
1- The physician transfers to the patient all of the relevant information, on both diagnosis and 
therapy 
2- The physician ascertains that the patients comprehended the meaning of the communication  
3- Patient makes final decisions. 
 
 
In the case of DES, the patient‘s capacity to give his/her consent to the treatment can be influenced 
by the seriousness of his/her clinical conditions. With elective patients all of the three steps of the 
informed consent process can take place. In emergency situations it may be difficult to obtain truly 
informed consent from the patient, because: 
a. the patient is considered to be neurologically incompetent, or  
b. although the patient is conscious, clinical and psychological pressure caused by his/her 
clinical conditions, make him/her incapable to make an aware decision  
In these circumstances then the law allows emergency medical treatment to be administered without 
consent
2
. 
 
Nowadays, relevance of patient decisions on health care procedures has been legally recognised. 
Regulations provided are clear: physicians must provide patients with clear and complete 
information and they can proceed only after patient‘s consent.  
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Comment 
 
The crucial issue in DES implant procedure is physicians‘ capacity to inform patients properly. In 
fact,  since DES are a new generation technology (first DES have been merchandised in 2002), only 
now clinical trials identify medium, long-term effects, which highlight the occurrence of new 
possible risks, respect to the optimistic forecast of the first trial conducted. Therefore, physicians 
are not acquainted with all of the effects of a DES procedure on patient‘s health.  
This issue undoubtedly overlaps with the ethical domain. 
 
Can the patient understand the implications of using/not using DES? 
Methods 
Several patients‘ information papers concerning PTCA (performed either with or without stent 
insertion), selected by an internet search, have been analysed. 
Results 
Patients are usually able to understand the meaning of stent insertion and its clinical implications, if 
correctly explained, and thus legally competent to give his/her own consent. One of the few 
documents available explaining which information patients undergoing to PTCA (with or without 
stent implant) must receive, has been produced by Queensland Government
3
. It states that the 
doctor must explain to the patient his/her medical conditions and the procedure to follow, in order 
to make patient aware of the risks involved, both general and specific, and the possible outcome. 
The doctor should present also other diagnostic options and their risks. Finally, he must introduce to 
patients the prognosis and the risks of not following the procedure. 
Comment 
As highlighted in the previous paragraph, in case of a DES implant, information available on 
medium and long term risks are not sufficient, because there is still poor scientific evidence on this 
subject.  
Are there relevant optional technologies that the patient should be allowed to 
consider?  
Methods 
Comparative studies on PTCA with DES/BMS insertion versus bypass grafting have been analysed. 
These studies have been searched by Pubmed, using the follow keywords: ―CABG‖, ―PCI‖, 
―Bypass‖, ―Stent‖, ―DES‖ and ―BMS‖. This analysis included only comparative studies published 
in the last five years.  
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Results 
There are two levels of choices between available technological options: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First level: 
There is a relevant choice to stent (both DES and BMS) insertion, consisting in CABG (Coronary 
Artery Bypass Graft). The issues to be considered here are early and late morbidity and mortality 
for cardiovascular events
4,5,6
.   
 
Second level: 
Several studies have compared BMS versus DES. In addition to issues listed at the first level of 
choice, the issue of long-term medication after the intervention must be considered
7,8
. 
Comment 
Although coronary artery bypass grafting (CABG) remains the treatment of choice for certain types 
of coronary artery disease (CAD), percutaneous coronary intervention (PCI)--particularly coronary 
angioplasty with stenting--has become the most popular interventional treatment approach to CAD. 
Both CABG and PCI technologies will continue to advance, and longer-term data may change the 
evaluations.
10
 
 
Is it possible to give the patient enough time to consider his/her decision? 
Methods 
Analysis of legal sources at the different levels (European and National) and research of articles in 
scientific journals.  
Results 
As outlined before, angioplasty with stent insertion procedure can be twofold: primary or 
secondary. 
– in case of primary angioplasty (urgent/emergency cases) the patient may not have enough 
time to decide whether to accept the treatment, due to his/her clinical condition. A primary 
angioplasty must be performed within 30-40 minutes. For legal implications, please see 
issue ―Is the patient competent to make his/her own health care decisions?‖ 
PTCA 
CABG 
BMS 
DES 
Patient with CAD 
(Coronary artery disease) 
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– in case of secondary angioplasty, since it is an elective procedure, it is possible to plan in 
advance meetings with patients, so that they can receive all of the necessary information to 
make informed decisions on their health. For legal implications of not following the 
regulations on the informed consent, please see the issue “Is the patient competent to make 
his/her own health care decisions?” 
Comment 
Hospitals Clinical/Critical Pathways must take into account the time patients need to consider their 
decision. Even if clinical conditions of patients do not always allow for enough time to think about 
PTCI procedures, the time should be built in clinical pathways.  
 
Is it possible to obtain an advance directive on the use of DES? 
Results 
An advance directive is a legal document that helps ensure that the patient's wishes regarding health 
care will be respected if he becomes unable to speak or otherwise communicate. In the absence of a 
written document, sometimes an advance directive may be an oral communication, where patient 
express his wishes for care verbally to his family members or health care agent. An advance 
directive may become important if patient are severely injured or develop a serious illness that 
prevents him from actively participating in decisions about his medical care. 
 
Living wills and medical powers of attorney are types of advance directives. 
 A living will documents personal wishes about end-of-life medical treatment in case 
decision-making or communication abilities are lost such as ventilation, feeding tubes in the 
event you are in a terminal condition or persistent vegetative state.  
 A medical power of attorney is a legal document that lets you appoint someone (usually 
called a health care agent or health care proxy) to make medical treatment decisions for you 
not only at the end of life but any time you are unable to speak for yourself
11
.  
  
Convention On Human Rights And Biomedicine
1
 (art. 9 ) establishes that ‖The previously 
expressed wishes relating to a medical intervention by a patient who is not, at the time of the 
intervention, in a state to express his or her wishes shall be taken into account”.  
Each Country has proper Laws for assigning individuals their rights to decide on their own life, 
depending on the legal value they assign to ―life‖ as a good. As a consequence, different rights to 
decide on own life, could affect, in case of life danger, advance directives‘ relevance. 
 
The performed search produced no meaningful results that link advance directives with PTCA; it 
has been thought that it is not necessary to obtain an advance directive on the use of this specific 
technology. It may be possible find examples of advanced directive written by patients with CAD. 
In people with CAD, in fact, death often occurs without warning. Death can occur quickly, before 
any symptoms develop or before they become bothersome. Such a death may result from a heart 
attack or an abnormal heart rhythm. Or death can occur after a period of chronic illness with ups 
and downs. Such a death may result from heart failure. Consequently, people with CAD, even those 
without significant symptoms, should prepare advance directives, stating what kind of care they 
want at the end of life
12
. 
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A study have been shown that patients want to share in major decisions
 
with their physicians but 
prefer to be less involved in minor
 
decisions. For some illnesses, such as myocardial infarction,
 
prior experience with the illness increases the patients' desire
 
for participation in decision making
13
. 
 
Privacy of the patient  
Is the access to the patient data secured properly? 
Methods 
Analysis of the norm sources at various levels (European and national) has been performed. 
Results 
Specific information on managing the data of the patient with PTCA does not exist.  
 
Security and protection of patient health data in most developed countries, are required by law. This 
is of utmost importance, since patient health data are among the most sensitive personal data. In 
order to ensure the confidentiality and integrity of such kind of data, they need to be protected 
against manipulation, unauthorized access and abuse. 
Below it will be present some basic definitions of data protection and security that are given in the 
European Directive on the protection of individuals with regard to the processing of personal data 
and on the free movement of such data: 
 Data protection aims to protect the fundamental rights and freedoms of natural persons and in 
particular their right to privacy with respect to the processing of personal data. 
 Data security aims to protect personal data against accidental or unlawful destruction or 
accidental loss, alteration, unauthorized disclosure or access, in particular where the processing 
involves the transmission of data over a network, and against all other unlawful forms of 
processing. 
Together, data security and data protection aim to ensure the following five fundamental objectives: 
1. Confidentiality means the assurance that patient data are not made available or disclosed to 
unauthorized individuals. 
2. Integrity means to ensure that patient data cannot be changed or deleted by unauthorized 
individuals or parties. 
3. Authentication means the corroboration that a person is the one claimed. 
4. Accountability means that the actions of a person, especially the modifications that he/ she 
performs on data stored in an EPR, can be traced. 
5. Availability means that upon demand patient data can be accessed and used by authorized 
people. 
When using, storing and exchanging patient health data, all these fundamental objectives have to be 
taken into account and their achievement has to be ensured by appropriate methods and tools
14
. 
Within the European Union several legal regulations shall cover all the different legal aspects. 
 The fundamental right to the protection of personal data is essentially based on Article 8 of the 
European Convention for the Protection of Human Rights and Fundamental Freedoms (ECHR) 
and on Article 8 of the EU Charter of Fundamental Rights. More precise rules are in particular 
laid own in the EC Data Protection Directive 95/46/EC and in Directive 002/58/EC on privacy 
and electronic communications. 
 Secure data exchange is regulated by means of the European Directive from 1999 on a 
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Community framework for electronic signatures (Directive 1999/93/EC of the European 
Parliament and of the Council of 13 December 1999 on a Community framework for electronic 
signatures). 
The latter directive also aims at the creation of a foundation for the legal equality of electronically 
signed documents and hand-signed documents. All directives have to be implemented in the 
national legislation of the member states of the European Union. 
 
In EU, processing of personal data is regulated by the articles 7 and 8 of the EU Directive of 1995. 
Article 7 applies to all forms of personal data, whereas in article 8 specific regulations are laid down 
that apply to the processing of special categories of data, which amongst others also cover patient 
health data. By means of the latter article the processing of special categories of data shall be 
prohibited by the Member States.  
When the processing of such personal data relates to a person's health, processing is particularly 
sensitive and therefore requires special protection. 
 
Article 8 (1) 
The definition of special categories of data contained in Article 8 (1) of the Directive reads as 
follows: 
“Member States shall prohibit the processing of personal data revealing racial or ethnic origin, 
political opinions, religious or philosophical beliefs, trade-union membership, and the processing 
of data concerning health or sex life.” 
This definition also applies to personal data when they have a clear and close link with the 
description of the health status of a person: data on consumption of medicinal products, alcohol or 
drugs as well as genetic data are doubtlessly "personal data on health" especially if they are 
included in a medical file. Also any other data – e.g. administrative data (social security number, 
date of admission to hospital etc) – contained in the medical documentation of the treatment of a 
patient will have to be considered as being sensitive: if they were not relevant in the context of the 
treatment of the patient, they would and should not have been included in a medical file. 
Article 8 (1) of the Data Protection Directive 95/46/EC prohibits the processing of personal data 
concerning health in general. So does Article 6 of the Council of Europe Convention No 108. This 
special protection contained in Article 8 (1) complements the other provisions of theDirective, in 
particular Article 6 on the principles relating to data quality and Article 7 on the criteria for making 
data processing legitimate. 
However, considering the importance of using information about a patient in order to medically 
treat him appropriately, there are exemptions to the general prohibition of processing medical data. 
The Data Protection Directive provides for mandatory derogations laid down in Article 8 (2) and 
(3) plus an optional exemption in Article 8 (4). 
All these derogations are limited, exhaustive and have to be construed in a narrow fashion. 
 
Article 8 (2) (a): “Explicit consent” 
According to Article 8 (2) (a) of the Directive: 
“Paragraph 1 shall not apply where: (a) the data subject has given his explicit consent to the 
processing of those data, except where the laws of the Member State provide that the prohibition 
referred to in paragraph 1 may not be lifted by the data subject's giving his consent;” to be valid, 
consent – whatever the circumstances are in which it is expressed – must be a ―freely given, specific 
and informed indication of the data subject’s wishes‖, as defined in Article 2(h) of the Directive. 
a) Consent must be given freely: ‗Free‘ consent means a voluntary decision, by an individual 
in possession of all of his faculties, taken in the absence of coercion of any kind, be it social, 
financial, psychological or other. Any consent given under the threat of non-treatment or 
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lower quality treatment in a medical situation cannot be considered as ‗free‘. Consent given 
by a data subject who has not had the opportunity to make a genuine choice or has been 
presented with a fait accompli cannot be considered to be valid. 
b) Consent must be specific: ‗Specific‘ consent must relate to a well-defined, concrete situation 
in which the processing of medical data is envisaged. Therefore a ‗general agreement‘ of the 
data subject e.g. to the collection of his medical data for an EHR and to subsequent transfers 
of these medical data of the past and of the future to health professionals involved in 
treatment would not constitute consent in the terms of Article 2 (h) of the Directive. 
c) Consent must be informed: ‗Informed‘ consent means consent by the data subject based 
upon an appreciation and understanding of the facts and implications of an action. The 
individual concerned must be given, in a clear and understandable manner, accurate and full 
information of all relevant issues, in particular those specified in Articles 10 and 11 of the 
Directive, such as the nature of the data processed, purposes of the processing, the recipients 
of possible transfers, and the rights of the data subject. This includes also an awareness of 
the consequences of not consenting to the processing in question. 
In contrast to the provisions of Article 7 of the Directive, consent in the case of sensitive personal 
data and therefore in a Health care Record must be explicit. Written consent is, however, not 
required. 
Article 8 (2) (c): “vital interests of the data subject” 
The processing of sensitive personal data can be justified if it is necessary to protect the vital 
interests of the data subject or of another person where the data subject is physically or legally 
incapable of giving his consent. 
 
Article 8 (3): “processing of (medical) data by health professionals” 
Article 8 (3) allows for the processing of sensitive personal data under three cumulative conditions: 
the processing of sensitive personal data must be “required”, and this processing takes place “for 
the purposes of preventive medicine, medical diagnosis, the provision of care or treatment or the 
management of health-care services” and the personal data in question “are processed by a health 
professional subject under national law or rules established by national competent bodies to the 
obligation of professional secrecy or by another person also subject to an equivalent obligation of 
secrecy”. 
This derogation only covers processing of personal data for the specific purpose of providing 
health-related services of a preventive, diagnostic, therapeutic or after-care nature and for the 
purpose of the management of these healthcare services, e.g. invoicing, accounting or statistics. 
 
Article 8 (4): substantial public interest exemptions 
A number of provisions of the Directive contain a substantial degree of flexibility, so as to 
strike the appropriate balance between the protection of the data subject‘s rights on the one 
side, and on the other side the legitimate interests of data controllers, third parties and the 
public interest which may exist. 
 
Article 29 Working Party
15
 provides guidance on the interpretation of the applicable data protection 
legal framework for health in electronic health records EHR systems and explains some of the 
general principles. The Working Document also gives indications on the data protection 
requirements for setting up EHR systems, as well as the applicable safeguards. The Article 29 
Working Party first examines the general legal data protection framework for EHR systems. The 
Article 29 Working Party recalls the general prohibition of the processing of personal data 
concerning health of Article 8 (1) of the Data Protection Directive 95/46/EC, and then discusses the 
possible application of the derogations in Article 8 (2), (3) and (4) of the Directive in the context of 
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EHR systems by stressing the need for interpreting such derogations in a narrow fashion. The 
Article 29 Working Party also reflects on a suitable legal framework for EHR systems and provides 
recommendations on eleven topics where special safeguards within HER systems seem particularly 
necessary in order to guarantee the data protection rights of patients and individuals. These topics 
are: 
1. Respecting self determination 
2. Identification and authentication of patients and health care professionals 
3. Authorization for accessing EHR in order to read and write in EHR 
4. Use of EHR for other purposes 
5. Organisational structure of an EHR system 
6. Categories of data stored in EHR and modes of their presentation 
7. International transfer of medical records 
8. Data security 
9. Transparency 
10. Liability issues 
11. Control mechanisms for processing data in EHR 
 
Below – with a focus on consent - a cross sectional overview of main European countries‘ fitting to 
EC directive has been reported:  
 
United Kingdom position 
The Data Protection Act 1998 does not contain a definition of consent. According to Paul Boyle 
(the official responsible for data protection at the Department for Constitutional Affairs) this is one 
of the aspects of UK implementation of the Data Protection Directive which has been queried by the 
EU Commission. 
There are no specific formal requirements (such as consent being in writing). 
 
The Netherlands 
The Dutch Data Protection Act reproduces the definitions in the Data Protection Directive and uses 
consent in similar situations. There are no specific formal requirements in the Dutch Data 
Protection Act. This is a change to the old Data Protection Act which did require consent to be 
given in writing. Guidance from the Ministry of Justice does, however, note that written evidence of 
consent can be helpful. 
 
Spain 
The Organic Law 15/99 uses the same definition as the Directive. However, it goes further than the 
Directive and also requires that consent must be ―unequivocal‖. 
Article 7.2 of the LOPD requires consent to be express and in writing for the processing of 
information relating to ideology, religion, beliefs and trade union membership. Under Article 7.3 
consent for processing of other sensitive personal data needs to be express but does not necessarily 
need to be in writing. 
In accordance with the Spanish Civil Code, minors older than 14 are mature enough to give consent. 
For minors who have not yet reached 14, consent is to be given by their legal representatives. 
Note that the LOPD does not allow data to be processed based on the data controller‘s ―legitimate 
interests‖ (i.e. Article 7(f) of the Directive has not been implemented in Spanish law). Accordingly, 
organizations in Spain must, as a practical matter, make greater use of consent. 
One of the exceptions to the principle of consent is where the data is in sources accessible to the 
public which are solely and exclusively: 
 the promotional census (i.e. electoral roll data to be used for direct marketing); 
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 telephone directories; 
 list of members of professional groups; and 
 Newspapers, official gazettes and the media. 
 
Belgium 
Belgian law follows the Directive‘s definition of consent. 
Articles 6 and 7 of the Belgian Data Protection Act require consent to be in writing to process 
sensitive and health related personal data. Other than this, there are no requirements for formalities. 
In addition, Article 39 provides that acts of violence or threats made with the purpose of obtaining a 
person‘s consent are illegal and punishable by fine. 
 
Italy 
The Italian Data Protection Code (Legislative Decree Number 196/2003) does not contain a specific 
definition of consent. The requirements of the Data Protection Directive are reproduced in Article 
23. In addition, this also provides that consent must be express (i.e. not implicit, for instance, by 
simply going ahead and using a service) and must be documented in writing or, in the case of 
sensitive data, actually given in writing. Consent may either be given by the data subject or by the 
person entitled to act on the data subject‘s behalf. 
 
Sweden 
In the Swedish Personal Data Act (1998:204), section 3, consent is defined as:  
“Every kind of voluntary, specific and unambiguous expression of will, by which the registered 
person, after having received information, accepts processing of personal data concerning him or 
her.”There are no formal requirements, such as consent being in writing. 
 
France 
The French Data Protection Act reproduces the definitions in the Data Protection Directive. There 
are no specific formal requirements in the French Data Protection Act. 
The French Data Protection Authority (Commission Nationale de l’Informatique et des Libertés: 
CNIL) considers that consent must be given in writing. 
 
Germany 
German data protection law defines consent as a free and informed declaration: Section 4a para. 1 
sentence 1 Federal Data Protection Act (Bundesdatenschutzgesetz), which is applicable to the 
private sector, requires that consent must be a result of a free decision of the data subject. The data 
subject must be informed about the purpose of the data collection, processing or use and the 
consequences of a refusal to give consent if necessary or if the data subject so requests (Section 4a 
para. 1 sentence 2 Federal Data Protection Act). 
To the extent sensitive data are concerned the consent must refer explicitly to such sensitive data 
(Section 4a para. 3 Federal Data Protection Act). 
 
As regards formal requirements, German law requires (Section 4a para. 1 sentence 3 Federal Data 
Protection Act) the written form unless another form is appropriate. If consent is included with 
other provisions, the consent wording must be highlighted (Section 4a para. 1 sentence 4 Federal 
Data Protection Act). 
 
The information related to Directive and its application in the european countries are from 
http://www.twobirds.com/english/publications/articles/Use_of_Consent_in_Data_Protection.cfm 
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Comment 
National situation all over the Europe is very similar according to EU directive.  
 
 
How many people in the care pathway need to get access to the patient 
information?  
Methods 
Analysis of the norm sources at various levels (European and national) has been performed. 
Results 
According to privacy Law the access to patient data must be allowed to health professionals 
(clinicians and nurses) responsible for patient‘s care process and to patient‘s caregivers. 
Comment 
National situation all over the Europe is very similar according to EU directive. 
Equality in health care 
Is DES equally accessible to all needing members of society?  
Methods 
Analysis of the norm sources at various levels (European and national) has been performed. A 
research on different funding system has been performed by internet tools.   
Results 
Drug-eluting stents became commercially available in 2002 in Europe and Canada, and in 2003 in 
the United States. They are now widely used in the treatment of coronary artery disease
16
.  
 
The penetration of the coronary stent market by drug-eluting stents from a common launch in 2002 
to the third quarter of 2004 is very similar in different countries of Europe. All countries had a very 
similar market penetration of coronary artery stents, except Switzerland and France.  
Penetration in Switzerland increased rapidly to a plateau of over 70 percent within 2 years of 
availability. In France the penetration was slower than elsewhere for the first year of use, but then 
caught up with the majority. In Denmark the penetration was similar to all the other countries 
except in 2004, when the rate of increase was much greater than in the others. Consequently, the 
utilization of DES in the European Countries seems uniform.  
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Fig 1 - Penetration of the coronary stent market by drug-eluting stents 
 
A problem related to the safety and appropriateness of this particular technology – and in some way 
to its equal utilization - is apparent. It is not clear yet which treatment strategy would be optimal, 
when considering various treatment options.
17, 18
. 
 
Comparing international utilization of stents is naturally not a robust proof of equal societal 
accessibility. Although national numbers compare well, significant variation may exist within 
countries and their societal groups. These issues are addressed also in the chapter "Social aspects". 
Comment 
It is also possible that DES technology is overused in wealthy health care systems. The international 
scientific and political debate is generally focused on the necessity to increase the appropriate use of 
DES.  
 
 
Is DES subsidized by the society? 
Methods 
Analysis of the norm sources at various levels (European and national) has been performed. A 
research on different funding system has been performed by internet tools.   
Results 
Judging from the large number of publications on the cost-effectiveness of drug-eluting stents, the 
price tag for the commercially available drug-eluting stents is excessive (approximately $1500 to 
$3000 per stent in Canada). Because drug-eluting stents are considerably more expensive than bare-
metal stents, with an estimated world market of $6 billion annually, some health care systems are 
trying to control their diffusion in clinical practice.
19
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Subsidizing policies are related to DES diffusion and the characteristics of the health care system.  
In particular an above average health spenditure is positively associated with diffusion and cost 
enhancement.  A single state agency controlling expenditure on health care may make it easier to 
control diffusion compared with multiple insurance schemes, which are likely to favour high-tech 
innovation. An important means of controlling (both restricting and promoting) diffusion is through 
a national decision making system
20
. 
 
In the UK system for example at current UK prices, DESs are not cost-effective compared with 
conventional stents except for a small minority of patients. Although the technology is clearly 
effective, general substitution is not justified unless the price premium falls substantially
21
. At the 
Health Care Organization level it seems that public hospitals have been more selective than private 
facilities in their use of these stents.  
 
Interestingly, in Italian the private sector has adopted unrestricted use of drug-eluting stents without 
a change in overall cardiac surgery volumes. Although the number of isolated CABG procedures 
has decreased in both private and public hospitals, the level of reduction has been significantly 
greater in the public hospitals. The small reduction in private hospitals suggests reluctance to move 
from CABG (and the high revenues it generates) to PCI (and its lower revenue margins due to the 
high cost of drug-eluting stents). The fact that PCI numbers have not decreased, has likely been a 
business decision to maintain a ―high technology veneer‖ that would appeal to patients and referring 
physicians
22
. 
Comment 
Different subsidizing activities have been performed at different level in European Countries 
(macro-policy level, institutional meso-level)  
 
Equality in health care  
Is there a wide variation in permissibility of the technology across Europe? 
Methods 
To answer this issue we searched in the European Court of Justice Database, using  the keywords 
―stent‖ and ―permissibility‖. We also searched in the Medline database using the keywords ―stent‖ 
and ―permissibility‖. 
Results 
The research in European Court of Justice Database not found anything on stents. Also the search in 
Medline not found articles with the keywords. The conclusion is that there is nothing specific on 
stents permissibility. 
 
DES legislation, as far as permissibility is concerned, is ruled by general laws on devices 
permissibility. The European reference law on this issues is the Council Directive 93/42/EEC of 14 
June 1993 concerning medical devices established, in the article 2, that ―Member States shall take 
all necessary steps to ensure that devices may be placed on the market and put into service only if 
they do not compromise the safety and health of patients, users and, where applicable, other persons 
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when properly installed, maintained and used in accordance with their intended purpose‖. In 
addition article 17 states that ―Devices … must bear the CE marking of conformity when they are 
placed on the market‖. In Italy this directive has been ratified with Law n. 46 of 24-02-97 
On the base of this Law, it doesn‘t seem to exist wide variation in permissibility among European 
Countries. 
Comment 
There is no variation permissibility of the technology across Europe. Indirect variation 
permissibility could be linked to different funding system across Europe.  
Is health care tourism expected from/to other European countries? 
Methods 
Medline was searched using as keywords ―stent‖, ―angioplasty‖ and ―mobility‖. Also other non 
scientific search engines were consulted. 
Results 
No specific articles on this issues were found.  
Comment 
DES seems not to have consequences on patient mobility among European States, when compared 
with BMS. This could probably be linked to the very similar penetration of DES across Europe.  
Another possible reason for mobility is the waiting lists for angioplasty procedure. National waiting 
lists for angioplasty could push patients to health care tourism. 
 
In Italy an agreement was signed during 2006 between the State and Region (28/03/06) to guarantee 
adequate services to patients. It defines waiting times for several interventions. According to this 
agreement, the maximum waiting time for angioplasty intervention is 60 days. 
 
Authorisation & safety  
Has the technique proper national/EU authorisation? 
Methods 
Use of EMEA document (EMEA/CHMP/EWP/56477/2006, London, February 2006)
23
 and Council 
directive 93/42/EEC
24
, MEDDEV 2.1/3 rev 2 guidelines relating to the application of The Council 
Directive 90/385/EEC
25
 on active implantable medical devices. 
Results 
The introduction of medicinal substance-eluting stents has dramatically impacted the market size 
and growth rates for coronary stents worldwide. Many new companies are currently entering the 
field. Guidance is needed with regard to the non-clinical and clinical data required for the 
evaluation of the medicinal substances contained in medicinal substance-eluting stents. Differences 
have been noted in the amount of non-clinical and clinical information: in some case producers 
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strengthen their application dossier by introducing pharmacological data, in other cases application 
dossiers are supported by wide, multi-centred, randomized controlled clinical studies. 
Comments 
These medicinal substance-eluting stents are combination products composed of medicinal products 
and medical devices, where the medicinal product has an ancillary function to the device. They are 
classified in the Community as medical devices, in accordance with Council Directive 93/42/EEC 
concerning medical devices and in line with the MEDDEV 2.1/3 rev 2 guidelines relating to the 
application of: The Council Directive 90/385/EEC on active implantable medical devices and the 
Council Directive 93/42/EEC on medical devices. The authorisation of such combinations falls 
ultimately under the remit of the relevant Notified Bodies. According to the medical device 
legislation, the Notified Body shall consult one of the competent bodies of the Member States or the 
EMEA with regards to the quality, safety and usefulness of the medicinal substance incorporated as 
integral part of the device, taking into account the intended purpose of the device. 
2
 
Does DES need to be listed in a national/EU register? 
Methods 
Study and description of the procedure for registration of medical devices, MEDDEV 2.1/3 rev 2 
guidelines 
Results 
A Medical Device is defined in Directive (93/42/EEC) as ―any instrument, apparatus, appliance, 
material or other article, whether used alone or in combination, including the software necessary for 
the proper application, intended by the manufacturer to be used for human beings for the purpose 
of:  
 Diagnosis, prevention, monitoring, treatment or alleviation of a disease, an injury or a 
handicap.  
 Investigation, replacement or modification of the anatomy or of a physiological process.  
 control of conception  
And which does not achieve its principal intended action in or on the human body by 
pharmacological, immunological or metabolic means, but which may be assisted by such means‖.  
The 2001 guidelines (see MEDDEV 2.4) classify the medical devices into 3 classes, mainly on the 
basis of 17 rules that identify safety level and potential risks. The classification on which a MDD 
falls into constitutes the basic frame for the product to receive the CE marking.   
For a number of products it is not clear whether they are medical devices or not. There are a number 
of examples of products that may or may not be classified into medical devices depending on the 
Intended Purpose for Use, assigned by the manufacturer to the products. Drug eluting stents are 
classified in the EU as medical devices falling into MEDDEV class III.  
                                                 
2
 Each member state specifies some Competent Body(ies) (CB), also called "Competent Authority(ies)" to enact the 
directive within its territory. Each CB can specify one or more Notified Bodies (NB), to act as third party assessors of 
the manufacturer‘s compliance. A NB may be Notified for accessing the products under all allowed conformity modules 
under the particular directive or only part of modules.  
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In April 2002, CYPHER™, a sirolimus-eluting stent of Cordis Inc received CE conformity marking 
in Europe and in January 2003 the TAXUS medical device, a Paclitaxel-eluting stent of Boston 
Scientific received CE conformity marking in Europe for treatment of de novo coronary artery 
lesions in native coronary arteries. 
Does DES fulfil product/tissue safety requirements? 
Methods 
Consultation of the directive 2001/104/EC
26
, EMEA document
24
 (EMEA/CHMP/EWP/56477/2006, 
London, February 2006). 
 
Results 
Sirolimus-based DES reduces restenosis risk with respect to Paclitaxel, although a limited follow-
up does not reveal significant differences in the reducing risk for thrombosis, myocardial infarction 
and death.  At present there is no evidence of the link between restenosis and mortality.  Long-term 
evidence is required. 
 
The evaluation of medicinal substance-eluting stents introduces additional considerations for 
preclinical and clinical testing, and for manufacturing. Aspects of manufacturing, mechanical 
performance & testing regimens, chemistry, animal experimentation, pharmacology and safety and 
efficacy evaluation call for an integrated assessment. Furthermore, taken into account that the 
clinical studies are performed in highly selected patient groups but the devices after launching are 
commonly used beyond the main study selection criteria, recommendations for post-marketing 
surveillance should also be considered. Regulatory harmonization regarding requested information 
about safety and usefulness of the medicinal substances contained in drug-eluting stents is needed to 
achieve optimal care for all patients. 
Comments  
The EMEA CHMP Efficacy Working Party and the Safety Working Party recommend to draft a 
guidance document detailing what data are required to be included in the dossier of a medicinal 
substance eluting stents for an adequate assessment of the safety and usefulness of a medicinal 
product used as an ancillary medicinal substance in a medical device in the context of a Notified 
body consultation procedure and of the post-marketing programs to be recommended. 
Recommendations will also be given on presentation and interpretation of results. 
 
Ownership & liability  
Does DES infringe some intellectual property rights? 
Methods 
Internet search was performed.  
Results 
In Europe CYPHER™ (J&J Cordis corp.) and TAXUS (Boston Scientific) were registered 
respectively in 2002 and 2003. On 5 April 2007 a U.S. federal court ruled that the stent made by 
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Johnson and Johnson unit Cordis Corp. does not infringe a patent held by Boston Scientific Corp. 
according to court documents.  Actually Conor Medsystems completed enrollment of COSTAR II 
piloted Randomized Drug-Eluting Stent Trial to test the development of an innovative controlled 
vascular drug delivery technology, COSTAR II (CObalt chromium STent with Antiproliferative for 
Restenosis). If the results of this clinical trial prove favourable, the company will submit an 
application for marketing approval to U.S. Food and Drug Administration for its CoStar(TM) stent 
in early 2007, and it may receive regulatory approval in late 2007 or early 2008. Nevertheless, the 
company advised potential investors, that among the risk factors that could influence the results of 
the experimentation‘s, the chance of infringing property rights should be included. 
Does the introduction of DES presume some additional licensing fees to be paid? 
Methods 
Internet search, manufacturer web-sites 
Results 
No licensing fees apply to health care organisations that use drug eluting stents. 
 
Companies which intend to produce Drug Eluting Stents, should pay an additional licensing fee, for 
loading the devices with a drug registered under another company‘s label. Some examples of 
additional licensing fees are reported: 
- To develop CYPHER, Cordis Corporation. paid an additional fee to SurModics Inc.; 
- BIOTRONIK AG and Conor MedSystems signed an agreement with NOVARTIS to 
develop a next-generation Drug Eluting Stents; 
- Singapore-based Biosensors International sold certain assets of its everolimus eluting 
stent programme to Guidant Corporation (part of Boston Scientific). 
Furthermore, DES producers should pay an additional fee to other companies to run clinical trials 
which compare stents loaded with different drugs. 
What are the width, depth and length of the manufacturers guarantee? 
Methods 
Internet search, manufacturer web-sites, technology brochures and users-guide 
Results 
Manufacturers provide information on the guarantee in their documentation that is sometimes freely 
available online. In some cases the guidelines are available only through specific request. 
 
Is the user  guide of DES comprehensive enough? 
Methods 
Internet search, manufacturer web-sites, technology brochures and users-guide 
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Results 
Some users‘ guides have been downloaded and examined. In our opinion the best guide found is 
available for free and is structured as follows: 
1. device and drug component description 
2. indications 
3. contraindications 
4. warnings 
5. precautions 
6. drug information 
7. overview of clinical studies 
8. adverse events 
9. clinical studies 
10. individualization of treatment 
11. patient counselling information 
12. how supplied 
13. operators instructions 
14. in vitro information 
15. reuse precaution statement 
16. warranty. 
The user guide seems to be very comprehensive and satisfactory for patients and clinicians. In 
particular, the section about clinical evidence appears very clear. Other users‘ guides are not 
available immediately on the web. User is expected to fill out a request form. Nevertheless, a 
company web-site is linked with a site dedicated to stents that provides information for patients. 
Regulation of the market  
Is DES subject to price control? 
Methods 
The European Court of Justice Database has been searched by using the keyword ―stent‖. 
Medline database has also been searched by using keywords ―stent‖ and ―price control‖. 
In addition, a grey literature research regarding the Italian system has been performed. 
Results 
European Court of Justice Database research did not indentify any useful information on stents. 
Medline research identified 15 articles but they are not directly linked to this issue. According to the 
authors, there is not an explicit price control of the stent market. Stent financing methods (i.e. 
centralized purchasing by Regional Health System, in the Italian region Emilia-Romagna) can be 
considered indirect systems to control price.  
Is DES subject to acquisition regulation? 
Methods 
―Directive 2004/18/Ec‖ was consulted to verify if it contains prescriptions that may influence stents 
acquisition 
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Results 
―Directive 2004/18/Ec‖ does not contain prescriptions on stents acquisition. This is a general law on 
the coordination of procedures for the award of public works contracts, public supply contracts and 
public service contracts, without explicit reference to medical devices or stents sector. 
Is the marketing of DES to the patients restricted? 
Methods 
Medline was searched using keywords such as ―stent‖, ―device‖ and ―marketing‖ (―stent or device 
and marketing‖) in title. Also other non-scientific search engines were consulted. 
Italian Ministry of Health website and ―Eurolex‖ were searched, in order to identify national laws 
on marketing in Italy and in the EU. 
Results 
Articles from Medline were not pertinent to this issue. Other search engines underlined the role of 
CE certification to allow the introduction of a new device into the market. No information was 
found about the possibility to perform marketing activities directly to patients. 
 
The Council Directive 93/42/EEC of 14 June 1993 concerning medical devices defines, in the 
article 2, that ―Member States shall take all necessary steps to ensure that devices may be placed on 
the market and put into service only if they do not compromise the safety and health of patients, 
users and, where applicable, other persons when properly installed, maintained and used in 
accordance with their intended purpose‖. In addition article 17 states that ―Devices … must bear the 
CE marking of conformity when they are placed on the market‖. In Italy this directive has been 
ratified with Law n. 46 of 24-02-97. Italian Ministry of Health website published national laws on 
advertising of devices. In particular, the Italian Law states that medical devices which need medical 
assistance must not be advertised (Ministry of Health Law of 23.2.2006, GU 21.4.2006, art 1, part1, 
letter d) 
Comment 
Marketing and advertising activities are usually restricted by national laws. In Europe, pre-
marketing requirements are based on the CE mark 
Legal regulation of novel/experimental techniques  
Are new legislative measures needed? 
Methods 
A search of grey literature on the European level was performed. We searched in EURLEX 
database and in the websites of EMEA and EUCOMED.  
Results 
Given the complexity and rapid evolution of this sector, a regular review of Directive 93/42/EEC 
has been provided for by the regulator. On 22 December 2005, the European Commission published 
its proposed amendments after extensive stakeholder consultation. The text is now with the 
European Parliament Environment in first reading.  
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APPENDIX: Table template for translating assessment 
elements 
 
Domain Topic Issue 
Relevance in the context of 
DES 
Yes/No 
Research 
question(s) in the 
context of DES 
Importance 
3=critical 
2=important 
1=optional 
Transfera-
bility 
3=complete 
2=partially 
1=not 
       
Legal 
aspects 
Autonomy of the 
patient 
Is the patient 
competent to make 
his/her own health care 
decisions? 
YES 
 3 3 
  
Can the patient 
understand the 
implications of 
using/not using the 
technology? 
YES 
 3 2 
  
Are there relevant 
optional technologies 
that the patient should 
be allowed to 
consider? 
YES 
 3 2 
  
Is it possible to give 
the patient enough 
time to consider 
his/her decision? 
YES 
 2 2 
  
Is it possible to obtain 
an advance directive 
on the use of the 
technology? 
NO because it is not necessary 
to obtain an advance directive 
on the use of this specific 
technology. 
 2 1 
  
Has the patient 
prescribed such a 
directive? 
NO because it is not necessary 
to obtain an advance directive 
on the use of this specific 
technology. 
 3 1 
 
Privacy of the 
patient 
Does the use of the 
technology produce 
some additional (i.e. 
diagnostically or 
therapeutically 
irrelevant) information 
on the patient? 
NO because PTCA procedure 
with Stent insertion (both DES 
and BMS) doesn‘t produce 
additionally information, 
diagnostically and/or 
therapeutically irrelevant regard 
PTCA. 
 3 3 
  
Does the use of the 
technology produce 
some additional (i.e. 
diagnostically or 
therapeutically 
irrelevant) information 
on the relatives of the 
patient? 
NO because PTCA procedure 
with Stent insertion (both DES 
and BMS) doesn‘t produce 
additionally information, 
diagnostically and/or 
therapeutically irrelevant regard 
PTCA. 
 3 1 
  
Is the access to the 
patient data secured 
properly? 
YES 
 2 1 
  
How many people in 
the chain of care need 
to get access to the 
patient information? 
YES 
 1 1 
 
Equality in health 
care 
Is the technology 
equally accessible to 
all needing members in 
a given society? 
YES 
 3 2 
  
Is the technology 
subsidized by the 
society? 
YES 
 2 1 
  
Is there a wide 
variation in the 
permissibility of the 
technology across 
Europe? 
No because there is nothing 
specific on DES permissibility. 
 3 3 
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Is health-care tourism 
expected from/to other 
European countries? 
YES 
 2 3 
 
Authorisation & 
safety 
Has the technique 
proper national/EU 
level authorisation? 
YES 
 3 3 
  
Does the technology 
need to be listed in a 
national/EU register? 
YES 
 2 2 
  
Does the technology 
fulfil product safety 
requirements? 
YES 
 3 3 
  
Does the technology 
fulfil tissue safety 
requirements? 
YES 
 3 3 
 
Ownership & 
liability 
Does the technology 
infringe some 
intellectual property 
right? 
YES 
 2 3 
  
Does the introduction 
of the technology 
presume some 
additional licensing 
fees to be paid? 
YES 
 2 2 
  
What are the width, 
depth and length of the 
manufacturers 
guarantee? 
YES 
 3 3 
  
Is the user guide of the 
technology 
comprehensive 
enough? 
YES 
 3 3 
 
Regulation of the 
market 
Is the technology 
subject to price 
control? 
YES 
 3 2 
  
Is the technology 
subject to acquisition 
regulation? 
NO because DES doesn‘t 
determine variations on laws in 
comparison with BMS. 
 3 2 
  
Is the marketing of the 
technology to the 
patients restricted? 
YES 
 3 2 
 
Legal regulation of 
novel/experimental 
techniques 
Is the technology so 
novel that no legal 
rules are directly 
applicable? 
NO (don‘t applicable to DES 
technology) 
 3 1 
  
How the liability 
issues are solved 
according to existing 
legislation? 
NO (don‘t applicable to DES 
technology) 
 3 1 
  
Are new legislative 
measures needed? 
 
 2 1 
  
Is the voluntary 
participation of 
patients guaranteed 
properly? 
NO (don‘t applicable to DES 
technology) 
 3 1 
 
 
